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Summary 
Bypass surgery is a vascular surgeon’s fundamental tool in the treatment of some 
arterial and venous diseases, many of which are caused by atherosclerosis. The 
procedure uses a vascular graft to replace, bypass or maintain function of damaged, 
occluded or diseased blood vessels. The most common approach is to use a native 
vessel, such as the saphenous vein, from the patient as the bypass conduit. 
Alternatively, when an autologous vessel is not available due to progression of the 
disease or prior surgeries, synthetic alternatives are used. However, the current 
synthetic alternatives have been plagued with little success in small caliber vessels 
(<6mm).  
Bacterial cellulose (BC) has been presented as an alternative material for the 
production of a vascular graft. It presents good mechanical characteristics allied 
with non-thrombogenicity, hemo- and biocompatibility. Several methods have been 
suggested in the literature that allow the production of tubular BC grafts. The work 
developed and presented in this thesis had two aims: further development and 
performance enhancement of a current production method and also, the 
development of a new and effective method for graft production. 
A current, and common, method of graft production takes advantage of the way in 
which the Gluconacetobacter bacteria produces BC at air-culture medium interfaces. 
By providing an oxygen permeable tubular scaffold it is possible to produce tubular 
BC constructs. However, the tubular BC constructs produced in this method were 
found to be lacking in mechanical strength. Towards enhancing their performance a 
nanocomposite of BC and poly(vinyl alcohol) (PVA) was developed. 
Blood contacting materials have necessarily to be able to perform well in regards to 
their hemocompatibility and thrombogenicity and, as such, the BC/PVA 
nanocomposite was so tested, as well as BC. The standard characterization of the 
whole blood clotting time, plasma recalcification and hemolysis index were all 
determined. In addition, as a more in depth analysis, complement system and Factor 
XII activation along with a detailed characterization of platelet adhesion and 
activation was also assessed. Results suggested that both BC and BC/PVA induced 
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low levels of Factor XII and platelet activation and this is possibly the main cause for 
the good hemocompatibility presented by of both materials. The presence of PVA in 
the nanocomposite did not hinder the hemocompatibility of BC, in some cases 
adding to the performance of the material. 
Along with the, aforementioned, necessary characterization of the BC/PVA 
nanocomposite, the mechanical and morphological characteristics of the material 
were also tested and shown to be significantly different in terms of fiber structure 
and organization upon drying. The performance of the nanocomposite regarding 
mechanical characteristics was expected to outperform those of BC. However, the 
tensile tests performed suggested otherwise. A more detailed morphological 
analysis of BC/PVA showed that, once dried, the fiber structure changed 
dramatically; presenting two very distinct, dense and porous, regions. These 
structural characteristics were found to be associated with a heterogeneous 
distribution of PVA throughout the nanocomposite which affected the mechanical 
performance and permeability of the dried nanocomposite. 
Finally, through the course of several developmental stages of the graft, an 
alternative method of production that allied both technical facility and low cost was 
discovered. This method was able of outperforming the previous iteration of the BC 
grafts and was, later, shown to be a viable and cost effective method of graft 
production. The grafts produced by this novel method allowed for mechanically 
strong and yet compliant grafts to be produced, as was demonstrated by the 
mechanical characterization performed, in a reproducible way. Continued 
characterization showed a luminal topography similar to that of a native vessel, far 
exceeding ePTFE and Dacron in this regard. Additionally, an important mechanical 
characteristic; and frequent cause of graft failure, compliance was also determined 
and shown to be comparable on the luminal surface when compared to native 
arteries and again outperforming the current industry standards. The grafts were 
later shown to perform well in vivo in pigs. Surgical implantation was performed in 
a femoro-femoral arterial bypass bridge to study the in vivo viability of the graft. 
Results demonstrated patency after 1 month of implantation with the presence of 
an endothelial cell population on the luminal surface of the graft.
Resumo 
AF Leitão 
vii 
Resumo 
Cirurgia de bypass é uma ferramenta fundamental no tratamento de algumas 
doenças arteriais e venosas, muitas destas doenças causadas por aterosclerose. Este 
procedimento utiliza uma prótese vascular para substituir, formar uma ponte ou 
manter o funcionamento de um vaso danificado, obstruído ou doente. O processo 
mais comum utiliza um vaso nativo, como a veia safena, como a prótese vascular. 
Quando um vaso autólogo não estiver disponível, devido à progressão natural da 
doença ou cirurgias anteriores, utilizam-se alternativas sintéticas. Contudo, as 
actuais alternativas sintéticas têm obtido pouco sucesso em vasos de pequeno 
calibre (<6mm). 
Celulose bacteriana (BC) apresenta-se como uma alternativa para a produção de 
próteses vasculares. Apresenta boas características mecânicas aliadas a não-
trombogenicidade, hemo- e biocompatibilidade. Vários métodos de produção de 
vasos de celulose bacteriana têm sido propostos na literatura. O trabalho 
desenvolvido e apresentado nesta tese teve dois objectivos: continuar o 
desenvolvimento e melhorar o desempenho dos actuais métodos de produção, bem 
como, o desenvolvimento de uma nova e eficaz maneira de produzir próteses. 
O actual e mais comum, método de produção aproveita a forma como as bactérias 
do género Gluconacetobacter produzem BC nos interfaces ar-meio de cultura. 
Utilizando um suporte tubular permeável a oxigénio é possível produzir estruturas 
tubulares de celulose. Contudo, as estruturas tubulares produzidas por estes 
métodos demonstraram fracas propriedades mecânicas. Com o objectivo de 
melhorar o desempenho mecânico desenvolveu-se um nanocompósito de BC e 
poli(vinil álcool) (PVA). 
Materiais que contactam com sangue têm que ser capazes de ter um bom 
desempenho em termos de hemocompatibilidade e trombogenicidade e como tal, o 
nanocompósito de BC/PVA, bem como a BC, foram testadas. Foi feita a 
caracterização do tempo de coagulação de sangue total, recalcificação do plasma e 
índice de hemólise. Para além destes, foi analisada a activação do sistema de 
complemento e Factor XII bem como uma caracterização detalhada da adesão e 
Resumo 
AF Leitão 
viii 
activação de plaquetas. Os resultados sugerem que a BC e o BC/PVA, induzem baixos 
níveis de activação do Factor XII e plaquetas, o que poderá ser a principal razão pela 
boa hemocompatibilidade apresentada pelos materiais. A presença de PVA no 
nanocompósito não afecta a hemocompatibilidade da BC, em alguns casos até 
melhorando o seu desempenho. 
Para além desta caracterização do BC/PVA, o nanocompósito foi caracterizado a 
nível mecânico e morfológico e os resultados mostraram diferenças significativas 
em termos de estrutura e organização das fibras após secagem. Esperava-se que o 
desempenho do nanocompósito, em termos de características mecânicas, seria 
superior à BC, no entanto isto não se veio a verificar. Uma análise morfológica mais 
detalhada do BC/PVA mostrou que, após secagem, a estrutura das fibras sofre 
alterações profundas; apresentando duas regiões distintas, uma densa e outra 
porosa. Estas distintas regiões devem-se à distribuição heterogénea do PVA no 
nanocompósito, por seu turno, afecta o desempenho mecânico e permeabilidade do 
nanocompósito seco. 
Por fim, a longo do curso de várias fases de desenvolvimento das próteses, foi 
descoberto um método alternativo de produção que aliava facilidade técnica e baixo 
custo. Este método mostrou ser capaz de produzir próteses melhores que todas as 
versões anteriores e, mais tarde, mostrou ser um método de produção viável e de 
baixo-custo. As próteses produzidas por este método novo permitem obter forças 
mecânicas superiores sem perder a complacência do material, como foi 
demonstrado pela caracterização mecânica, de forma reprodutível. A continuada 
caracterização das próteses mostrou uma topografia luminal semelhante ao dos 
vasos nativos, superando o ePTFE e o Dacron. Adicionalmente, uma importante 
característica mecânica, e frequente causa de falha das próteses, a complacência foi 
também determinada e mostrou ser comparável à complacência da superfície 
luminal de artérias nativas, tendo portanto um melhor desempenho que as próteses 
industriais actuais. As próteses mostraram, mais tarde, ter também um bom 
desempenho in vivo em porcos. As próteses foram implantadas numa ponte femoral 
de forma a estudar a viabilidade in vivo. Os resultados obtidos demonstraram 
patência ao fim de 1 mês de implantação com a presença de células endoteliais na 
superfície luminal da prótese.
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Figure 2-7 - Mean fluorescence intensities (MFIR) , as obtained by flow cytometry, for the expression 
of CD62P (A), CD63 (B), PS (C) and GPIIB/IIIa (D) on platelet surface after exposure to BC, PC/PVA 
and ePTFE for 10, 30, 50 and 180 minutes. The surface were incubated with platelet rich plasma 
(PRP) and also a platelet solution with (Plt+Ca) and without (Plt-Ca) 2mM Ca added to the solution. 
Figure 2-8 - Representative images of Western Blot and Percentage of C3 Cleavage for BC and 
BC/PVA. Both BC and BC/PVA were tested under 5 conditons: (1) 2 hour preincubation at 37oC with 
active plasma and then 1 hour incubation with plasma and Veronal buffer at 37oC; (2) ) 2 hour 
preincubation at 37oC with inactive plasma and then 1 hour incubation with plasma and Veronal 
buffer at 37oC, (3) 1 hour incubation with plasma and Veronal buffer for 1hour at 37oC, (4) 3 hour 
incubation with plasma at 37oC and (5) 3 hour incubation with plasma and Veronal buffer at 37oC. 
 
Chapter 3 
Figure 3-1 - SEM micrographs of (A) never-dried bacterial cellulose (BC); (B) never-dried 
BC/poly(vinyl alcohol) (PVA); (C) dried BC; and (D) BC/PVA at 100,000× magnification. 
Figure 3-2 - Three SEM micrographs of the same dry BC/PVA membrane at 15,000× magnification 
with two very distinct regions of densely compacted fibers and regions with large pores. 
Figure 3-3 Stress-strain curves of dry strips of BC and BC/PVA. Each strip of 5 × 1 cm (length × width) 
was cut from a single sheet of material and measured multiple times (n = 6). The results here are the 
averaged curves obtained up to the rupture point. 
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Chapter 4 
Figure 4-1 - Schematic representation BC vascular graft formation process. From left to right: the BC 
perforated with a sharp metallic needle, dried by capillary action and shaped into a cylinder and 
finally freeze-dried. 
Figure 4-2 - Surface profiles of Porcine Femoral Artery (A), BC graft (B), ePTFE graft (C) and a PET 
graft (D). The plots were obtained from 5 separate linear measurements (2000 points/mm) over 2 
cm (3cm for BC), spaced 1mm apart and plotted in a 3D graph. 
Figure 4-3 - Cryo-SEM images of a portion of the cross-section of the graft wall. (A) and (B) 4000x 
magnification with noticeable dense regions layered between open-pore structures; (C) 10000x 
magnification of the dense BC regions; (D) 10000x magnification of the open-pore structures and (E) 
10000x magnification of the edge of the luminal surface of the graft. (F) is a schematic representation 
of the interface between the luminal surface and inner wall structure. 
Figure 4-4 - Endotoxin (LPS) concentration in EU/ml (Endotoxin Units/ml) as determined over 3, 24 
hour, washes in 5% SDS and water (negative control). 
Figure 4-5 - Representative photographs of the microscopy images of in vivo tests. (A) Femoral-
femoral artery BC graft placement, (B) luminal surface of the graft with cell adhesion on the surface 
of the graft along and some cell infiltration, (C) external surface of BC graft showing formation of neo-
vessels (arrow), (D) external surface of the BC grafts showing a smooth transition from surrounding 
tissues into the BC graft with cell infiltration, (E) immunohistochemistry staining of CD31 positive 
cells forming neo-vessels on the luminal surface of the graft, (F) CD31 positive cell clusters on the 
luminal surface of the grafts. 
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Figure A-1 - Schematic representation BC vascular graft formation process. From left to right: the BC 
perforated with a sharp metallic needle, dried by capillary action and shaped into a cylinder and 
finally freeze-dried. 
Figure A-2 - Surface profiles of Porcine Femoral Artery (A), BC graft (B), ePTFE graft (C) and a PET 
graft (D). The plots were obtained from 5 separate linear measurements (2000 points/mm) over 2 
cm (3cm for BC), spaced 1mm apart and plotted in a 3D graph. 
Figure A-3 - Cryo-SEM images of a portion of the cross-section of the graft wall. (A) and (B) 4000x 
magnification with noticeable dense regions layered between open-pore structures; (C) 10000x 
magnification of the dense BC regions; (D) 10000x magnification of the open-pore structures and (E) 
10000x magnification of the edge of the luminal surface of the graft. (F) is a schematic representation 
of the interface between the luminal surface and inner wall structure. 
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Figure A-4 - Endotoxin (LPS) concentration in EU/ml (Endotoxin Units/ml) as determined over 3, 24 
hour, washes in 5% SDS and water (negative control). 
Figure A-5 Representative photographs and Haematoxylin and Eosin histopathological microscopy 
images of in vivo tests. (A) Femoral-femoral artery BC graft placement, (B) Doppler Sonography 
screenshot showing blood flow through the BC graft after one month of implantation, (C) 100x 
magnification of the luminal surface of the graft with cell adhesion on the surface of the graft along 
and some cell infiltration, (D) 200x External surface of BC graft showing formation of neo-vessels 
(arrow), (E) External surface of the BC grafts showing a smooth transition from surrounding tissues 
into the BC graft with cell infiltration, (F) 200x magnification of a cell population in a transitional 
region from adventitia into the BC grafts. 
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Table 2 - 1 - Hemoglobin index blood after contact with of bacterial cellulose (BC), bacterial 
cellulose/polyvinyl alcohol (BC/PVA) and expanded polytetrafluoroethylene (ePTFE). 
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Table 3-1 - Diffusion coefficients of four different Mw polyethylene glycol (PEG) in BC and BC/PVA 
samples. 
 
Chapter 4 
Table 4-1 - Mechanical test results for Porcine Femoral Artery (PFA), ePTFE the BC Graft and 
unprocessed BC (n=5). Values marked with an asterisk (*) are not statistically different from each 
other in their respective columns (p>0.05). Data is presented as mean ± standard deviation. 
Table 4-2 - Suture Retention strength (N) of several autologous and synthetic grafts for Tissue 
Engineered Blood Vessels (TEBV), Internal Mammary Artery (IMA), Polytetrafluoroethylene 
(ePTFE), Fibrin and Fibrin/polylactic acid (PLA), Human Saphenous Vein (HSV), Collagen and 
Bacterial Cellulose (BC). Suture retention strength for the BC graft and untreated BC are not 
statistically different (p>0.05; n=4) 
Table 4-3 - Compliance (presented as value x10-2 %/mmHg) with standard deviation (SD) as 
collected from the literature for Internal Mammary Artery (IMA), Human Saphenous Vein (HSV), 
Human Iliac Artery (HIA), Tissue Engineered Blood Vessel (TEBV), Polyurethane (PU), Polyethylene 
terephthalate (PET), expanded Polytetrafluoroethylene (ePTFE), Bacterial Cellulose/Chitosan blend 
(BC/Chi) and measurements for the compliance of the BC grafts as measured externally and 
internally (n=5). 
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Table A-1 - Mechanical test results for Porcine Femoral Artery (PFA), ePTFE the BC Graft and 
unprocessed BC (n=5). Values marked with an asterisk (*) are not statistically different from each 
other in their respective columns (p>0.05). Data is presented as mean ± standard deviation. 
Table A-2 Suture Retention strength (N) of several autologous and synthetic grafts for Tissue 
Engineered Blood Vessels (TEBV), Internal Mammary Artery (IMA), Polytetrafluoroethylene 
(ePTFE), Fibrin and Fibrin/polylactic acid (PLA), Human Saphenous Vein (HSV), Collagen and 
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Bacterial Cellulose (BC). Suture retention strength for the BC graft and untreated BC are not 
statistically different (p>0.05; n=4) 
Table A-3 - Compliance (presented as value x10-2 %/mmHg) with standard deviation (SD) as 
collected from the literature for Internal Mammary Artery (IMA), Human Saphenous Vein (HSV), 
Human Iliac Artery (HIA), Tissue Engineered Blood Vessel (TEBV), Polyurethane (PU), Polyethylene 
terephthalate (PET), expanded Polytetrafluoroethylene (ePTFE), Bacterial Cellulose/Chitosan blend 
(BC/Chi) and measurements for the compliance of the BC grafts as measured externally and 
internally (n=5). 
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Aims and Thesis Outline 
Cellulose is the most common naturally occurring polymer on the planet. Bacterial 
cellulose (BC) is identical to plant cellulose but is excreted pure by bacteria of the 
Gluconacetobacter genus. It is a linear chain of glucose monomers linked by β (1→4) 
polysaccharide bonds that forms a hydrogel that has been widely studied for 
potential biomedical applications among which are vascular grafts. The aim of this 
thesis is precisely to address one of those potential applications: BC and BC/PVA as 
potential vascular bypass grafts. 
Chapter 1 starts by presenting the reasoning behind the need for a vascular graft 
and the requirements a functional graft must meet. It goes on to present a review on 
some of the current polymers being studied for their potential application with a 
short state of the art for each. 
The initial approach of the work presented here was to use a method described in 
the literature for graft production and develop it in order to produce a viable graft 
solution. The method adopted for this was the development of a BC/PVA 
nanocomposite material. The theory was that BC and PVA would produce an 
interpenetrated network of fibers. The resulting nanocomposite would take on 
properties of both polymers.  
Any blood contacting material, especially in the case of a vascular graft, must be well 
characterized in regards to hemocompatibility and thrombogenicity. The work 
pertaining to this characterization resided in Chapter 2. Three common 
hemocompatibility indicators were assessed along with a more in depth analysis 
that allowed a greater assessment of the mechanics behind the good 
hemocompatibility and non-thrombogenicity of both BC and BC/PVA. 
In Chapter 3 further characterization of the nanocomposite is presented; now on a 
mechanical and morphological level. The nanocomposite would necessarily need to 
perform well on a mechanical level in order to be viable. As such mechanical 
characterization was a necessary requirement. However, during the course of the 
study presented in this chapter, dramatic changes to the fibrilar structure of the 
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dried nanocomposite were revealed. The chapter focuses closely on those 
morphological changes and their significance to the performance of BC/PVA 
Through several different modifications performed to the production methods of 
the graft and formulations of the nanocomposite a novel method for production was 
found, studied and developed. The methodology allowed the production of a graft 
that outperformed all previous iterations in mechanical strength and compliance 
while retaining the hemocompatibility qualities of BC. The small differences found 
between the behaviors of BC/PVA and BC did not seem to justify the continued use 
of PVA and so, PVA was abandoned, at least for now, in favor of a more cost-efficient 
and logistically simpler methodology.  
This production method is described in Chapter 4 along with a mechanical and 
morphological characterization, of special note the study of the mechanical 
compliance. Furthermore, in chapter 4, the performance of the graft in a live animal 
model was also studied and is also presented The novel methodology outlined in 
this chapter proved effective and reproducible having ultimately led to an 
application for a provisionary patent (included as Annex A). 
In the final Chapter (5) a general conclusion of the work is presented and future 
perspectives, in regards to the further development of the graft, are outlined. 
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Chapter 1 
Polymers in Vascular Grafts 
 
Adapted from: Leitão, AF; Silva, I; Faria, M; Gama, M; Polymers in Vascular Grafts in Encyclopedia of 
Biomedical Polymers and Polymeric Biomaterials; Taylor & Francis; 2014 (in Press) (DOI: 10.1081/e-ebpp-
120050697) 
 
 
Cardiovascular disease (CVD) is one of the major leading causes of death in today's world. 
Among the most common is atherosclerosis, a thickening of the arterial wall to the 
buildup of plaque. When the disease causes complications, due to occlusion of the vessel 
or arterial wall lesions that ultimately lead to thrombosis, usually a bypass is required to 
redirect blood flow around the occluded vessel. The preferred vessels for the bypass 
procedure are autografts, veins and arteries culled from the patient. When these vessels 
are not available, due to the natural progression of the disease or prior procedures, 
synthetic alternatives must be used. These alternatives are created from polymeric 
materials that can substitute the autografts completely and remain in the patients for 
years and decades or serve as a temporary substitute that will allow tissue-engineering. 
In this chapter we intend to show some of the polymers that are currently being studied, 
and two in particular that have been in use for over 50 years; that can one day serve the 
purpose of substituting the autografts completely and provide a better future for patients 
worldwide. 
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Introduction 
 
Cardiovascular disease (CVD) is a broad term encompassing several different diseases 
among which atherosclerosis and hypertension are the most common. The causes, 
prevention, and/or treatment of all forms of CVD remain active fields of biomedical 
research, with hundreds of scientific studies being published on a weekly basis. The 
ongoing research in the various fields that are related to this topic all have one single 
objective: improving the quality of life of patients worldwide via prevention of the disease 
and by finding better courses of treatment.  
The leading cause of death associated with vascular disease is atherosclerosis, a 
syndrome that affects arterial blood vessels. Atherosclerosis is defined as a chronic 
inflammatory response in the walls of arteries, closely associated with high cholesterol 
levels in the blood, and can remain asymptomatic for decades. Eventually the blood flow 
through the affected arteries can be cut off completely and blood flow must be 
reestablished around the occluded vessel. In these extreme cases the most common 
procedures performed are bypass surgeries. 
Since the 1950s, when autologous vessels are not available to perform the bypass 
procedure, synthetic alternatives have to be used. The current, most common synthetic 
alternatives, are known simply as Dacron and expanded polytetrafluoroethylene 
(ePTFE). They have been used countless times in life saving procedures. While they 
perform well, as long as certain conditions are met, they are not perfect and do not 
provide a definitive solution.  
Much research has focused on improving the current grafts and/or discovering new 
better grafts and material combinations. Research has focused on polymeric materials; 
either non-degradable polymers that remain in vivo for undetermined periods of time or 
biodegradable polymers that serve as tissue-engineering scaffolds, ultimately allowing 
for native tissue to form a new blood vessel. Our objective in this entry is to outline the 
need for the prosthetics, the standardized methodologies to assess their viability, an 
unbiased review of the current state of research being performed on several polymers 
with the objective of developing new synthetic vascular grafts and finally what we 
consider to be the future perspectives of the research performed in this ongoing field. 
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CVD: the need for vascular grafts 
 
The World Health Organization (WHO) estimates that 17.3 million people died in 2008 of 
cardiovascular disease (CVD), of which 80% occurred in low- and middle-income 
countries. The American Heart Association (AHA) estimates that, from 1999 to 2009, the 
relative rate of death attributable to CVD declined by 32.7%. Yet, it is still responsible for 
1 of every 3 deaths in the United States (one every 40 seconds) [1]. On the basis of CVD is 
atherosclerosis, a complex disease involving the heart and blood vessels and is 
responsible for several disorders such as stroke, myocardial infarction and peripheral 
arterial disease (PAD). 
Atherosclerosis was described for the first time in 1904 by Marchand to define arterial 
stiffening in association with fatty degeneration. Atherosclerosis is a systemic disease 
affecting large and medium-sized arteries. Accumulation of lipids in both smooth muscle 
cells (SMCs) and macrophages leads to inflammatory response and arterial thickening, 
which plays a major role in atherogenesis [2]. 
Atherosclerotic plaques remain asymptomatic, below critical stenosis (>70%), due to 
compensatory vessel enlargement and to the development of collateral circulation in 
response to chronic hypoxia. Chronic injury leads to endothelium dysfunction, increased 
oxidative stress and reduction in bioactivity or synthesis of endothelium-derived nitric 
oxide (NO), which results in a reduced vascular tone and ischemia [3-5]. The 
atherosclerotic plaque may become unstable, ulcerate and rupture with subsequent 
distal embolization or vessel occlusion due to exposure of the highly thrombogenic sub-
intimal surface. The exposure of the sub-intimal surface promotes platelet adherence and 
activation – atherothrombosis [6] – leading to the acute clinical presentations or 
worsening of a chronic controlled disease, followed by a high morbidity and mortality. 
Despite significant improvement in medical and surgical management of CVD, 
atherosclerosis still remains a serious life-threatening disease [2]. 
Cardiovascular risk factors play a major role in atherosclerosis pathogenesis. They may 
be hereditary or acquired, related to behavioral or environmental factors. The 
INTERHEART study, spearheaded by Dr. Yusuf and colleagues over 52 countries, found 
that 90% of myocardial infarction risk factors were abnormal lipids, smoking, 
hypertension, diabetes, abdominal obesity, psychosocial factors, irregular diet and an 
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absence of a planned exercise program [7]. We now have overwhelming evidence that 
risk factor control is highly cost-effective and significantly reduces CVD morbidity and 
mortality. 
Clinical manifestations of CVD manifest mainly as cerebral vascular disease, coronary 
heart disease and PAD, and can cause severe disability with great limitations in patient 
habits and decreased quality of life or even death. PAD is a chronic disease with 
prevalence in several epidemiologic studies in the range of 3-10%, increasing to 15-20% 
in people over 70 years of age [5]. Initially asymptomatic, it can become progressively 
symptomatic presenting with pain in the calves due to exercise – intermittent 
claudication (IC) – and, when severe, evolves to critical ischemia (CI) with a high risk of 
limb loss. Patients with CI have high amputation rates: 25% will be amputated at time of 
diagnosis and another 30% over the following year [8]. In association with PAD, these 
patients have other co-morbidities as a consequence of diffuse atherosclerosis 
involvement with the heart, cerebral-vascular and kidney disease. In PAD´s treatment we 
have to recognize the disease, quantify the extent of local and systemic disease, identify 
and control risk factors, and establish a comprehensive treatment program [8]. 
In vascular surgery, surgical bypass is fundamental in the treatment of arterial and some 
venous diseases (Figure 1-1A). Vascular grafts are used to replace, bypass or maintain 
function of damaged, occluded or diseased blood vessels of small, medium and large 
diameter. The chosen conduit and its success depend on several factors such as 
availability, size, ease of handling and technical facility, thrombogenicity, resistance to 
infection and dilation, durability, long-term patency and price. 
Depending on the target vessel different options of autografts can be considered. In 
coronary surgery the best conduits are internal mammary artery, radial artery and long 
saphenous veins (LSV). Visceral arteries are also best substituted by LSV or by the iliac 
vessels, hypogastric and more uncommonly by the external iliac artery [9]. In PAD 
surgery the most common autograft in use is the long saphenous vein (using either the 
reversed or “in situ” techniques) and diameters of 3mm are required for good long term 
results [10]. Short saphenous vein or arm veins can be an alternative when no LSV is 
available. Autologous vein grafts remain the conduit of choice for infrainguinal 
revascularization, and long-term results are quite good when a good run-off is present 
[10]. Infrainguinal vein graft failure still occurs in 20- 50% of cases, and remains a major 
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problem for vascular surgeons and patients. Recovery of the thrombosed vein graft has a 
very low patency. Furthermore, replacement of a failed bypass graft with a new one 
requires that the surgeon finds an alternative graft for limb salvage. Thus, the results of 
repeat bypass surgery, after failed previous bypass, are inferior to those of primary 
bypass surgery. It is therefore imperative to maintain the patency of infrainguinal bypass 
grafts [11]. Autogenous arterial or venous conduits are not always available, due to 
venous insufficiency or inadequate LSV diameter/length, previous harvest of vein for 
cardiac surgery or previous varicose vein surgery. These factors raise the need for 
alternative grafts. At present, these include autologous or non-autologous biological 
grafts (obtained using different methods for harvesting and preservation), tissue 
engineering (using either synthetic- or biological-based scaffolds for cell seeding), 
endovascular methodologies [12], gene therapy [13] and non-degradable synthetic 
grafts. 
For large vessel replacement, graft size match, resistance to infection and durability are 
of great importance. Aorto-iliac reconstructions have blood flow properties that allow 
long patency due to minimal tissue ingrowth and endothelial repopulation [9]. Infra-renal 
aortic graft diameters range from 16 to 22 mm and, Poly(ethylene terephthalate) (PET) 
or ePTFE prosthesis—single tube or bifurcated—are the most commonly used (Figure 1-
1B and 1C). The size of the graft should be as close as possible to that of the native artery 
that is replaced. Ten-year primary patency is 89.2% for aorto-iliac bypass and 78% for 
aorto-bifemoral bypass [14]. The replacement of an aortic infected graft can be made with 
prosthetic grafts, arterial homografts or deep veins of the lower limb. The latter present 
a high grade of morbidity and increased operative time. Alternatively, arterial homografts 
are a solution with good early results but a high grade of late degeneration. A study 
comparing cryo-preserved arterial homograft with silver-coated Dacron grafts for the 
treatment of infected aortic grafts demonstrated comparable effectiveness with respect 
to early mortality and midterm survival. Graft-inherent complications, aneurismal 
homograft degeneration, and reinfection of the silver-coated grafts, have also been 
observed [15]. 
In peripheral lower limb bypass there are two types of arteries to be replaced: femoral 
and popliteal arteries, with a medium size (6-8mm), and distal popliteal, tibial, peroneal 
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and foot arteries with small size arteries (<6mm) [9]. With the expanding use and 
indications for endovascular surgery, the number of vessels needing replacement is 
decreasing, with a lower rate of preoperative morbidity. Treatment of the common 
femoral artery has limitations due to increased rate of infection in groin surgeries. 
Bypasses at and from common femoral artery should, when possible, be performed with 
an autologous graft. 
In small size arteries (< 6mm), intimal hyperplasia at the proximal or distal anastomosis 
site is of paramount importance. In these grafts, thromboresistance of the inner lining, 
shear stress and behavior of the conduits are important aspects in the choice of the graft. 
In these cases, autologous grafts are again the best choice. 
Figure 1-1 - Photographs of the surgical 
application of the three most common bypass 
grafts. A) a vein graft, B) Dacron graft and C) 
and ePTFE graft. 
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Femoro-popliteal bypass may be made with a synthetic graft when the distal anastomosis 
is above the knee and the patient has no ulcer that can increase the risk of graft infection. 
In the case of bellow knee bypass, LSV is the preferred choice. A meta-analysis of femoral-
popliteal bypass grafts for lower extremity arterial insufficiency refers that primary graft 
patency was 57.4% for above-knee ePTFE, 77.2% for above-knee vein, and 64.8% for 
below-knee vein at 5 years; there was a significant difference between above-knee grafts 
at 3, 4 and 5 years [14]. Another study reported a similar patency, to the aforementioned 
study, for infragenicular bypasses with ePTFE for limb salvage in above-knee (27%) and 
below-knee (25%) over 5 years [16]. 
When LSV is unavailable, alternative techniques have been applied to increase patency, 
such as the use of a cryopreserved allografts, composed synthetic-LSV graft, vein cuffs 
and ePTFE cuffs at the distal anastomosis in order to reduce the risk of intimal 
hyperplasia [10]. These technical maneuvers and the use of numerous pharmacological 
adjuvants, included at the time of production or implantation, are of paramount 
importance to increase artificial vascular grafts patency. In carotid surgery Dacron 
patches are used routinely in most centers for carotid endarterectomy and carotid 
bypasses are used in the treatment of aneurismal disease of the carotid artery. 
Autogenous LSV, again, is the first choice for carotid bypass, although high rate of 
restenosis has been described [17]. Alternative, PTFE prosthesis can be used due to the 
high flow and short length, with long term graft patency of 95-97% [18]. 
Arteriovenous grafts (AVG), used to connect an artery to a vein, are commonly used in 
hemodialysis patients. In these patients it is need a high flow graft that is also durable, 
resistant to infection and to continuous trauma (due to multiple puncture, two to three 
times a week) to guarantee an efficient hemodialysis for the patient. Autogenous veins 
are the conduct of choice, with an emerging of new techniques to recover the arm veins, 
and only in extreme cases, prosthetic grafts are considered. 
 
Vascular Graft Requirements 
 
As described above, by far, the preferred grafts are autogenous, i.e., the donor and the 
patient are the same individual and this vastly decreases the risk of rejection. However, 
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the progression of the disease in these patients many times limits the availability of viable 
vessels. When this occurs two alternatives are available: biological (which can be 
allografts or xenografts) or synthetic grafts (which consist of polymers that can be either 
synthetic or biological).  
The biological alternative to the autogenous vessels are allografts and xenografts. 
Theoretically, biografts meet all the conditions for the best vascular graft. They promise 
“off-the-shelf” availability, a wide variety of sizes, excellent handling characteristics, and 
patency rates similar to those of autogenous vessels [9]. Disappointingly, clinical 
applications of these grafts have not met the high expectancy awaited. This is in large part 
due to the lack of long-term patency associated with tissue degeneration. 
Therefore a large amount of study has gone into assessing and discovering a synthetic 
alternative graft vessel. A viable synthetic vascular graft should combine fundamental 
characteristics that are inherent to autografts: biocompatibility, namely 
hemocompatibility, and mechanical compliance. Hemocompatibility is linked with the 
blood-material interaction, the mechanisms of which are still not completely understood. 
However, it is well established that the material should provide a minimal risk of 
hemolysis, clotting and thrombosis, along with a minimal risk of infection or triggering of 
the immune response.  
Biocompatibility, particularly in the case of a tissue engineering approach, ultimately 
refers to the ability of the biomaterial to stimulate cell adhesion, invasion and 
proliferation. The grafts should allow for the migration of cells from the surrounding 
tissues in order to, at least, produce an endothelium on the luminal surface of the graft. 
In tissue engineered approaches, where cell-seeding might be adopted, this will allows 
for gradual cell migration, proliferation and production of an extra-cellular matrix while 
at the same time the material is slowly degraded.  This approach allows the synthetic graft 
to be completely substituted by newly formed native tissue, thus reducing the risk of 
long-term deterioration and improve the overall long-term patency. 
Finally, and of no less importance, is the matching of mechanical properties. The grafts 
should provide mechanical characteristics similar to those of the native vessels, 
especially in terms of compliance, in order to allow for a consistent and uninterrupted 
blood flow through the graft. This will ultimately avoid problems such as intimal 
hyperplasia, which is closely associated with mismatch of mechanical properties [19, 20]. 
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Methods for Analysis and Testing 
 
Over the years several assays and tests have been suggested in order to determine the 
viability of synthetic grafts before advancing to any clinical assays. The main guidelines 
for hemocompatibility testing are laid out in ISO 10993-4. Essentially, the ISO lays out 
that it is necessary to perform assays for immunology (complement system), hematology, 
platelets, thrombosis and coagulation. 
Complement activation- is the most relevant test for determining the immune response 
to a blood contacting material. It can be performed in vitro by exposing isolated 
complement proteins to the material surface and determining the decrease in total CH50 
levels, a classical approach, alternatively the determination of C3- and C5-convertase 
cleavage products formed over time. The amount of cleaved products can be easily 
determined by semi-quantitative Western blot and compared with baseline levels in 
order to determine activation of the complement system. Currently there are no clearly 
determined acceptable levels and data is generally presented as comparisons with other 
materials. The American Society for Testing and Materials (ASTM) F1984-99 and ASTM 
F2065-00 standards should be considered when assessing this particular parameter. 
Hematology– is generally assessed by determination of the hemolytic index and can be 
determined by the method suggested by the Standard Practice for Assessment of 
Hemolytic Properties of Materials from the ASTM F756-00, 2000. Additionally, leukocyte 
activation via microscopic analysis or flow cytometry, for determination of L-selectin and 
CD11b expression, are also indicators of hemolytic activity of a material. 
Pro-coagulant Activity– several tests can be explored in order to thoroughly evaluate the 
potential activation of the coagulation cascade by surface-material interaction, i.e., 
coagulation triggered by the intrinsic (or contact) activation pathway. The contact 
activation pathway is a result of direct activation of Factor XII, via conformational change 
induced by exposure to the material surface. Direct quantification of how much activated 
Factor XII is produced can be achieved by use of a chromogenic, or fluorogenic, substrate 
that is broken down by the activated form of Factor XII [21, 22]. Alternatively, indirect 
assessment of the activation of this pathway can be made by determination of the partial 
thromboplastin time or plasma recalcification profiles [23, 24].  
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Thrombogenicity- Platelet-material interactions can lead to both platelet activation 
and/or adhesion, depending on their state of activation and the presence of ligands [25, 
26]. Ultimately, the involvement of activated platelets along with the coagulation cascade 
results in the formation of a thrombus (Figure 1-2). The clearest in vitro measure of the 
thrombogenicity is the determination of whole blood clotting time through 
spectrophotometric analysis. Scanning Electron Microscopy, and to a lesser extent light 
microscopy, are also useful tools in determining platelet adhesion and activation, though 
the cues here are visual (formation of pseudopodia and platelet aggregates) rather than 
biochemical. Activation and subsequent adhesion of platelets can also be determined by 
fluorescence and confocal microscopy. Most assays suggested for determination of 
thrombogenicity must be tested in dynamic (preferably in vivo) conditions. Angiography, 
intravascular ultrasound, Doppler ultrasound, computer assisted tomography (CAT) and 
magnetic resonance imaging (MRIs) are useful tools for the determination of the in vivo 
performance in regard to percentage of occlusion and flow reduction. Also it is important 
to analyze, after in vivo placement, the gravimetric analysis of the thrombus mass and 
histological inspection of the prosthesis and surrounding tissues. 
Figure 1-2 -  - Schematic representation of activation and amplification pathways of coagulation by activator complexes 
(generating thrombin for platelet activation and fibrin formation) and thrombus formation on disrupted atherosclerotic 
plaques. 
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Platelet activation- It is paramount that platelet activation be minimized in blood 
contacting materials. The extent of free platelet activation can be easily determined by 
cytometric analysis. Platelets are exposed to the material surface and the presence of 
certain activation markers (like CD62P or CD63) determined with the use of fluorescent 
antibodies. Also, the formation of platelet aggregates due to material activation should be 
determined by means of an aggregometer. These tests can be performed both in vitro and 
in vivo. Other in vivo tests that are important for assessment of platelet activation are 
determination of platelet count, template bleeding time (as a measure of platelet 
function) or alternatively platelet function analysis with collagen filters. Additionally 
gamma labeling and platelet lifespan assays are good measures of platelet viability.  
Mechanical properties - The mechanical properties of the graft must assure adequate 
mechanical compliance. As discussed above the mechanical compliance is paramount in 
order to allow an uninterrupted pulsatile flow through the vessel matching the 
mechanical characteristics of the surrounding tissue. This parameter can be quantified 
by setting up a pulsatile flow into a graft and measuring the volume changes caused by 
the increase in pressure. The best possible graft will match the compliance of the native 
vessel it is intended to substitute. Assuring mechanical strength and compliance will 
minimize the risk of mechanical failure of the graft. 
In vivo tests - The final assays before potentially moving on to a clinical trial are in vivo 
tests. The in vivo tests can produce useful information to build on any of the 
aforementioned assays and also provide a realistic view of the behavior of the grafts in a 
complex and dynamic system that simply cannot be reproduced in vitro. These assays 
generally are performed simultaneously with some of the above tests in order to provide 
a back and forth feedback. Care should be taken into choosing an appropriate animal 
model. A rat or mouse model is an appropriate one in order to determine the feasibility 
of the graft over a significant portion of the animal´s life, since their life cycle is short 
(circa 24 months), rapidly providing insight into feasibility. However, the mechanics and 
body response of a small animal model are significantly different from those of a larger 
one and therefore other models such as dog (though today it is rarely used due to ethical 
and social issues), sheep and pig should also be considered. These larger animals provide 
many more surgical implantation options and a longer life cycle that can produce results 
that are more in line with what can be expected in humans. Another important parameter 
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is precisely the placement of the prosthetic graft. The placement in a high-flow vessel, 
such as the rat aorta or a sheep's carotid artery, will provide different results from a low-
flow vessel, such as the femoral artery of a dog or pig. Nevertheless, translation of in vivo 
results to humans is not always straightforward. 
 
Non-Degradable Polymers 
 
The current standard polymers for synthetic vascular grafts are PET (Dacron) and ePTFE 
grafts, synthetic non-degradable polymers that offer a conduit for life and limb saving 
surgeries when autografts are not available. However, as present in the market today, 
these materials have inherent problems that need to be overcome. One of the broad 
possibilities that are currently being researched is the development of novel graft that 
can be readily implanted. The solution may very well be the development of permanent 
grafts that can out-perform the current options in regards to long-term patency (Figure 
1-3). Towards that end the following are the current focus in research in this field. 
 
Poly(ethylene terephthalate) 
 
Poly(ethylene terephthalate) (PET) is a thermoplastic polymer resin of the polyester 
family. It can exist as both an amorphous and a semi-crystalline polymer depending on 
processing and thermal history. Since, its introduction in 1939 by DuPont, later patented 
in 1950 as Dacron®, it has found numerous applications namely as a synthetic fiber (over 
60% of its applications). Thermoforming applications make up the bulk of remaining uses 
found for this polymer with a small percentage being used as an engineering resin often 
in combination with glass fiber. 
It is a relatively inert, hydrophobic and bio-stable polymer that presents a high tensile 
strength (40-180MPa) and Young's modulus (3-14GPa), values varying widely based on 
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preparation and dimensions [27]. PET has been widely studied for biomedical 
applications in cardiovascular surgery, as ligaments, joint replacements, implantable 
sutures and surgical meshes [28-32]. Under the aforementioned name Dacron, it has been 
used as an aortic vascular graft as far back as 1957 when DeBakey performed a 
substitution of thoracic and abdominal aorta and of proximal peripheral vessels. To this 
day, PET is still one of the most commonly used synthetic grafts in large caliber (>8mm) 
bypass surgery performed above the waist [33] since it is a cheaper alternative to ePTFE. 
Patency rates for PET have been continuously improved and have been shown to remain 
patent for up to 8 years after implantation [34]. A prior study actually showed that PET 
Figure 1-3 - Chemical structure of non-protein polymer monomers. The chemical structure for 
polyurethane is a representation of one possible polyurethane. 
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patency could go up to 25 years, though the follow-up rate was under 20% after 10 years 
[35]. 
However, when PET vascular grafts are implanted they trigger the activation of the 
intrinsic pathway of blood coagulation resulting in surface-induced thrombosis [36]. This 
is most prevalent when the diameter of PET vascular grafts is smaller than 6mm. There 
is a considerable reaction between PET and the native artery, as well as with blood, 
causing a rapid build-up of fibrin at the blood/graft interface [37]. This is due to both the 
hydrophobic nature of PET, which has been shown to induce protein adhesion [38], and 
also the low-flow of small caliber vessels. This ultimately results in graft failure and poor 
clinical results. Hence, the patency of small-diameter PET vascular grafts needs to be 
improved. The PET vascular grafts are produced by two different methods. Woven, in an 
over-and-under pattern in the lengthwise and circumferential directions, or the more 
commonly used knit grafts, by looping the fibers in an interlocking chain, into cylindrical 
and longitudinally crimped grafts [39]. The crimping of the graft increases flexibility, 
elasticity, and kink resistance. However, after implantation, these properties are lost as a 
consequence of tissue ingrowth on average after 7 years [40]. The grafts incorporate a 
velour finish which increases the surface area. This elevates the number of anchorage 
points for both fibrin and cells in order to promote tissue integration. The 
weaving/knitting method of producing the grafts allows them to be shaped and branched 
so as to fit any needed requirements and mechanical properties can be tailored so as to 
allow for better compliance with the native arterial wall at the site of anastomosis. 
The production method of the grafts has remained essentially the same over the years. 
The knit PET grafts have been impregnated with gelatin [41], albumin [42] or collagen 
[43] in order to improve their hemocompatibility. Another approach to ameliorate 
hemocompatibility is surface modification. The chief methods of surface modification of 
blood-contacting biomaterials involve coupling bio-agents or increasing hydrophilicity. 
Heparin has been bonded onto PET grafts showing positive results, namely increasing 
plasma recalcification times [44] and overall in-patient patency [45]. Silver particles have 
also been bound to the PET grafts to reduce infection and are currently used in cases 
where an infected graft has to be substitute [15, 46, 47]. Amination, may also lead to 
improved patency without any loss of mechanical properties [48, 49]. However, the 
chemically inert nature of PET impedes significant bonding of functional groups and so 
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surface modification, such as plasma treatments, have been explored in order to augment 
the number of e.g. heparin-PET bonds.  
 
Expanded polytetrafluoroethylene 
 
Polytetrafluoroethylene (PTFE) was discovered in 1938, patented in 1941 and its 
commercial name, Teflon, trademarked in 1945 by the DuPont Co. Roy Plunkett. 
Expanded polytetrafluoroethylene (ePTFE) is a processed version of PTFE. PTFE is 
heated and rapidly stretched, the end result is that a microporous structure with 70% air 
is obtained. The process was discovered in 1969 and patented, under the name Gore-Tex, 
in 1976. PTFE and ePTFE have found numerous applications such as high-performance 
fabrics, medical implants, filter media, wire and cable insulation, gaskets, lubricants and 
sealants. 
The PTFE molecule is chemically inert and biostable, due to the nature of the carbon-
fluorine bond, and has been found to be less prone to biological deterioration than PET 
[50]. It is also very hydrophobic, due to mitigated London dispersion forces associated 
with the high electronegativity of fluorine. The electronegativity of the graft surface 
minimizes its reaction with blood components [51]. Mechanically ePTFE is stiffer than 
both the native arterial walls and PET. This can be a cause of graft failure due to pseudo-
intimal hyperplasia. The Young's modulus for these grafts is around 3-6MPa [52, 53]. 
Comparatively in native arteries and veins (in a canine model) the Young's modulus is 
around 600 (circumferentially) and 900kPa (longitudinally), while PET registers 12MPa 
circumferentially and 0.7 MPa longitudinally.  
The ePTFE graft for vascular applications, produced by extrusion, is a non-textile porous 
tube composed of irregular-shaped solid membranes (“nodes”). Between these solid 
nodes are fibrous regions and so the overall porosity of the graft is defined by its inter-
nodal distance (IND) (available options vary between 30-90µm). The first ePTFE grafts 
were first introduced experimentally in 1972 and clinically in 1975 in a portal vein 
replacement [54, 55]. PET and ePTFE are the most widely used synthetic vascular 
replacements with little difference in performance between them [56].  
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Despite the aforementioned mechanical compliance issues, ePTFE grafts are commonly 
used for peripheral vessel bypass, particularly for femoral artery bypass. However, over 
30 years since their initial appearance, research has achieved little improvement in 
regards to patency rates of ePTFE grafts [57]. Over a 5-year time period approximately 
50% of implanted grafts have been shown to be blocked [58] and over a 10 year time 
period a maximum of 28% primary patency (in above-knee femoro-popliteal bypass 
grafts) [59]. The problem with patency is exacerbated in small caliber grafts. The main 
cause of graft failure is strongly associated with thrombosis, due to the lack of endothelial 
cell coverage which leads to protein adhesion that ultimately promotes thrombosis [60-
62].  
Animal studies have demonstrated rapid endothelization after relatively short periods of 
time however, this has not transitioned into humans. After 10 years of implantation in 
human patients, the same grafts that provided a complete endothelization in animals, are 
almost completely deprived of endothelium [63]. Clinically, when endothelization does 
occur it is generally limited to 1-2cm from the anastomosis site [64]. This is partially due 
to low porosity of the standard ePTFE grafts (IND of 30µm). The low porosity does not 
allow for adequate transanastomic or trans-mural endothelization [33]. Studies have 
shown that a higher IND (60 or 90µm) promoted a more rapid endothelization in animal 
models [65, 66]. However, none of these studies have been demonstrated and proven 
clinically.  
In order to resolve the patency issues, a two-stage endothelial cell seeding protocol has 
shown to greatly enhance clinical patency rates to 90%, up to 52 weeks after 
implantation, on 3mm diameter coronary grafts [67]. Additionally, surface modification 
by carbon coating/impregnation [68], heparin coating (with the commercial name 
Propaten) [69, 70] and growth factor coating, with fibrin glue [71], have been attempted, 
though the latter seems to have been abandoned in recent years. Both carbon-coating and 
impregnation have been tested clinically and demonstrated no significant improvement 
in patency after 36 months [72, 73].  Heparin coating has been tested as a means to 
improve non-thrombogenicity and has demonstrated that, a luminal coating with 
immobilized heparin, improves primary patency and reduces intimal hyperplasia 
development over standard ePTFE grafts up to one year after implantation [74, 75].  
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Polyurethane 
 
Polyurethanes (PUs) belong to a class of compounds called reaction polymers. They arise 
from the reaction of an isocyanate with a polyol, via carbamate links. PUs are 
thermosetting polymers that form a foam that does not melt when heated. They can also 
be manufactured into a harder thermoplastic form that is used in medical applications. 
The thermoplastic PU used in medical settings present a high tensile strength, elasticity 
and ease of manipulation [76]. These mechanical and physical properties are extremely 
important in providing good mechanical compliance that ultimately prevents problems 
such as intimal hyperplasia. Along with its physical/mechanical properties, PU also 
presents good hemocompatibility, biocompatibility and microbial resistance [77, 78].  
Hemocompatibility of PU is, at least, on par with ePTFE [79]. Yet another aspect that has 
encouraged further study of PU is porosity. Fibrilar PU grafts can be produced by 
weaving, knitting, electrospinning, or winding [76, 78] while foam PU grafts can be cast 
and porosity controlled by gas expansion and laser perforation [76]. Results have shown 
good in vivo biocompatibility and accelerated endothelization in small caliber grafts 
(4mm) associated with the improved porosity. Incorporation of carbon nanotubes have 
also been explored in order to improve endothelization, in vitro, showing promising 
results [80]. Rapid endothelization (12 weeks after implantation) has been shown critical 
in preventing hyperplasia and improving patency [81]. Another approach, recently 
studied, involves a PU graft capable of controlled release of rapamycin, which inhibits the 
migration and proliferation of smooth muscle cells, thus avoiding intimal hyperplasia 
[82].  However, pore interconnectivity, a mandatory requirement in order to provide 
better tissue ingrowth, remains an issue with no clear solution. Blends of PU with 
collagen/elastin and also polycaprolactone have shown improvements in both 
mechanical compliance and cell invasion [83, 84]. 
First-generation PU grafts suffered hydrolytic biodegradation which ultimately led to the 
abortion of clinical trials [85]. Second generation PU have shown a pressing disadvantage, 
the material’s tendency to oxidize and degrade in vivo, creating problems after 
implantation, which could be overcome by chemically coating the surface with an 
antioxidant aids in reducing oxidation [86]. Given the good mechanical compliance (a 
step up as compared to ePTFE), hemocompatibility and potential for controlled porosity 
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- and despite in vivo degradation - several PU grafts are or have been studied. Mitrathane, 
Pulse-Tec, Vectra and Vascugraft are all brand names for PU grafts. Of these only Vectra 
is FDA approved however, the only application is for vascular access during hemodialysis 
which is a short-term application [87]. Continued study is necessary in order to produce 
small caliber PU graft for clinical applications. 
 
Polyvinyl Alcohol 
 
Polyvinyl Alcohol (PVA) is a nontoxic water-soluble synthetic polymer that forms a 
hydrogel once polymerized. It has excellent film-forming, emulsifying and adhesive 
properties. PVA is not prepared by polymerization of the vinyl alcohol monomer but 
rather partial or complete hydrolysis of poly(vinyl acetate). The removal of the acetate 
group can be controlled and alters the physical characteristics of the resulting PVA. This 
polymer presents high tensile strength and its flexibility is dependent on humidity. The 
water acts as a plasticizer, reducing tensile strength, but increasing elongation and tear 
strength. 
PVA-based materials can be prepared by casting and then cross-linked by irradiation, 
physical (by thermal cycling) or chemical treatment [88, 89]. The resulting hydrogels can 
be fine-tuned to present varying mechanical and physical properties, depending on 
number of hydrogen bonds. The hydrogel is biocompatible and non-irritating to soft 
tissues and, therefore, it has been of great interest in pharmaceutical and biomedical 
applications [90-92]. The FDA approved the use of PVA microspheres as an embolization 
agent and further applications have been found as contact lenses, wound dressings, 
coating agent for pharmaceuticals and catheters [93, 94]. 
As a potential vascular graft, PVA has been studied both on its own [95] and composited 
with other materials [96-98]. Several combinations of PVA with other synthetic and 
natural polymers, such as gelatin, chitosan, starch and bacterial cellulose, have been 
proposed and studied. In general, these studies have all presented positive results in 
regards to hemocompatibility, biocompatibility and mechanical compliance. The intent 
behind the formulation of these composites is generally to enhance endothelial cell 
adhesion and proliferation. Gelatin and chitosan are probably the most well studied of 
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these combinations and have demonstrated good hemocompatibility and endothelization 
[99-102]. The PVA/bacterial cellulose composite was conceived as a means to enhance 
the mechanical properties of the PVA hydrogel, while still maintaining elasticity and 
malleability [96-98]. One of the rare studies demonstrating the in vivo performance of 
PVA based tubular structures was produced by Chaouat and colleagues [95]. In this study, 
a PVA sheet was either stitched or glued into a tubular shape and showed good patency 
after 1 week in a rat model. Extensive in vivo studies of vascular grafts of this kind are still 
lacking and so further work is needed to demonstrate its potential.  
 
Bacterial Cellulose 
 
Cellulose is the most abundant organic compound on Earth, a linear polysaccharide with 
β (1→4)–linked D-glucose monomers. Chemically, bacterial and plant cellulose are 
identical; however, bacterial cellulose (BC) is obtained pure (free of lignin, pectin or 
hemicellulose). It is produced, mainly by the Gluconacetobacter genus, as a fibrous 
network hydrogel at air-medium interfaces [103, 104]. The bacteria that produce 
cellulose are obligatory aerobes and produce the hydrogel as a pellicle [104], which can 
be exploited to grow into three-dimensional structures given that a three-dimensional 
oxygen permeable support is provided [105-107]. 
The BC hydrogel has several beneficial properties for use in the biomedical field, namely: 
high purity, high water-holding capacity, morphology, tensile strength, malleability, 
hemocompatibility and biocompatibility [103, 108, 109]. These characteristics have led 
to BC being long studied for biomedical applications such as wound dressings [110-112], 
artificial skin [113], tissue engineering scaffold [23, 104, 109, 114], synthetic dura mater 
[115] and as a vascular graft [107, 108, 116-118].  
Several studies addressed the use of BC as a vascular graft and have shown its potential. 
Dieter Klemm and his group have looked at the in vivo behavior of small diameter BC 
tubes. These studies, carried out over 4weeks, and later over 3 months, in a rat model, 
showed that a small diameter BC tube can remain patent in vivo [108, 118]. These studies 
also showed that in the course of the 4 weeks the BC grafts were completely covered with 
connective tissue and, after 3 months, the formation of a neointima. Another study later 
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demonstrated that, under the registered name BASYC, BC tubes remained patent, in mice, 
for up to a year. However, in vitro studies have shown that, while minimal, BC does 
slightly trigger coagulation. Indeed, studies by both Andrade et al and Fink et al [23, 119, 
120] showed that BC minimally activates coagulation. However, another study from the 
same group demonstrate that, comparing to ePTFE, BC has superior hemocompatibility, 
as assessed by the analysis of the activation of platelets and of the intrinsic pathway of 
hemostasis [24]. Attempting to improve the BC hemocompatibility, these authors used 
engineered cell-adhesion peptides (such as RGD), linked to a carbohydrate binding 
module, allowing the number and proliferation of endothelial cells on BC to be further 
improved [104].  
Surface modification via plasma treatment and addition of aminoalkyl groups has been 
shown to alter the surface properties of BC. Cell adhesion and proliferation was improved 
with plasma treatment and addition of aminoalkyl groups demonstrated antimicrobial 
properties similar to chitosan, these approaches may ultimately prove useful for 
improving vascular grafts [121, 122]. 
A drawback to BC is that it is not biodegradable; furthermore, its porosity is insufficient 
for cell ingrowth to take place. This limits the potential in regards to producing a graft 
that could, eventually, be substituted integrally by newly formed tissue. Despite this, the 
potential of BC for in vitro and in vivo tissue regeneration continues to be explored and 
shows great promise [107, 109, 116, 117]. 
 
Degradable Polymers and Tissue Engineered vessels 
 
A large portion of recent research into the development of novel vascular grafts has been 
focused on tissue-engineering approaches, by prior cell-seeding or by providing a scaffold 
that can be colonized in vivo by native cells, through migration and adhesion. A 
permanent vascular graft must offer definitive solutions especially in regards to long-
term patency and structural integrity that, at the moment, have yet to be achieved. 
Therefore, a possible solution has focused on providing a biodegradable scaffold, which 
temporarily serves as a conduit for blood flow while allowing cells to grow and break-
down the grafts, simultaneously producing native tissue and ultimately a new vessel 
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(Figure 1-4). The following degradable polymers are the current focus of research in 
attempts to provide a tissue-engineered approach to the vascular graft development field. 
 
Polycaprolactone 
 
Polycaprolactone (PCL) is a hydrophobic synthetic biodegradable polyester that has 
received a great deal of attention for use as an implantable biomaterial. This is due to its 
good mechanical properties, good biocompatibility and also, in large part, due to its slow 
biodegradability. PCL sheets have good mechanical properties but are somewhat limited 
in terms of compliance, though it is at least comparable to ePTFE and PET. It is however 
generally accepted that, as it is degraded and substituted by native tissue, compliance 
should improve over time due to elastogenesis [19]. 
Under physiological condition, such as in the human body, PCL suffer hydrolysis of its 
ester linkages. Generally, biodegradable graft approaches are viewed with some reserve. 
If in vivo degradation occurs too rapidly, as compared to overall cell growth, mechanical 
failure may occur ultimately leading to subsequent aneurysms and ruptures, which in 
turn can lead to internal bleeding and death. Degradation of PCL occurs at slow enough a 
pace, taking over 24 months to be completely absorbed, such that mechanical strength is 
guaranteed during cell invasion [19].  
PCL grafts can be easily generated by electrospinning with varying pore sizes and 
prosthesis thicknesses. This has led to several studies focusing on determining the 
Figure 1-4 - ECM organization and quantification at 90 days. (a) Verhoeff's, Masson's trichrome, and safranin O staining 
show elastin (black), collagen (blue), and glycosaminoglycansin (red). Immunofluorescent staining shows distribution of 
elastin (red), collagen I (green), and collagen III (red). Top: day 90 explant, bottom: native aorta. (Adapted by permission 
from Macmillan Publishers Ltd: Nature Medicine (Wu et al. J Mater Sci Mater Med. 2010, 21(12)3207-3215), copyright 
2012) 
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feasibility of an electrospun PCL vascular graft over the last 6 years [19, 123-127]. Several 
studies, performed in rat, both showed rapid and stable endothelization which were 
responsible for good cell invasion and patency over the course of the studies, as 
compared to ePTFE [19, 127-129]. However, the poor mechanical compliance and loose 
cell attachment showed some development of intimal hyperplasia in all the studies [19]. 
The long term studies also revealed a propensity for calcification of the prosthesis over 
time (usually in the last months of the assays) although they did not affect the end-term 
patency of the graft. 
In order to improve the mechanical compliance, issues that PCL has exhibited in vivo, 
several studies have focused on either pre-seeding the grafts with vascular endothelium 
cells [130] or creating nanocomposite grafts, with collagen, elastin and polylactide 
(Figure 1-5), all showing improved in vivo patency [131-133]. Similar approaches involve 
surface functionalization or the creation of a polymeric system (inclusion of bioactive 
molecules in the polymer fibers during the electrospinning process) which have also 
shown promising results, improving endothelial cell adhesion and hemocompatibility 
[134, 135]. Hybrid approaches of both incorporating other polymers and bioactive 
molecules have shown positive results [136, 137]. 
 
Collagen 
 
Collagen is the most abundant group of proteins found in animals, the most common 
among which is Collagen I. Once irreversibly hydrolyzed, collagen originates gelatin. It is 
the main component of the body; making up 25 to 35% of the protein content. As 
elongated fibrils, collagen can be found in many fibrous tissues of the body, such as 
tendons, ligaments and skin, and is also abundant in cartilage, bone, gut, inter-vertebral 
discs and blood vessels [138].  
As one of the major body components, it is biocompatible, biodegradable and has the 
advantage of being easily synthesized. This has led to it being abundantly researched for 
application in fields such as skin, cartilage, bone and vascular engineering and, 
additionally, as a drug delivery system [139-141]. The most common method of 
producing vascular collagen grafts is by electrospinning; however, the chemical nature of 
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collagen makes it sensible to deterioration during the process. The alternate option is to 
use a cross-linking agent to create the tubular prosthesis. Glutaraldehyde is used for this 
purpose, and while increasing strength it often carries the risk of increased toxicity and 
calcification. Also, without the aided mechanical support provided by seeded cells or 
other stabilizing polymers, collagen tubes are mechanically weak [142]. On top of all this, 
it is difficult to precisely control the mechanical behavior of the grafts due to a lack of 
means to do so. Other than the mechanical compliance issues, and most importantly, 
Figure 1-5 - Macroscale characterization of a tissue engineering approach using a 
polycaprolactone/poly(l-lactic acid) grafts. (A) A graft before implantation. (B) A graft 
right after implantation. (C) A heparin-SDF-1α-treated graft at 4 weeks after implantation. 
Arrow indicates microvessels in the wall of the graft. (D–F) H&E staining of an untreated 
graft (D), a heparin-treated graft (E) and a heparin-SDF-1α-treated graft (F) at 4 weeks 
after implantation. Arrows in D indicate thrombus formation. (Adapted from Biomaterials, 
33(32), Yu et al, The effect of stromal cell-derived factor-1alpha/heparin coating of 
biodegradable vascular grafts on the recruitment of both endothelial and smooth muscle 
progenitor cells for accelerated regeneration, 8062-74, Copyright 2012, with permission 
from Elsevier) 
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collagen is also well documented as thrombogenic and a pro-coagulant [143-146]. 
Indeed, while a constituent of the extra cellular matrix, collagen is normally not exposed 
to circulating blood. Once exposed, it triggers the activation of the Hageman factor and 
promote clotting and healing of an injured site [146]. 
Studies have, therefore, mainly focused on combinations of collagen and other polymers 
[125, 142, 147, 148], bioactive molecules [145] or cell seeding [149]. Cells easily adhere 
to collagen matrices and so many studies have focused on cell seeding (as mentioned 
above) with the dual intention of enhancing mechanical compliance and especially 
hemocompatibility. These approaches have provided a scaffold with adequate 
characteristics for small diameter vessels. A cell seeded collagen substrate with 
immobilized heparin demonstrated enhanced hemocompatibility and endothelial cell 
adhesion [145]. Some studies have researched the possibility of pure collagen prosthesis. 
A 2 mm (outer diameter) collagen vessel, seeded with both endothelial and smooth 
muscle cells, remained patent, in vivo, after 12 weeks [149].  
Ultimately, collagen I and its blends outperform many synthetic polymers by providing 
an extracellular matrix that is beneficial to cell differentiation and proliferation, with 
adequate mechanical behavior, given certain conditions are met [150]. The greatest 
application of collagen seems to be associated with enhancing other polymer grafts in a 
"supporting" role. Collagen shows therefore great potential; a construct consisting solely 
of collagen with no harmful crosslinking agent and adequate mechanical compliance and 
hemocompatibility would be a serious competitor in vascular tissue engineering. 
 
Elastin 
 
Elastin is a hydrophobic connective tissue protein polymer consisting of post-
translational modified and cross-linked tropoelastin monomers. As its name suggests it 
is elastic and allows tissues to retain shape memory, dictating tissue mechanics at low 
strains and preventing tissue creep [151]. At higher mechanical strains collagen then 
assumes the role of providing mechanical resistance, due to the low maximum tensile 
strength of elastin.  Elastin is the dominant extracellular matrix protein in arterial walls; 
organized as concentric rings around the medial layer of arteries and making up roughly 
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50% of their dry weight [152]. Elastin exhibits low thrombogenicity and several vascular 
devices, coated with elastin-based polypeptides, demonstrated reduced platelet adhesion 
and activation, overall improving in vivo patency [153, 154]. Additionally, elastin is an 
autocrine regulator of smooth muscle cell (SMC) activity that has an essential role in 
preventing fibrocellular pathology and regulating proliferation [155].  
The importance of the elastic properties and SMC regulatory activity has led to many 
studies aimed at inducing elastin biosynthesis in tissue-engineered vascular grafts. 
Several studies, using static collagen scaffolds seeded with SMC, did not show adequate 
elastin production [156-158]. However, further studies have shown that elastogenesis 
can be significantly improved by changing the scaffold substrate [151, 159], providing a 
mechanical stimuli [160-163] and also by the use of growth factors [151]. These cell 
seeding approaches have shown some success in promoting elastin deposition, the end 
result being the intended improvement in mechanical behavior, biocompatibility and 
hemocompatibility.  
Besides cell seeding, several methods of producing vascular grafts that incorporate 
elastin have been studied [164, 165]. Collagen [166], polyurethane [167], 
polydioxanone[168], PCL [169], gelatin and recently polyethylene glycol [170], and also 
combinations of these polymers [125], have all been electrospun into hybrid tubular 
grafts, with elastin, to produce viable vascular grafts. These approaches all have similar 
objectives, to limit the degradation rate and provide high mechanical resistance while 
allowing for the beneficial mechanical and chemotactic performance of elastin. As such, 
they have all shown potential in regards to mechanical, bio- and hemocompatibility.  
Attempts of incorporating elastin in tissue-engineered products and designing 
biocompatible synthetic elastic polymers are, however, still insufficient. A major 
drawback of a viable elastin graft is cost related. Tropoelastin is hydrophilic and easily 
susceptible to proteolysis, it is hard to isolate and readily reacts with other monomers. 
The main source of elastin - extraction from animal tissues - provides small amounts of 
the polymer at relatively high cost due to its insolubility in water, which prevents the use 
of conventional wet-chemistry techniques [171]. Further studies are needed to 
understand elastin biosynthesis in order to produce adequate elastin-incorporating 
and/or elastin-based grafts at cost-efficient methods. 
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Fibrin 
 
Fibrin is the end-product of the coagulation cascade, produced by the conversion of 
fibrinogen to fibrin monomers, which polymerizes into an insoluble fibrin hydrogel 
network [172]. Fibrin seems an ideal scaffold for tissue regeneration since, in vivo, it acts 
as a "physiological scaffold" and plays a role in hemostasis, inflammation, wound healing 
and angiogenesis [173-175]. It has also been shown to promote cell migration into tissue-
engineered constructs, the cells then gradually replace the fibrin scaffold with native 
extra cellular matrix [176, 177].  
Fibrinogen can be isolated from the same patient that would receive the graft, thus 
lowering the risks of body reaction and infection [172, 178]. Conventionally fibrinogen is 
isolated from platelet poor plasma after freezing and thawing. However, this method of 
isolation has disadvantages: the quantity yield is relatively low (20-25%) and the 
production process is time consuming (2 days) [179]. The low yields would require large 
amounts of donor blood which is not a viable option. Alternative precipitation methods 
have been studied and, among them; ethanol precipitation, was found to be the most 
efficient with ~80% of fibrinogen precipitated [180].  
Fibrin has been used as a coating in vascular prosthetics in order to enhance the hemo- 
and biocompatibility of synthetic grafts [181]. Fibrin based vascular grafts have been 
studied towards applications in coronary and peripheral artery bypass, arterio-venous 
access grafts or for congenital pulmonary artery reconstruction in children [179]. 
However, the fibrin gel lacks suitable mechanical properties. The grafts generally contain 
a supporting, bioresorbable, macroporous mesh. The meshes provide the required 
mechanical support while prior cell seeding remodels the fibrin matrix. Polylactide [182] 
and polyglactin [183] have been used as support structures. The tubular prosthesis is 
then generally seeded with different combinations of EC, SMC and myofibroblasts and 
incubated before implantation [182] and have been shown to remain patent for up to 6 
months [184]. The major drawback with these approaches is the extremely long 
production time for the graft (circa 22 days) which prevents its application as an 
immediate alternative to current synthetic alternatives ePTFE and PET. 
 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
30 
Silk 
 
Silk is a natural protein polymer composed of two proteins: fibroin, the insoluble protein 
that is the main structural center of the silk fiber; and sericin, a water soluble protein that 
forms a gum coating the fibers and allowing them to stick to each other. Most of the silk 
produced and used worldwide is obtained from the pupating larvae of the mulberry 
silkworm Bombyx mori. The cocoons are then soaked in boiling water, to soften the 
sericin, and the fibers unwound to produce a continuous silk thread.  Fibroin and sericin 
are separated in a degumming process. The resulting silk fibroin forms protein fibers 
with high tensile strength and high toughness, which have long found a home in medicine 
as a suture. From aqueous or organic solutions of silk fibroin it's also possible to form 
films, sponges, powder, gels and the regenerated fibers.  
Silk fibroin has many of the requirements of a good biomaterial: it has good mechanical 
properties, biocompatibility, hemocompatibility, low immunogenicity and is 
biodegradable [185-187]. This has led to it being extensively studied for biomedical 
applications [186, 188-195]. For vascular grafts, in particular, the biocompatibility of silk 
is extremely important. Cell adhesion and growth on silk scaffolds has been shown to be 
very good [196-199] and, with the aid of recent biotechnology developments, 
improvements can be made further enhancing cell adhesion [200]. The inclusion of cell-
adhesive sequences into the fibroin amino-acid sequence has been shown to enhance cell 
adhesion [195, 199, 201]. This cytocompatibility of silk fibroin has even led it to be 
studied as a coating for other polymeric materials in order to enhance cell adhesion [202]. 
As vascular grafts, silk fibroin can be woven [203], knitted [204], braided [205] or 
electrospun (using polyethylene oxide as an additive) [199] in order to produce tubular 
grafts with an open porous structure, this can easily be controlled through control of the 
flow rate [206]. Knitting and braiding require coating with an aqueous solution of silk 
fibroin, and usually another polymer such as poly(propylene glycol) dimethyl ether, in 
order to seal the graft and control permeability, mechanical behavior and pore size [204]. 
Some studies have already shown that vascular grafts of silk fibroin can be successful in 
small diameter applications [199, 204, 205]. A 1.5mm (inner diameter) by 10mm (length) 
graft was sutured, end-to-end, to a rat abdominal aorta and was shown to remain patent 
for 12 weeks in 85% of the cases [205]. The patency of the silk graft was largely due to 
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the almost complete cell coverage of the luminal surface, which was achieved after 9 
weeks [205]. A similar study was also performed on the carotid artery of a canine model 
using 3mm diameter tubes and showing of up to one year in one of the implanted grafts 
[204]. 
 
Next Steps for Polymeric Grafts 
 
The future of synthetic vascular graft development seems very promising. The field is 
every growing and the lack of a clear optimal polymer has led, and continues to lead, to 
many potential options. Either by further development and research into the already 
existing grafts (PET and ePTFE), the further development of new non-degradable grafts 
(PU, PVA and BC) or researching and developing temporary grafts that ultimately allow 
for a tissue engineered solution, either by prior cell-seeding or allowing for native cell 
migration, attachment and ingrowth, ultimately producing a new vessel out of native 
tissue (collagen, fibrin, elastin, silk and PCL). 
In further years research seems like it will focus on the end development and fine tuning 
of either a nanocomposite or surface modified solution, with bioactive molecules, through 
in vivo testing. The nanocomposites approach seems to be the most common trend in the 
development of a tissue-engineered vessel. This method offers the possibility of 
combining the favorable properties of one polymer with the favorable properties of 
another, usually providing positive results with little or none of the drawbacks. 
Those that have been mentioned here are the basis of the research that is currently 
ongoing and each has a beneficial aspect to contribute to the field. Alternatively, the 
surface modification of some of the above mentioned polymers may provide a viable 
alternative for a ready and off-the-shelf solution. The efforts of all the researchers in these 
fields will almost certainly provide a new graft that can out-perform the current 
standards and vastly improve the quality of life for millions. 
  
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
32 
References 
 
[1] Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart Disease 
and Stroke Statistics—2013 Update A Report From the American Heart Association. 
Circulation. 2012. 
[2] Defraigne J-O. Development of Atherosclerosis for the Vascular Surgeon. In: Liapis C, 
Balzer K, Benedetti-Valentini F, Fernandes e Fernandes J, editors. Vascular Surgery: 
Springer Berlin Heidelberg; 2007. p. 23-34. 
[3] Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. 
Angiotensin II-mediated hypertension in the rat increases vascular superoxide 
production via membrane NADH/NADPH oxidase activation. Contribution to alterations 
of vasomotor tone. J Clin Invest. 1996;97:1916-23. 
[4] Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial 
superoxide anion production. J Clin Invest. 1993;91:2546-51. 
[5] Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused 
by elevated glucose. Am J Physiol. 1992;263:H321-6. 
[6] Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical 
therapeutic approaches. Vasc Med. 1998;3:231-9. 
[7] Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially 
modifiable risk factors associated with myocardial infarction in 52 countries (the 
INTERHEART study): case-control study. Lancet. 2004;364:937-52. 
[8] Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society 
Consensus for the Management of Peripheral Arterial Disease (TASC II). Journal of 
vascular surgery. 2007;45 Suppl S:S5-67. 
[9] Rutherford RB. Vascular Surgery, 2 Volume Set. Philadelphia, PA: W.B. Saunders 
Company; 2000. 
[10] Panneton JM, Hollier LH, Hofer JM. Multicenter randomized prospective trial 
comparing a pre-cuffed polytetrafluoroethylene graft to a vein cuffed 
polytetrafluoroethylene graft for infragenicular arterial bypass. Ann Vasc Surg. 
2004;18:199-206. 
[11] Nguyen LL, Conte MS, Menard MT, Gravereaux EC, Chew DK, Donaldson MC, et al. 
Infrainguinal vein bypass graft revision: factors affecting long-term outcome. Journal of 
vascular surgery. 2004;40:916-23. 
[12] White CJ, Gray WA. Endovascular Therapies for Peripheral Arterial Disease: An 
Evidence-Based Review. Circulation. 2007;116:2203-15. 
[13] Mughal NA, Russell DA, Ponnambalam S, Homer-Vanniasinkam S. Gene therapy in 
the treatment of peripheral arterial disease. The British journal of surgery. 2012;99:6-15. 
[14] Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FG, Gillespie I, et al. Bypass versus 
Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and 
overall survival by treatment received. Journal of vascular surgery. 2010;51:18S-31S. 
[15] Bisdas T, Wilhelmi M, Haverich A, Teebken OE. Cryopreserved arterial homografts 
vs silver-coated Dacron grafts for abdominal aortic infections with intraoperative 
evidence of microorganisms. Journal of vascular surgery. 2011;53:1274-81 e4. 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
33 
[16] Moawad J, Gagne P. Adjuncts to improve patency of infrainguinal prosthetic bypass 
grafts. Vasc Endovascular Surg. 2003;37:381-6. 
[17] Fabiani JN, Julia P, Chemla E, Birnbaum PL, Chardigny C, D'Attellis N, et al. Is the 
incidence of recurrent carotid artery stenosis influenced by the choice of the surgical 
technique? Carotid endarterectomy versus saphenous vein bypass. Journal of vascular 
surgery. 1994;20:821-5. 
[18] Veldenz HC, Kinser R, Yates GN. Carotid graft replacement: a durable option. Journal 
of vascular surgery. 2005;42:220-6. 
[19] de Valence S, Tille JC, Mugnai D, Mrowczynski W, Gurny R, Moller M, et al. Long term 
performance of polycaprolactone vascular grafts in a rat abdominal aorta replacement 
model. Biomaterials. 2012;33:38-47. 
[20] Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage 
specification. Cell. 2006;126:677-89. 
[21] Sperling C, Fischer M, Maitz MF, Werner C. Blood coagulation on biomaterials 
requires the combination of distinct activation processes. Biomaterials. 2009;30:4447-
56. 
[22] Fink H, Faxalv L, Molnar GF, Drotz K, Risberg B, Lindahl TL, et al. Real-time 
measurements of coagulation on bacterial cellulose and conventional vascular graft 
materials. Acta biomaterialia. 2010;6:1125-30. 
[23] Andrade FK, Silva JP, Carvalho M, Castanheira EM, Soares R, Gama M. Studies on the 
hemocompatibility of bacterial cellulose. Journal of biomedical materials research Part A. 
2011;98:554-66. 
[24] Leitão AF, Gupta S, Silva JP, Reviakine I, Gama M. Hemocompatibility study of a 
bacterial cellulose/polyvinyl alcohol nanocomposite. Colloids and Surfaces B: 
Biointerfaces. 2013;111:493-502. 
[25] Godo MN, Sefton MV. Characterization of transient platelet contacts on a polyvinyl 
alcohol hydrogel by video microscopy. Biomaterials. 1999;20:1117-26. 
[26] Sheppard JI, McClung WG, Feuerstein IA. Adherent platelet morphology on adsorbed 
fibrinogen: Effects of protein incubation time and albumin addition. Journal of Biomedical 
Materials Research. 1994;28:1175-86. 
[27] Northolt MG, den Decker P, Picken SJ, Baltussen JJM, Schlatmann R. The Tensile 
Strength of Polymer Fibres.  Polymeric and Inorganic Fibers: Springer Berlin Heidelberg; 
2005. p. 1-108. 
[28] Rajendran S, Anand SC. DEVELOPMENTS IN MEDICAL TEXTILES. jotp. 2002;32:1-42. 
[29] Ventura A, Terzaghi C, Legnani C, Borgo E, Albisetti W. Synthetic grafts for anterior 
cruciate ligament rupture: 19-year outcome study. Knee. 2010;17:108-13. 
[30] Bodugoz-Senturk H, Macias CE, Kung JH, Muratoglu OK. Poly(vinyl alcohol)-
acrylamide hydrogels as load-bearing cartilage substitute. Biomaterials. 2009;30:589-96. 
[31] Buchensk J, Slomkowski S, Tazbir JW, Sobolewska E. Poly(ethylene terephthalate) 
yarn with antibacterial properties. Journal of biomaterials science Polymer edition. 
2001;12:55-62. 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
34 
[32] Zieren J, Neuss H, Paul M, Müller J. Introduction of polyethylene terephthalate mesh 
(KoSa hochfest&lt;sup&gt;®&lt;/sup&gt;) for abdominal hernia repair: An animal 
experimental study. Bio-Medical Materials and Engineering. 2004;14:127-32. 
[33] Menu P, Stoltz JF, Kerdjoudj H. Progress in vascular graft substitute. Clinical 
Hemorheology and Microcirculation. 2013;53:117-29. 
[34] Prager MR, Hoblaj T, Nanobashvili J, Sporn E, Polterauer P, Wagner O, et al. Collagen- 
versus gelatine-coated Dacron versus stretch PTFE bifurcation grafts for aortoiliac 
occlusive disease: Long-term results of a prospective, randomized multicenter trial. 
Surgery. 2003;134:80-5. 
[35] Nevelsteen A, Wouters L, Suy R. Long-term patency of the aortofemoral Dacron graft. 
A graft limb related study over a 25-years period. J Cardiovasc Surg (Torino). 
1991;32:174-80. 
[36] Hanson SR, Kotze HF, Savage B, Harker LA. Platelet interactions with Dacron vascular 
grafts. A model of acute thrombosis in baboons. Arteriosclerosis, Thrombosis, and 
Vascular Biology. 1985;5:595-603. 
[37] Salacinski HJ, Goldner S, Giudiceandrea A, Hamilton G, Seifalian AM, Edwards A, et al. 
The mechanical behavior of vascular grafts: a review. Journal of biomaterials 
applications. 2001;15:241-78. 
[38] Holmberg M, Hou X. Competitive protein adsorption of albumin and immunoglobulin 
G from human serum onto polymer surfaces. Langmuir. 2010;26:938-42. 
[39] Hake U, Gabbert H, Iversen S, Jakob H, Schmiedt W, Oelert H. Evaluation of the healing 
of precoated vascular dacron prostheses. Langenbecks Archiv für Chirurgie. 
1991;376:323-9. 
[40] Van Damme H, Deprez M, Creemers E, Limet R. Intrinsic Structural Failure of 
Polyester (Dacron) Vascular Grafts. A General. Acta chir belg. 2005;105:249-55. 
[41] Vogt PR, Brunner-LaRocca HP, Lachat M, Ruef C, Turina MI. Technical details with 
the use of cryopreserved arterial allografts for aortic infection: influence on early and 
midterm mortality. Journal of vascular surgery. 2002;35:80-6. 
[42] Cziperle DJ, Joyce KA, Tattersall CW, Henderson SC, Cabusao EB, Garfield JD, et al. 
Albumin impregnated vascular grafts: albumin resorption and tissue reactions. J 
Cardiovasc Surg (Torino). 1992;33:407-14. 
[43] Scott SM, Gaddy LR, Sahmel R, Hoffman H. A collagen coated vascular prosthesis. J 
Cardiovasc Surg (Torino). 1987;28:498-504. 
[44] Koromila G, Michanetzis GP, Missirlis YF, Antimisiaris SG. Heparin incorporating 
liposomes as a delivery system of heparin from PET-covered metallic stents: effect on 
haemocompatibility. Biomaterials. 2006;27:2525-33. 
[45] Lev EI, Assali AR, Teplisky I, Rechavia E, Hasdai D, Sela O, et al. Comparison of 
outcomes up to six months of Heparin-Coated with noncoated stents after percutaneous 
coronary intervention for acute myocardial infarction. Am J Cardiol. 2004;93:741-3. 
[46] Kowalik Z, Kucharski A, Hobot J. Use of dacron vascular prosthesis impregnated with 
salts of silver, in treatment of extraanatomical axilla-femoral by-pass's infection. 
Infections in vascular surgery. Polim Med. 2002;32:80-4. 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
35 
[47] Jeanmonod P, Laschke MW, Gola N, von Heesen M, Glanemann M, Dold S, et al. Silver 
acetate coating promotes early vascularization of Dacron vascular grafts without 
inducing host tissue inflammation. Journal of vascular surgery. 2013. 
[48] Noel S, Liberelle B, Yogi A, Moreno MJ, Bureau MN, Robitaille L, et al. A non-damaging 
chemical amination protocol for poly (ethylene terephthalate)–application to the design 
of functionalized compliant vascular grafts. Journal of Materials Chemistry B. 2013;1:230-
8. 
[49] Li P, Cai X, Wang D, Chen S, Yuan J, Li L, et al. Hemocompatibility and anti-biofouling 
property improvement of poly(ethylene terephthalate) via self-polymerization of 
dopamine and covalent graft of zwitterionic cysteine. Colloids and Surfaces B: 
Biointerfaces. 2013;110:327-32. 
[50] Guidoin R, Chakfe N, Maurel S, How T, Batt M, Marois M, et al. Expanded 
polytetrafluoroethylene arterial prostheses in humans: histopathological study of 298 
surgically excised grafts. Biomaterials. 1993;14:678-93. 
[51] Chlupac J, Filova E, Bacakova L. Blood vessel replacement: 50 years of development 
and tissue engineering paradigms in vascular surgery. Physiol Res. 2009;58 Suppl 
2:S119-39. 
[52] Grigioni M, Daniele C, D'avenio G, Barbaro V. Biomechanics and hemodynamics of 
grafting. Billerica, MA: WIT Press, 2003. 2003:41-82. 
[53] Lee JM, Wilson GJ. Anisotropic tensile viscoelastic properties of vascular graft 
materials tested at low strain rates. Biomaterials. 1986;7:423-31. 
[54] Soyer T, Lempinen M, Cooper P, Norton L, Eiseman B. A new venous prosthesis. 
Surgery. 1972;72:864-72. 
[55] Norton L, Eiseman B. Replacement of portal vein during pancreatectomy for 
carcinoma. Surgery. 1975;77:280-4. 
[56] Roll S, Muller-Nordhorn J, Keil T, Scholz H, Eidt D, Greiner W, et al. Dacron vs. PTFE 
as bypass materials in peripheral vascular surgery--systematic review and meta-analysis. 
BMC Surg. 2008;8:22. 
[57] Greisler HP. New biologic and synthetic vascular prostheses: R.G. Landes Co.; 1991. 
[58] Veith FJ, Gupta SK, Ascer E, White-Flores S, Samson RH, Scher LA, et al. Six-year 
prospective multicenter randomized comparison of autologous saphenous vein and 
expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. 
Journal of vascular surgery. 1986;3:104-14. 
[59] van Det RJ, Vriens BH, van der Palen J, Geelkerken RH. Dacron or ePTFE for femoro-
popliteal above-knee bypass grafting: short- and long-term results of a multicentre 
randomised trial. European journal of vascular and endovascular surgery : the official 
journal of the European Society for Vascular Surgery. 2009;37:457-63. 
[60] Pevec WC, Darling RC, L'Italien GJ, Abbott WM. Femoropopliteal reconstruction with 
knitted, nonvelour Dacron versus expanded polytetrafluoroethylene. Journal of vascular 
surgery. 1992;16:60-5. 
[61] Jensen LP, Lepantalo M, Fossdal JE, Roder OC, Jensen BS, Madsen MS, et al. Dacron or 
PTFE for above-knee femoropopliteal bypass. a multicenter randomised study. European 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
36 
journal of vascular and endovascular surgery : the official journal of the European Society 
for Vascular Surgery. 2007;34:44-9. 
[62] Lu S, Sun X, Zhang P, Yang L, Gong F, Wang C. Local hemodynamic disturbance 
accelerates early thrombosis of small-caliber expanded polytetrafluoroethylene grafts. 
Perfusion. 2013. 
[63] Zilla P, Brink J, Human P, Bezuidenhout D. Prosthetic heart valves: catering for the 
few. Biomaterials. 2008;29:385-406. 
[64] Berger K, Sauvage LR, Rao AM, Wood SJ. Healing of arterial prostheses in man: its 
incompleteness. Ann Surg. 1972;175:118-27. 
[65] Clowes AW, Kirkman TR, Reidy MA. Mechanisms of arterial graft healing. Rapid 
transmural capillary ingrowth provides a source of intimal endothelium and smooth 
muscle in porous PTFE prostheses. Am J Pathol. 1986;123:220-30. 
[66] Cameron BL, Tsuchida H, Connall TP, Nagae T, Furukawa K, Wilson SE. High porosity 
PTFE improves endothelialization of arterial grafts without increasing early 
thrombogenicity. J Cardiovasc Surg (Torino). 1993;34:281-5. 
[67] Laube HR, Duwe J, Rutsch W, Konertz W. Clinical experience with autologous 
endothelial cell-seeded polytetrafluoroethylene coronary artery bypass grafts. J Thorac 
Cardiovasc Surg. 2000;120:134-41. 
[68] Venkatraman S, Boey F, Lao LL. Implanted cardiovascular polymers: Natural, 
synthetic and bio-inspired. Progress in Polymer Science. 2008;33:853-74. 
[69] Heyligers JM, Lisman T, Verhagen HJ, Weeterings C, de Groot PG, Moll FL. A heparin-
bonded vascular graft generates no systemic effect on markers of hemostasis activation 
or detectable heparin-induced thrombocytopenia-associated antibodies in humans. 
Journal of vascular surgery. 2008;47:324-9; discussion 9. 
[70] Hoshi RA, Van Lith R, Jen MC, Allen JB, Lapidos KA, Ameer G. The blood and vascular 
cell compatibility of heparin-modified ePTFE vascular grafts. Biomaterials. 2013;34:30-
41. 
[71] Zarge JI, Gosselin C, Huang P, Vorp DA, Severyn DA, Greisler HP. Platelet deposition 
on ePTFE grafts coated with fibrin glue with or without FGF-1 and heparin. J Surg Res. 
1997;67:4-8. 
[72] Kapfer X, Meichelboeck W, Groegler FM. Comparison of carbon-impregnated and 
standard ePTFE prostheses in extra-anatomical anterior tibial artery bypass: a 
prospective randomized multicenter study. European journal of vascular and 
endovascular surgery : the official journal of the European Society for Vascular Surgery. 
2006;32:155-68. 
[73] Akers DL, Du YH, Kempczinski RF. The effect of carbon coating and porosity on early 
patency of expanded polytetrafluoroethylene grafts: an experimental study. Journal of 
vascular surgery. 1993;18:10-5. 
[74] Pedersen G, Laxdal E, Ellensen V, Jonung T, Mattsson E. Improved patency and 
reduced intimal hyperplasia in PTFE grafts with luminal immobilized heparin compared 
with standard PTFE grafts at six months in a sheep model. J Cardiovasc Surg (Torino). 
2010;51:443-8. 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
37 
[75] Saxon RR, Chervu A, Jones PA, Bajwa TK, Gable DR, Soukas PA, et al. Heparin-bonded, 
Expanded Polytetrafluoroethylene-lined Stent Graft in the Treatment of Femoropopliteal 
Artery Disease: 1-Year Results of the VIPER (Viabahn Endoprosthesis with Heparin 
Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) 
Trial. Journal of Vascular and Interventional Radiology. 2013;24:165-73. 
[76] Zilla P, Bezuidenhout D, Human P. Prosthetic vascular grafts: wrong models, wrong 
questions and no healing. Biomaterials. 2007;28:5009-27. 
[77] Peckham SM, Turitto VT, Glantz J, Puryear H, Slack SM. Hemocompatibility studies of 
surface-treated polyurethane-based chronic indwelling catheters. Journal of 
Biomaterials Science, Polymer Edition. 1997;8:847-58. 
[78] He W, Hu Z, Xu A, Liu R, Yin H, Wang J, et al. The Preparation and Performance of a 
New Polyurethane Vascular Prosthesis. Cell Biochem Biophys. 2013:1-12. 
[79] Maya ID, Weatherspoon J, Young CJ, Barker J, Allon M. Increased risk of infection 
associated with polyurethane dialysis grafts. Semin Dial. 2007;20:616-20. 
[80] Meng J, Cheng X, Kong H, Yang M, Xu H. Preparation and biocompatibility evaluation 
of polyurethane filled with multiwalled carbon nanotubes. Journal of nanoscience and 
nanotechnology. 2013;13:1467-71. 
[81] Hu Z-j, Li Z-l, Hu L-y, He W, Liu R-m, Qin Y-s, et al. The in vivo performance of small-
caliber nanofibrous polyurethane vascular grafts. BMC Cardiovascular Disorders. 
2012;12:1-11. 
[82] Han J, Farah S, Domb A, Lelkes P. Electrospun Rapamycin-Eluting Polyurethane 
Fibers for Vascular Grafts. Pharm Res. 2013;30:1735-48. 
[83] Wong CS, Liu X, Xu Z, Lin T, Wang X. Elastin and collagen enhances electrospun 
aligned polyurethane as scaffolds for vascular graft. J Mater Sci: Mater Med. 2013:1-10. 
[84] Nguyen T-H, Padalhin AR, Seo HS, Lee B-T. A hybrid electrospun PU/PCL scaffold 
satisfied the requirements of blood vessel prosthesis in terms of mechanical properties, 
pore size, and biocompatibility. Journal of Biomaterials Science, Polymer Edition. 2013:1-
15. 
[85] Zhang Z, Marois Y, Guidoin RG, Bull P, Marois M, How T, et al. Vascugraft 
polyurethane arterial prosthesis as femoro-popliteal and femoro-peroneal bypasses in 
humans: pathological, structural and chemical analyses of four excised grafts. 
Biomaterials. 1997;18:113-24. 
[86] Stachelek SJ, Alferiev I, Fulmer J, Ischiropoulos H, Levy RJ. Biological stability of 
polyurethane modified with covalent attachment of di-tert-butyl-phenol. Journal of 
biomedical materials research Part A. 2007;82:1004-11. 
[87] Glickman MH, Stokes GK, Ross JR, Schuman ED, Sternbergh Iii WC, Lindberg JS, et al. 
Multicenter evaluation of a polyurethaneurea vascular access graft as compared with the 
expanded polytetrafluoroethylene vascular access graft in hemodialysis applications. 
Journal of vascular surgery. 2001;34:465-73. 
[88] Chu KC, Rutt BK. Polyvinyl alcohol cryogel: An ideal phantom material for MR studies 
of arterial flow and elasticity. Magnetic Resonance in Medicine. 1997;37:314-9. 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
38 
[89] Bourke SL, Al-Khalili M, Briggs T, Michniak BB, Kohn J, Poole-Warren LA. A photo-
crosslinked poly(vinyl alcohol) hydrogel growth factor release vehicle for wound healing 
applications. AAPS PharmSci. 2003;5:E33. 
[90] Takeuchi H, Kojima H, Yamamoto H, Kawashima Y. Polymer coating of liposomes 
with a modified polyvinyl alcohol and their systemic circulation and RES uptake in rats. J 
Control Release. 2000;68:195-205. 
[91] Laurent A, Wassef M, Saint Maurice JP, Namur J, Pelage JP, Seron A, et al. Arterial 
distribution of calibrated tris-acryl gelatin and polyvinyl alcohol microspheres in a sheep 
kidney model. Invest Radiol. 2006;41:8-14. 
[92] Pal K, Banthia AK, Majumdar DK. Preparation and characterization of polyvinyl 
alcohol-gelatin hydrogel membranes for biomedical applications. AAPS PharmSciTech. 
2007;8:21. 
[93] Yang S-H, Lee Y-SJ, Lin F-H, Yang J-M, Chen K-s. Chitosan/poly(vinyl alcohol) 
blending hydrogel coating improves the surface characteristics of segmented 
polyurethane urethral catheters. Journal of Biomedical Materials Research Part B: 
Applied Biomaterials. 2007;83B:304-13. 
[94] Walker J, Young G, Hunt C, Henderson T. Multi-centre evaluation of two daily 
disposable contact lenses. Cont Lens Anterior Eye. 2007;30:125-33. 
[95] Chaouat M, Le Visage C, Baille WE, Escoubet B, Chaubet F, Mateescu MA, et al. A Novel 
Cross-linked Poly(vinyl alcohol) (PVA) for Vascular Grafts. Advanced Functional 
Materials. 2008;18:2855-61. 
[96] Millon LE, Wan WK. The polyvinyl alcohol-bacterial cellulose system as a new 
nanocomposite for biomedical applications. J Biomed Mater Res B Appl Biomater. 
2006;79:245-53. 
[97] Millon LE, Guhados G, Wan W. Anisotropic polyvinyl alcohol-Bacterial cellulose 
nanocomposite for biomedical applications. J Biomed Mater Res B Appl Biomater. 
2008;86:444-52. 
[98] Mohammadi H. Nanocomposite biomaterial mimicking aortic heart valve leaflet 
mechanical behaviour. Proc Inst Mech Eng H. 2011;225:718-22. 
[99] Chuang WY, Young TH, Yao CH, Chiu WY. Properties of the poly(vinyl 
alcohol)/chitosan blend and its effect on the culture of fibroblast in vitro. Biomaterials. 
1999;20:1479-87. 
[100] Koyano T, Minoura N, Nagura M, Kobayashi K-i. Attachment and growth of cultured 
fibroblast cells on PVA/chitosan-blended hydrogels. Journal of Biomedical Materials 
Research. 1998;39:486-90. 
[101] Mathews DT, Birney YA, Cahill PA, McGuinness GB. Vascular cell viability on 
polyvinyl alcohol hydrogels modified with water-soluble and -insoluble chitosan. Journal 
of Biomedical Materials Research Part B: Applied Biomaterials. 2008;84B:531-40. 
[102] Tudorachi N, Cascaval CN, Rusu M, Pruteanu M. Testing of polyvinyl alcohol and 
starch mixtures as biodegradable polymeric materials. Polymer Testing. 2000;19:785-99. 
[103] Leitão A, Silva J, Dourado F, Gama M. Production and Characterization of a New 
Bacterial Cellulose/Poly(Vinyl Alcohol) Nanocomposite. Materials. 2013;6:1956-66. 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
39 
[104] Andrade F, Pertile R, Douradoa F. Bacterial cellulose: properties, production and 
applications. Cellulose: structure and properties, derivatives and industrial uses Nova 
Science Publishers, Inc. 2010:427-58. 
[105] Jia S, Tang W, Yang H, Jia Y, Zhu H. Preparation and Characterization of Bacterial 
Cellulose Tube.  Bioinformatics and Biomedical Engineering, 2009 ICBBE 2009 3rd 
International Conference on: IEEE; 2009. p. 1-4. 
[106] Kaźmierczak D, Kazimierczak J. Biosynthesis of modified bacterial cellulose in a 
tubular form. Fibres & Textiles in Eastern Europe. 2010;18:82. 
[107] Bäckdahl H, Risberg B, Gatenholm P. Observations on bacterial cellulose tube 
formation for application as vascular graft. Materials Science and Engineering: C. 
2011;31:14-21. 
[108] Klemm D, Schumann D, Udhardt U, Marsch S. Bacterial synthesized cellulose — 
artificial blood vessels for microsurgery. Progress in Polymer Science. 2001;26:1561-
603. 
[109] Svensson A, Nicklasson E, Harrah T, Panilaitis B, Kaplan DL, Brittberg M, et al. 
Bacterial cellulose as a potential scaffold for tissue engineering of cartilage. Biomaterials. 
2005;26:419-31. 
[110] Alvarez O, Patel M, Booker J, Markowitz L. Original Research Effectiveness of a 
Biocellulose Wound Dressing for the Treatment of Chronic Venous Leg Ulcers: Results of 
a Single Center Randomized Study Involving 24 Patients. Wounds. 2004;16:224-33. 
[111] Czaja W, Krystynowicz A, Bielecki S, Brown Jr RM. Microbial cellulose—the natural 
power to heal wounds. Biomaterials. 2006;27:145-51. 
[112] Solway DR, Consalter M, Levinson DJ. Microbial cellulose wound dressing in the 
treatment of skin tears in the frail elderly. Wounds. 2010;22:17-9. 
[113] Fontana JD, de Souza AM, Fontana CK, Torriani IL, Moreschi JC, Gallotti BJ, et al. 
Acetobacter cellulose pellicle as a temporary skin substitute. Appl Biochem Biotechnol. 
1990;24-25:253-64. 
[114] Backdahl H, Helenius G, Bodin A, Nannmark U, Johansson BR, Risberg B, et al. 
Mechanical properties of bacterial cellulose and interactions with smooth muscle cells. 
Biomaterials. 2006;27:2141-9. 
[115] Mello LR, Feltrin LT, Fontes Neto PT, Ferraz FAP. Duraplasty with biosynthetic 
cellulose: an experimental study. Journal of Neurosurgery. 1997;86:143-50. 
[116] Wippermann J, Schumann D, Klemm D, Kosmehl H, Salehi-Gelani S, Wahlers T. 
Preliminary results of small arterial substitute performed with a new cylindrical 
biomaterial composed of bacterial cellulose. European journal of vascular and 
endovascular surgery : the official journal of the European Society for Vascular Surgery. 
2009;37:592-6. 
[117] Andrade FK, Costa R, Domingues L, Soares R, Gama M. Improving bacterial cellulose 
for blood vessel replacement: Functionalization with a chimeric protein containing a 
cellulose-binding module and an adhesion peptide. Acta Biomater. 2010;6:4034-41. 
[118] Schumann DA, Wippermann J, Klemm DO, Kramer F, Koth D, Kosmehl H, et al. 
Artificial vascular implants from bacterial cellulose: preliminary results of small arterial 
substitutes. Cellulose. 2009;16:877-85. 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
40 
[119] Fink H, Faxalv L, Molnar GF, Drotz K, Risberg B, Lindahl TL, et al. Real-time 
measurements of coagulation on bacterial cellulose and conventional vascular graft 
materials. Acta Biomater. 2010;6:1125-30. 
[120] Fink H, Hong J, Drotz K, Risberg B, Sanchez J, Sellborn A. An in vitro study of blood 
compatibility of vascular grafts made of bacterial cellulose in comparison with 
conventionally-used graft materials. Journal of biomedical materials research Part A. 
2011. 
[121] Flynn CN, Byrne CP, Meenan BJ. Surface modification of cellulose via atmospheric 
pressure plasma processing in air and ammonia–nitrogen gas. Surface and Coatings 
Technology. 2013. 
[122] Fernandes SCM, Sadocco P, Alonso-Varona A, Palomares T, Eceiza A, Silvestre AJD, 
et al. Bioinspired Antimicrobial and Biocompatible Bacterial Cellulose Membranes 
Obtained by Surface Functionalization with Aminoalkyl Groups. ACS Applied Materials & 
Interfaces. 2013;5:3290-7. 
[123] Lee SJ, Liu J, Oh SH, Soker S, Atala A, Yoo JJ. Development of a composite vascular 
scaffolding system that withstands physiological vascular conditions. Biomaterials. 
2008;29:2891-8. 
[124] Ju YM, Choi JS, Atala A, Yoo JJ, Lee SJ. Bilayered scaffold for engineering cellularized 
blood vessels. Biomaterials. 2010;31:4313-21. 
[125] McClure MJ, Sell SA, Simpson DG, Walpoth BH, Bowlin GL. A three-layered 
electrospun matrix to mimic native arterial architecture using polycaprolactone, elastin, 
and collagen: a preliminary study. Acta Biomater. 2010;6:2422-33. 
[126] Ye L, Wu X, Mu Q, Chen B, Duan Y, Geng X, et al. Heparin-Conjugated PCL Scaffolds 
Fabricated by Electrospinning and Loaded with Fibroblast Growth Factor 2. Journal of 
biomaterials science Polymer edition. 2010. 
[127] Pektok E, Nottelet B, Tille JC, Gurny R, Kalangos A, Moeller M, et al. Degradation and 
healing characteristics of small-diameter poly(epsilon-caprolactone) vascular grafts in 
the rat systemic arterial circulation. Circulation. 2008;118:2563-70. 
[128] Mugnai D, Tille JC, Mrowczynski W, de Valence S, Montet X, Moller M, et al. 
Experimental noninferiority trial of synthetic small-caliber biodegradable versus stable 
vascular grafts. J Thorac Cardiovasc Surg. 2012. 
[129] Walpoth B, Mugnai D, de Valence S, Mrowczynski W, Tille J, Montet X, et al. Non-
inferiority of synthetic small-calibre biodegradable vs. stable ePTFE vascular prosthesis 
after long-term implantation in the rat aorta. The Thoracic and Cardiovascular Surgeon. 
2013;61:OP56. 
[130] Singh S, Wu BM, Dunn JC. Accelerating vascularization in polycaprolactone scaffolds 
by endothelial progenitor cells. Tissue Eng Part A. 2011;17:1819-30. 
[131] Tillman BW, Yazdani SK, Lee SJ, Geary RL, Atala A, Yoo JJ. The in vivo stability of 
electrospun polycaprolactone-collagen scaffolds in vascular reconstruction. 
Biomaterials. 2009;30:583-8. 
[132] Mun CH, Kim S-H, Jung Y, Kim S-H, Kim A-k, Kim D-I, et al. Elastic, double-layered 
poly(l-lactide-co-ε-caprolactone) scaffold for long-term vascular reconstruction. Journal 
of Bioactive and Compatible Polymers. 2013. 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
41 
[133] Diban N, Haimi S, Bolhuis-Versteeg L, Teixeira S, Miettinen S, Poot A, et al. Hollow 
fibers of poly(lactide-co-glycolide) and poly(ε-caprolactone) blends for vascular tissue 
engineering applications. Acta Biomater. 2013;9:6450-8. 
[134] Yuan S, Xiong G, Roguin A, Teoh SH, Choong C. Amelioration of Blood Compatibility 
and Endothelialization of Polycaprolactone Substrates by Surface-Initiated Atom 
Transfer Radical Polymerization. 2013. 
[135] Del Gaudio C, Ercolani E, Galloni P, Santilli F, Baiguera S, Polizzi L, et al. Aspirin-
loaded electrospun poly(ε-caprolactone) tubular scaffolds: potential small-diameter 
vascular grafts for thrombosis prevention. J Mater Sci: Mater Med. 2013;24:523-32. 
[136] Wang S, Mo XM, Jiang BJ, Gao CJ, Wang HS, Zhuang YG, et al. Fabrication of small-
diameter vascular scaffolds by heparin-bonded P(LLA-CL) composite nanofibers to 
improve graft patency. Int J Nanomedicine. 2013;8:2131-9. 
[137] Lu G, Cui SJ, Geng X, Ye L, Chen B, Feng ZG, et al. Design and preparation of 
polyurethane-collagen/heparin-conjugated polycaprolactone double-layer bionic small-
diameter vascular graft and its preliminary animal tests. Chin Med J (Engl). 
2013;126:1310-6. 
[138] Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. Collagen: The 
Fibrous Proteins of the Matrix. 2000. 
[139] Olsen D, Yang C, Bodo M, Chang R, Leigh S, Baez J, et al. Recombinant collagen and 
gelatin for drug delivery. Adv Drug Deliv Rev. 2003;55:1547-67. 
[140] Smith M, McFetridge P, Bodamyali T, Chaudhuri JB, Howell JA, Stevens CR, et al. 
Porcine-Derived Collagen as a Scaffold for Tissue Engineering. Food and Bioproducts 
Processing. 2000;78:19-24. 
[141] Kose GT, Korkusuz F, Ozkul A, Soysal Y, Ozdemir T, Yildiz C, et al. Tissue engineered 
cartilage on collagen and PHBV matrices. Biomaterials. 2005;26:5187-97. 
[142] Sell SA, McClure MJ, Garg K, Wolfe PS, Bowlin GL. Electrospinning of 
collagen/biopolymers for regenerative medicine and cardiovascular tissue engineering. 
Adv Drug Deliv Rev. 2009;61:1007-19. 
[143] Amarnath LP, Srinivas A, Ramamurthi A. In vitro hemocompatibility testing of UV-
modified hyaluronan hydrogels. Biomaterials. 2006;27:1416-24. 
[144] Miyata T, Taira T, Noishiki Y. Collagen engineering for biomaterial use. Clin Mater. 
1992;9:139-48. 
[145] Wissink MJ, Beernink R, Pieper JS, Poot AA, Engbers GH, Beugeling T, et al. 
Immobilization of heparin to EDC/NHS-crosslinked collagen. Characterization and in 
vitro evaluation. Biomaterials. 2001;22:151-63. 
[146] Wilner GD, Nossel HL, LeRoy EC. Activation of Hageman factor by collagen. J Clin 
Invest. 1968;47:2608-15. 
[147] McClure MJ, Simpson DG, Bowlin GL. Tri-layered vascular grafts composed of 
polycaprolactone, elastin, collagen, and silk: Optimization of graft properties. Journal of 
the Mechanical Behavior of Biomedical Materials. 2012;10:48-61. 
[148] Kumar VA, Caves JM, Haller CA, Dai E, Li L, Grainger S, et al. Acellular Vascular Grafts 
Generated from Collagen and Elastin Analogues. Acta Biomater. 2013. 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
42 
[149] Wu H, Fan J, Chu CC, Wu J. Electrospinning of small diameter 3-D nanofibrous 
tubular scaffolds with controllable nanofiber orientations for vascular grafts. J Mater Sci 
Mater Med. 2010;21:3207-15. 
[150] Berglund JD, Mohseni MM, Nerem RM, Sambanis A. A biological hybrid model for 
collagen-based tissue engineered vascular constructs. Biomaterials. 2003;24:1241-54. 
[151] Long JL, Tranquillo RT. Elastic fiber production in cardiovascular tissue-
equivalents. Matrix Biology. 2003;22:339-50. 
[152] Karnik SK, Brooke BS, Bayes-Genis A, Sorensen L, Wythe JD, Schwartz RS, et al. A 
critical role for elastin signaling in vascular morphogenesis and disease. Development. 
2003;130:411-23. 
[153] Jordan SW, Haller CA, Sallach RE, Apkarian RP, Hanson SR, Chaikof EL. The effect of 
a recombinant elastin-mimetic coating of an ePTFE prosthesis on acute thrombogenicity 
in a baboon arteriovenous shunt. Biomaterials. 2007;28:1191-7. 
[154] Woodhouse KA, Klement P, Chen V, Gorbet MB, Keeley FW, Stahl R, et al. 
Investigation of recombinant human elastin polypeptides as non-thrombogenic coatings. 
Biomaterials. 2004;25:4543-53. 
[155] Li DY, Brooke B, Davis EC, Mecham RP, Sorensen LK, Boak BB, et al. Elastin is an 
essential determinant of arterial morphogenesis. Nature. 1998;393:276-80. 
[156] Weinberg CB, Bell E. A blood vessel model constructed from collagen and cultured 
vascular cells. Science. 1986;231:397-400. 
[157] L'Heureux N, Germain L, Labbe R, Auger FA. In vitro construction of a human blood 
vessel from cultured vascular cells: a morphologic study. Journal of vascular surgery. 
1993;17:499-509. 
[158] Hirai J, Matsuda T. Venous reconstruction using hybrid vascular tissue composed 
of vascular cells and collagen: tissue regeneration process. Cell Transplant. 1996;5:93-
105. 
[159] Ramamurthi A, Vesely I. Evaluation of the matrix-synthesis potential of crosslinked 
hyaluronan gels for tissue engineering of aortic heart valves. Biomaterials. 2005;26:999-
1010. 
[160] Ziegler T, Alexander RW, Nerem RM. An endothelial cell-smooth muscle cell co-
culture model for use in the investigation of flow effects on vascular biology. Ann Biomed 
Eng. 1995;23:216-25. 
[161] Kolpakov V, Rekhter MD, Gordon D, Wang WH, Kulik TJ. Effect of mechanical forces 
on growth and matrix protein synthesis in the in vitro pulmonary artery. Analysis of the 
role of individual cell types. Circ Res. 1995;77:823-31. 
[162] Kim BS, Mooney DJ. Scaffolds for engineering smooth muscle under cyclic 
mechanical strain conditions. J Biomech Eng. 2000;122:210-5. 
[163] Kim BS, Nikolovski J, Bonadio J, Mooney DJ. Cyclic mechanical strain regulates the 
development of engineered smooth muscle tissue. Nat Biotechnol. 1999;17:979-83. 
[164] Berglund JD, Nerem RM, Sambanis A. Incorporation of intact elastin scaffolds in 
tissue-engineered collagen-based vascular grafts. Tissue engineering. 2004;10:1526-35. 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
43 
[165] Sell S, McClure MJ, Barnes CP, Knapp DC, Walpoth BH, Simpson DG, et al. 
Electrospun polydioxanone–elastin blends: potential for bioresorbable vascular grafts. 
Biomedical Materials. 2006;1:72. 
[166] Caves JM, Kumar VA, Martinez AW, Kim J, Ripberger CM, Haller CA, et al. The use of 
microfiber composites of elastin-like protein matrix reinforced with synthetic collagen in 
the design of vascular grafts. Biomaterials. 2010;31:7175-82. 
[167] Sarkar S, Schmitz-Rixen T, Hamilton G, Seifalian AM. Achieving the ideal properties 
for vascular bypass grafts using a tissue engineered approach: a review. Medical & 
biological engineering & computing. 2007;45:327-36. 
[168] Smith MJ, McClure MJ, Sell SA, Barnes CP, Walpoth BH, Simpson DG, et al. Suture-
reinforced electrospun polydioxanone–elastin small-diameter tubes for use in vascular 
tissue engineering: a feasibility study. Acta Biomater. 2008;4:58-66. 
[169] Wise SG, Byrom MJ, Waterhouse A, Bannon PG, Ng MK, Weiss AS. A multilayered 
synthetic human elastin/polycaprolactone hybrid vascular graft with tailored mechanical 
properties. Acta Biomater. 2011;7:295-303. 
[170] Chuang T-H, Stabler C, Simionescu A, Simionescu DT. Polyphenol-stabilized tubular 
elastin scaffolds for tissue engineered vascular grafts. Tissue Engineering Part A. 
2009;15:2837-51. 
[171] Mecham RP. Methods in elastic tissue biology: elastin isolation and purification. 
Methods. 2008;45:32-41. 
[172] Weisel JW. Fibrinogen and fibrin. Adv Protein Chem. 2005;70:247-99. 
[173] Laurens N, Koolwijk P, de Maat MP. Fibrin structure and wound healing. Journal of 
thrombosis and haemostasis : JTH. 2006;4:932-9. 
[174] Lominadze D, Dean WL. Involvement of fibrinogen specific binding in erythrocyte 
aggregation. FEBS Letters. 2002;517:41-4. 
[175] Grassl ED, Oegema TR, Tranquillo RT. A fibrin-based arterial media equivalent. 
Journal of biomedical materials research Part A. 2003;66:550-61. 
[176] Ahmed TA, Dare EV, Hincke M. Fibrin: a versatile scaffold for tissue engineering 
applications. Tissue engineering Part B, Reviews. 2008;14:199-215. 
[177] Koroleva A, Gittard S, Schlie S, Deiwick A, Jockenhoevel S, Chichkov B. Fabrication 
of fibrin scaffolds with controlled microscale architecture by a two-photon 
polymerization-micromolding technique. Biofabrication. 2012;4:015001. 
[178] Kaijzel EL, Koolwijk P, van Erck MG, van Hinsbergh VW, de Maat MP. Molecular 
weight fibrinogen variants determine angiogenesis rate in a fibrin matrix in vitro and in 
vivo. Journal of thrombosis and haemostasis : JTH. 2006;4:1975-81. 
[179] Jockenhoevel S, Zund G, Hoerstrup SP, Chalabi K, Sachweh JS, Demircan L, et al. 
Fibrin gel -- advantages of a new scaffold in cardiovascular tissue engineering. European 
journal of cardio-thoracic surgery : official journal of the European Association for 
Cardio-thoracic Surgery. 2001;19:424-30. 
[180] Dietrich M, Heselhaus J, Wozniak J, Weinandy S, Mela P, Tschoeke B, et al. Fibrin-
based tissue engineering: comparison of different methods of autologous fibrinogen 
isolation. Tissue Eng Part C Methods. 2013;19:216-26. 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
44 
[181] Hasegawa T, Okada K, Takano Y, Hiraishi Y, Okita Y. Autologous fibrin-coated small-
caliber vascular prostheses improve antithrombogenicity by reducing immunologic 
response. J Thorac Cardiovasc Surg. 2007;133:1268-76, 76 e1. 
[182] Tschoeke B, Flanagan TC, Koch S, Harwoko MS, Deichmann T, Ella V, et al. Tissue-
engineered small-caliber vascular graft based on a novel biodegradable composite fibrin-
polylactide scaffold. Tissue Eng Part A. 2009;15:1909-18. 
[183] Aper T, Teebken OE, Steinhoff G, Haverich A. Use of a fibrin preparation in the 
engineering of a vascular graft model. European journal of vascular and endovascular 
surgery : the official journal of the European Society for Vascular Surgery. 2004;28:296-
302. 
[184] Koch S, Tschoeke B, Deichmann T, Ella V, Gronloh N, Gries T, et al. Fibrin-based 
tissue engineered vascular graft in carotid artery position-the first in vivo experiences. 
The Thoracic and Cardiovascular Surgeon. 2010;58:MP25. 
[185] Santin M, Motta A, Freddi G, Cannas M. In vitro evaluation of the inflammatory 
potential of the silk fibroin. J Biomed Mater Res. 1999;46:382-9. 
[186] Demura M, Asakura T. Porous membrane of Bombyx mori silk fibroin: structure 
characterization, physical properties and application to glucose oxidase immobilization. 
Journal of Membrane Science. 1991;59:39-52. 
[187] Asakura T, Kitaguchi M, Demura M, Sakai H, Komatsu K. Immobilization of glucose 
oxidase on nonwoven fabrics with bombyx mori silk fibroin gel. Journal of Applied 
Polymer Science. 1992;46:49-53. 
[188] Demura M, Asakura T. Immobilization of glucose oxidase with Bombyx mori silk 
fibroin by only stretching treatment and its application to glucose sensor. Biotechnol 
Bioeng. 1989;33:598-603. 
[189] Mhuka V, Dube S, Nindi M, Torto N. Fabrication and structural characterization of 
electrospun nanofibres from Gonometa Postica and Gonometa Rufobrunnae regenerated 
silk fibroin. Macromolecular Research. 2013;21:995-1003. 
[190] Tamada Y. New process to form a silk fibroin porous 3-D structure. 
Biomacromolecules. 2005;6:3100-6. 
[191] Meinel L, Hofmann S, Karageorgiou V, Zichner L, Langer R, Kaplan D, et al. 
Engineering cartilage-like tissue using human mesenchymal stem cells and silk protein 
scaffolds. Biotechnol Bioeng. 2004;88:379-91. 
[192] Altman GH, Diaz F, Jakuba C, Calabro T, Horan RL, Chen J, et al. Silk-based 
biomaterials. Biomaterials. 2003;24:401-16. 
[193] Zhang X, Wang X, Keshav V, Johanas JT, Leisk GG, Kaplan DL. Dynamic culture 
conditions to generate silk-based tissue-engineered vascular grafts. Biomaterials. 
2009;30:3213-23. 
[194] Makaya K, Terada S, Ohgo K, Asakura T. Comparative study of silk fibroin porous 
scaffolds derived from salt/water and sucrose/hexafluoroisopropanol in cartilage 
formation. J Biosci Bioeng. 2009;108:68-75. 
[195] Enomoto S, Sumi M, Kajimoto K, Nakazawa Y, Takahashi R, Takabayashi C, et al. 
Long-term patency of small-diameter vascular graft made from fibroin, a silk-based 
biodegradable material. Journal of vascular surgery. 2010;51:155-64. 
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
45 
[196] Rockwood DN, Gil ES, Park SH, Kluge JA, Grayson W, Bhumiratana S, et al. Ingrowth 
of human mesenchymal stem cells into porous silk particle reinforced silk composite 
scaffolds: An in vitro study. Acta Biomater. 2011;7:144-51. 
[197] Mauney JR, Sjostorm S, Blumberg J, Horan R, O'Leary JP, Vunjak-Novakovic G, et al. 
Mechanical stimulation promotes osteogenic differentiation of human bone marrow 
stromal cells on 3-D partially demineralized bone scaffolds in vitro. Calcif Tissue Int. 
2004;74:458-68. 
[198] Li C, Vepari C, Jin H-J, Kim HJ, Kaplan DL. Electrospun silk-BMP-2 scaffolds for bone 
tissue engineering. Biomaterials. 2006;27:3115-24. 
[199] Lovett M, Eng G, Kluge J, Cannizzaro C, Vunjak-Novakovic G, Kaplan DL. Tubular silk 
scaffolds for small diameter vascular grafts. Organogenesis. 2010;6:217-24. 
[200] Marelli B, Achilli M, Alessandrino A, Freddi G, Tanzi MC, Farè S, et al. Collagen-
Reinforced Electrospun Silk Fibroin Tubular Construct as Small Calibre Vascular Graft. 
Macromolecular Bioscience. 2012;12:1566-74. 
[201] Maskarinec SA, Tirrell DA. Protein engineering approaches to biomaterials design. 
Curr Opin Biotechnol. 2005;16:422-6. 
[202] Liu H, Li X, Niu X, Zhou G, Li P, Fan Y. Improved hemocompatibility and 
endothelialization of vascular grafts by covalent immobilization of sulfated silk fibroin on 
poly (lactic-co-glycolic acid) scaffolds. Biomacromolecules. 2011;12:2914-24. 
[203] Yang X, Wang L, Guan G, King MW, Li Y, Peng L, et al. Preparation and evaluation of 
bicomponent and homogeneous polyester silk small diameter arterial prostheses. Journal 
of biomaterials applications. 2013. 
[204] Aytemiz D, Sakiyama W, Suzuki Y, Nakaizumi N, Tanaka R, Ogawa Y, et al. Small-
Diameter Silk Vascular Grafts (3 mm Diameter) with a Double-Raschel Knitted Silk Tube 
Coated with Silk Fibroin Sponge. Advanced healthcare materials. 2012. 
[205] Nakazawa Y, Sato M, Takahashi R, Aytemiz D, Takabayashi C, Tamura T, et al. 
Development of small-diameter vascular grafts based on silk fibroin fibers from bombyx 
mori for vascular regeneration. Journal of Biomaterials Science, Polymer Edition. 
2011;22:195-206. 
[206] Soffer L, Wang X, Zhang X, Kluge J, Dorfmann L, Kaplan DL, et al. Silk-based 
electrospun tubular scaffolds for tissue-engineered vascular grafts. Journal of 
Biomaterials Science, Polymer Edition. 2008;19:653-64. 
 
  
Chapter 1 – Polymers in Vascular Grafts 
AF Leitão 
46 
 
 
 AF Leitão 47 
Chapter 2 
Hemocompatibility study of a bacterial 
cellulose/polyvinyl alcohol nanocomposite 
 
Adapted from: Leitão, A.F.; Gupta, S.; Silva, J.P.; Reviakine, I.; Gama, M.; Hemocompatibility study of a 
bacterial cellulose/polyvinyl alcohol nanocomposite; Colloids and Surfaces B: Biointerphases; Vol. 111, 
C:493-502; 2013 (DOI: 10.1016/j.colsurfb.2013.06.031) 
 
 
 
Bacterial cellulose (BC) has been suggested to be a suitable biomaterial for the 
development of cardiovascular grafts. The combination of BC with polyvinyl alcohol 
(PVA) results in nanocomposites with improved properties. Surprisingly, there are very 
few studies on the BC-blood interaction. This is the focus of this paper. We present the 
first thorough assessment of the hemocompatibility of the BC/PVA nanocomposite. 
Whole blood clotting time, plasma recalcification, Factor XII activation, platelet adhesion 
and activation, hemolytic index and complement activation are all determined. The 
platelet activation profiles on BC and BC/PVA surfaces are comprehensively 
characterized. BC and BC/PVA outperformed ePTFE - used as a point of comparison - thus 
evidencing their suitability for cardiovascular applications. 
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Introduction 
 
With the increase in the prevalence of cardiovascular diseases in the adult population, 
cardiovascular surgeries are becoming more and more common in operating rooms 
across the world. Among the most prevalent cardiovascular diseases is atherosclerosis 
which is generally treated by performing a bypass surgery. The procedure requires the 
application of a biological or a synthetic graft that will allow the blood flow to be 
redirected around an occluded portion of the vessel. Biological grafts deteriorate over 
time due to the natural progression of the patients’ disease or may be unavailable [1]. 
Therefore, synthetic grafts are used. These are commonly made of polyethylene 
terephthalate (PET, commercially known as Dacron) or expanded 
polytetrafluoroethylene (ePTFE). However, they do not perform well in medium or small-
caliber vessels such as coronary arteries [1]. In larger-caliber vessels characterized by 
high shear rates these materials do provide good mechanical compliance. However, they 
have a strong affinity for proteins, which adsorb on the surface of the material. This 
results in a layer, the pseudo-intima, which promotes platelet adhesion and activation 
and consequent clot formation [2, 3]. In low caliber vessels the protein build-up on the 
luminal surface and platelet activity ultimately lead to thrombosis.  There is therefore a 
strong need for new materials for the construction of vascular grafts for small-caliber 
vessel applications, and a large amount of work has been aimed at finding natural 
alternatives to the synthetic polymer materials for making grafts.  
In order to be suitable for this application, the material has to be hemocompatible, i.e., it 
must be able to remain in contact with blood without inducing toxicity or activating the 
intrinsic and extrinsic coagulation cascades or the complement system [4]. By triggering 
these blood reactions, foreign materials cause thrombosis and inflammation at the graft 
site or embolism. Emboli that occur due to the detachment of thrombi from the graft site 
or their formation downstream of the implant are the main cause of synthetic grafts 
failure [2].  
One promising candidate is bacterial cellulose (BC). This polymer is a highly pure linear 
polysaccharide, consisting of β (1→4)–linked D-glucose monomers. It is secreted by 
bacteria of the Gluconacetobacter genus. Once secreted, it forms a fibrous network 
hydrogel. BC has been extensively studied for biomedical applications due to its 
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morphology, high purity, water-holding capacity, tensile strength, malleability and 
biocompatibility [5-7] and has been proposed for applications such as wound dressings 
[8], artificial skin [9] or blood vessels [6, 10-12] and as a scaffold for tissue engineering 
[7, 13-15]. 
Polyvinyl alcohol (PVA) has also been studied for potential biomedical applications. Its 
uncomplicated structure allows crosslinking of the polymer chains by either chemical 
agents or by physical crosslinking through thermal cycling [16]. The hydrogels formed by 
PVA generally present good tensile strength, flexibility and elasticity [17], allied with high 
water retention capability, non-toxicity and non-carcinogenicity. PVA has been studied 
for applications in tissue reconstruction and replacements, drug delivery, cardiovascular 
stents and wound covering bandages, among others [16, 18].  
BC has high tensile strength but somewhat limited elasticity. On the other hand, PVA is 
highly elastic but its tensile strength is limited. A compromise would be ideal for potential 
applications in cardiovascular surgery: sufficient tensile strength allied with enough 
elasticity to allow for greater mechanical compliance. The BC/PVA nanocomposites 
indeed meet these criteria, as we and others reported [16, 19, 20]. We described 
previously one such nanocomposite, consisting of an interpenetrated polymer network 
of PVA fibers entangled inside the BC matrix, bridging gaps and linking individual BC 
fibers. The mechanical properties of the BC/PVA nanocomposites can be adjusted by 
thermal cycling. This allows tailoring of the nanocomposite mechanical properties to 
better mimic those of the arterial vessel walls.  
While the potential of BC as a biomaterial for cardiovascular applications has been 
reported [6, 10-12] its interactions with blood have not been carefully characterized [10, 
11]. Therefore, in this study, we assess the hemocompatibility of BC and of a BC/PVA 
nanocomposite.  
 
Experimental Section 
Bacterial Cellulose and Bacterial Cellulose/Polyvinyl Alcohol 
 
Gluconacetobacter xylinus (ATCC 700178) was grown in a modified Hestrin-Schramm 
medium, supplemented with 2% Corn Steep Liquor (Sigma Aldrich, Germany) and 0.6% 
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ethanol, at pH 5.0. The medium was inoculated and then added to 24-well polystyrene 
microtitter plates. The plates were then incubated at 30oC for 7 days.  
The resulting BC membranes were then washed thoroughly with distilled water and 
further purified with 4% NaOH at 60oC for 90min. The membranes were then, again, 
thoroughly washed until neutral pH was achieved. 
For BC/PVA production, purified BC membranes were immersed in a 10% PVA (Mw= 
31,000-50,000 g/mol) (Sigma Aldrich, Germany) solution for 24hr at 80oC. The 
membranes were then frozen at -20oC for 24hr, after which they were thawed at room 
temperature in distilled water and washed to remove any polymerized PVA particles on 
the surface of the membranes.  
All membranes were sterilized by washing in 70% (v/v) ethanol for 24hr and then with 
ultrapure autoclaved water in a vertical laminar air flow hood chamber until ethanol was 
fully removed. 
 
Preparation of Blood Samples 
 
Whole blood was collected from healthy donors at Hospital São João (Oporto, Portugal) 
with citrated (3.2%) 1.8ml vacuum blood-collection tubes and transported on ice. The 
blood samples were then, unless mentioned otherwise, centrifuged at 2000g for 10min 
at 4oC to obtain Platelet Poor Plasma (PPP), which was then used in the plasma 
recalcification and Factor XII activation assays.  
 
Whole Blood Clotting Times 
 
Whole blood kinetic clotting times of wet and dried BC and BC/PVA membranes were 
determined as previously described by Motlagh [21]. Clotting was induced by addition of 
360µl of 0.1M CaCl2 to 3.6ml of whole blood. The BC and BC/PVA membranes along with 
glass microspheres (positive control) and empty wells of a 24-well polystyrene 
microtitter plate (negative control) were incubated for 0, 5, 10, 15, 25 and 35min at room 
temperature (16-18oC) with 150µl of the activated whole blood for each time point. At 
Chapter 2 – Hemocompatibility study of a bacterial cellulose/polyvinyl alcohol nanocomposite 
AF Leitão 52 
the end of each time point 3ml of distilled water was added to the well and incubated for 
5min, in order to lyse the red blood cells which were not trapped in the thrombus, and 
release hemoglobin.  
The concentration of released hemoglobin was measured by transferring 200µl of the 
supernatant to a 96-well microtitter plate followed by spectrophotometric analysis at 
λ=540nm. The clot formation is followed by a reduction in the absorbance value. All 
samples, including ePTFE as a control, were analyzed in triplicate. 
 
Plasma Recalcification Profiles 
 
Plasma recalcification times for BC and BC/PVA membranes, along with empty 
polystyrene plate wells with (positive control) and without CaCl2 (negative control) were 
determined by the method described by Mortagh [21]. Samples containing 500µl of 
Platelet Poor Plasma (PPP) were incubated for 1hr, at 37oC, on an orbital shaker. After 
the incubation period, 100µl of the PPP from each sample well was transferred to a 96-
well plate and 100ml of CaCl2 was added to each well (except the previously mentioned 
negative control). The 96-well microtitter plate was then immediately placed in a plate 
reader, and the kinetics of the clotting measured and monitored by changes in the 
absorption at λ=405nm, every 30sec for 45min (curves generally stabilized after 30min). 
The measure of thrombogenicity was given by the time it took to achieve half maximum 
absorbance (EC50). Each sample was measured in triplicate (3 donors per sample) and 
averaged; ePTFE was also analyzed in the same way. 
 
Hemolysis Index 
 
Hemolysis studies were conducted in accordance with the procedures described by the 
American Society for Testing and Materials (ASTM F756-00, 2000). BC samples were 
equilibrated in phosphate buffer saline (PBS) and then transferred to a tube containing 
7ml of PBS. 1ml of diluted blood (hemoglobin concentration of 10 mg/ml) was added and 
incubated at 37oC for 3hr in a water bath. The tubes were gently inverted every 30min to 
promote contact between blood and samples. The membranes were then removed with 
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sterile tweezers and the diluted blood centrifuged at 750g for 15min. Then, 1ml of 
Drabkin’s reagent (Sigma-Aldrich, Germany) was added to 1ml of supernatant and 
incubated for 15 min at room temperature, and finally the absorbance was read at 
λ=540nm. 
Hemoglobin concentration was calculated using a calibration curve previously prepared 
with human hemoglobin (Sigma-Aldrich, Germany) and calculated using the formula: 
HC=A×m×d (A, Absorbance; m Slope of the hemoglobin curve; d, Dilution) and presented 
as percentage. Ultrapure water and PBS served as the positive and negative controls, 
respectively. ePTFE was analyzed in the same manner as control materials. 
 
Complement System Activation 
 
To determine whether the biomaterials activate the complement cascade, we performed 
the protocol described by the NCL (Nanotechnology Characterization Laboratory) for 
qualitative determination of total complement activation by Western blot analysis 
(http://ncl.cancer.gov/working_assay-cascade.asp) with slight modifications. Human 
plasma, from healthy donors, was incubated with BC and BC/PVA membranes in the 
presence of veronal buffer. Equal volumes (100μL) of plasma, buffer and sample were 
mixed together and incubated at 37°C for 60 min. Cobra venom factor (CVF) from Quidel 
Corporation (San Diego, CA, USA), and PBS were used as positive and negative controls, 
respectively.  
In order to determine if complement proteins could have unspecific adsorption on the BC 
and BC/PVA membranes, several pre-incubations were performed: 
1. Preincubation for 2 hr at 37oC with a pool of active plasma followed by a 1 hr 
incubation with plasma and veronal buffer at 37oC. 
2. Preincubation for 2 hr at 37oC with a pool of inactive plasma and then 1 hr 
incubation with plasma and veronal buffer at 37oC. 
3. Incubation for 1 hr with a pool of plasma and veronal buffer for 1 hr at 37oC. 
4. Incubation of 3 hr with a pool of plasma at 37oC. 
5. Incubation of 3 hr with a pool of plasma and veronal buffer at 37oC. 
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Proteins were resolved using 10% SDS-PAGE, and then transferred to a membrane 
(Immun-Blot PVDF Membrane, Biorad, Hercules, USA) using the transblot semidry 
apparatus BioRad transfer equipment (Trans blot SD, BioRad, Hercules, USA). The 
membranes were incubated for 90 min with a mouse monoclonal antibody against 
human C3, diluted to 1:1000 (Abcam, Cambridge, UK). The membranes were then washed 
and incubated with secondary polyclonal goat anti-mouse IgG antibodies conjugated with 
alkaline phosphatase, diluted to 1:2000 (Dako, Glostrup, Denmark). The membranes 
were finally revealed with 5-Bromo-4-Chloro-3-Indolyl Phosphate (BCIP) (Sigma Aldrich, 
Germany). 
 
Factor XII Activation 
 
Both free and adhered Factor XII (FXII) activation was determined by a method adapted 
from Sperling et al [22]. For the determination of free Factor XII activation BC and 
BC/PVA membranes were incubated with 300µl of PPP for 1, 5, 10 and 20 min at room 
temperature (16-18oC). Then, 30µl of the plasma was added to 200µl of 0.3M 
chromogenic substrate S-2302 (Chromogenix, Italy) in 50mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid buffer (HEPES) and 120mM NaCl at pH 7.4; the absorbance 
was immediately measured at λ=405nm for 30min (every 30sec). An empty polystyrene 
well and glass microspheres were used as the negative and positive controls. The slope 
of the resulting curves was calculated and used to compare Factor XII activation. All 
samples were analyzed in triplicate along with ePTFE. 
Additionally, to determine the activation of Factor XII adhered to the surface of BC and 
BC/PVA, samples incubated with PPP for the same time periods as above (1, 5, 10 and 20 
min) were immersed in 300µl of 0.3M chromogenic substrate S-2302 (Chromogenix) in 
50mM HEPES and 120mM NaCl at pH 7.4 for 30 min, the reaction was then stopped with 
75µl of 20% (v/v) acetic acid and 200µl of the reaction volume and the absorbance 
measured on a 96-well microtitter plate at λ=405nm.  
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Platelet Isolation, Characterization and Surface Activation Studies 
 
Platelet rich plasma (PRP) and purified platelets were obtained by centrifugation of 
sodium citrate-anticoagulated human blood [23]. Blood collection was organized by the 
Biobanco Vasco para la Investigación (Basque Biobank for Research, Galdakao, Spain) 
and performed with informed consent according to the appropriate legal and ethical 
guidelines. Donors were healthy volunteers without any history of exposure to 
medication (such as aspirin) or to alcohol in the two weeks prior to blood collection. 
Purified platelets were suspended in the buffer (145mM NaCl, 5mM Glucose, 1mM MgCl2, 
10mM HEPES, 5mM KCl, pH 7.4), with (Plt+Ca2+) or without (Plt-Ca2+) 2mM calcium. 
Platelet concentration was adjusted to ≈ 1 × 108 cells per ml.  
Flow cytometry was used to test platelets for their purity, state of activation in platelet 
rich plasma (PRP)/purified platelet suspensions and their ability to respond to agonists 
such as TRAP (thrombin receptor-activating peptide, Sigma-Aldrich, Madrid, Spain) or 
PMA (phorbol 12-myristate 13-acetate, Sigma-Aldrich, Madrid, Spain). Fluorescently 
labelled monoclonal antibodies specific for well-known platelet activation markers 
(CD62P, CD63, active form of GPIIb/IIIa) and fluorescent-annexin 5 (A5) that binds to 
phosphatidylserine (PS) were used in the flow cytometry experiments. Platelets were 
identified by staining with anti-CD41a (platelet specific marker). All antibodies and 
fluorescent markers were purchased from BD Biosciences (Madrid, Spain). Light scatter 
and fluorescence data from 10,000 events were collected with all the detectors in the 
logarithmic mode. Flow Jo software (Tree Star Inc, Oregon, USA) was used to determine 
the percentage of platelets positive for antibody binding for different platelet activation 
markers. Mean fluorescence intensity for the positive and negative events was 
determined to obtain the level of expression of various platelet activation markers. 
Once platelets were confirmed to be in a quiescent state, as well as responsive to agonists, 
purified platelets, with and without extracellular Ca2+ (Plt+Ca2+; Plt-Ca2+) or PRP were 
incubated with clean and sterile BC, BC/PVA and ePTFE membranes. For these 
experiments, the membranes were cut and deposited into autoclaved eppendorf tube 
caps. Purified platelets or PRP preparations were incubated with these materials for 
various time periods (10, 30, 50 and 180min) at 37oC. The entire set up was put inside a 
clean and covered Petri dish, which was then placed inside a 37oC incubator to avoid any 
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contamination. After incubation, the supernatants were removed and collected in an 
eppendorf tube for immediate analysis by flow cytometry. The non-adherent platelets in 
the supernatant from each sample were stained for the same markers (CD62P, CD63, PS 
and activated GPIIb/IIIa) to check for their activation state. The surface adhered platelets 
were fixed with 2.5% glutaraldehyde and stained with the antibodies specific for CD41a, 
CD62P and CD63, for their analysis by confocal microscopy to assess platelet adhesion 
and activation. 
 
Results and Discussion 
Whole Blood Clotting Time 
 
Whole blood was used to determine clotting times and provide information on the 
thrombogenicity and pro-coagulative activity of each biomaterial. In this assay, whole 
blood is allowed to clot in contact with a biomaterial. As clotting occurs, more red blood 
cells are retained in the clot, and therefore less hemoglobin is released by lysis upon 
addition of distilled water. A hemocompatible material will therefore maintain a higher 
absorbance value over time. Results show (Figure 2-1) that ePTFE and polystyrene 
(negative control) are the least thrombogenic; conversely, the glass microspheres 
present the quickest clotting time. BC appears more thrombogenic than either ePTFE or 
polystyrene, consistent with the results of Andrade et al [24]. The results for BC/PVA 
show no statistical difference (p≥0.05) compared to those of BC alone. Andrade and 
colleagues [24] observed, in agreement with others [25], that whole blood clotting time 
is related - to some extent - to the surface area of the material. The surface area of the 
bottom of the microtitter plate well is 1.21cm2. The ePTFE samples were cut and 
stretched in order to sit flush and cover the well bottom and so surface of contact was 
similar to that of the negative control. In the case of both BC and BC/PVA, these hydrogels 
are porous and present a dome shaped structure that does not sit flush to the bottom of 
the microtitter wells. This increases the surface of biomaterial-blood contact which may 
adversely affect the comparative analysis of the results. Once dried, BC and BC/PVA 
membranes lose most of their original thickness (from 3mm down to 0,068mm in the 
case of BC), hence they are less porous. The resulting dried membranes present a similar 
surface of contact to that of ePTFE and the negative control. As expected, the clotting time 
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observed on the dried membranes was closer to that of both the negative control and 
ePTFE. Once again, no significant difference was observed between BC and BC/PVA.  
 
Plasma Recalcification Profile  
 
The plasma recalcification profile obtained in response to PPP contact to a material is 
often used as a measure of activation of the intrinsic pathway [21, 26]. As plasma becomes 
more turbid due to the accumulation of clotting by-products, absorbance increases. The 
measure of pro-coagulative activity in this test is given by the time it takes to achieve half 
the maximum absorbance; the higher this value, the less thrombogenic the material.  For 
this assay (Figure 2-2) glass microspheres serve as a positive control. The glass 
microspheres are generally accepted as positive controls in this respect due to their 
negatively charged surface that triggers protein adsorption and activates coagulation 
factors.  
Figure 2-1 - Whole Blood Clotting Time for wet and dry bacterial cellulose (BC), bacterial cellulose/polyvinyl alcohol 
(BC/PVA) and expanded polytetrafluoroethylene (ePTFE). The positive (+) Control used were glass microspheres and the 
negative (-) control the polystyrene microtitter plate. 
 
Chapter 2 – Hemocompatibility study of a bacterial cellulose/polyvinyl alcohol nanocomposite 
AF Leitão 58 
The positive control was found to be significantly different (p<0.05), with no statistical 
differences found among the other tested samples. Similarly to what was reported by 
Andrade [24], ePTFE presents a lower pro-coagulating activity than BC (higher half 
maximum absorbance time - 6.5 versus 5.5min, respectively). Of particular note is the 
result for BC/PVA, which outperforms ePTFE. This suggests that the incorporation of PVA 
improves the performance of BC, as may be inferred from the higher half maximum 
absorbance time (7min). 
 
Factor XII Activation 
In order to further characterize the activation of the intrinsic pathway, direct 
quantification of the catalytic activity of both free (Figure 2-3) and adhered (Figure 2-4) 
activated Factor XII was performed using a chromogenic substrate. The chromogenic 
substrate (S-2302) is broken down, specifically, by the activated form of Factor XII 
(Factor XIIa). The results are expressed as the Factor XII activation upon exposure to the 
Materials, normalized to the value obtained using the positive control (glass 
microspheres).  
Figure 2-2 - Plasma Recalcification Profile of Platelet Poor Plasma (PPP) in the presence of bacterial cellulose (BC), 
bacterial cellulose/polyvinyl alcohol (BC/PVA) and expanded polytetrafluoroethylene (ePTFE) along with glass 
micoshperes. The positive control was obtained by addition CaCl2 to PPP in a polystyrene plate. 
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The results obtained with BC and BC/PVA present no statistical differences (p≥0.05). The 
thrombogenicity of both materials is however different from that of ePTFE: they induce 
less free Factor XII activation; the differences are statistically significant (Figure 2-3).  
All of the materials showed some adhered Factor XIIa (Figure 2-4). Similar amounts are 
detected on BC and ePTFE, with no statistical difference between them (p≥0.05). On the 
other hand, BC/PVA presents significantly (p<0.05) lower values for adhered Factor XIIa 
than the other two materials. Overall, BC/PVA seems to be triggering the lowest response 
of the intrinsic coagulation cascade. Thus, again, PVA seems to a have a beneficial impact 
on the BC hemocompatibility. 
It is generally accepted that synthetic materials with a negatively charged surfaces trigger 
the activation of Factor XII via conformational change to a Factor XIIa-similar molecule 
[4, 27-29]. We expect that the surface charges on BC, BC/PVA, and ePTFE are similar and 
small compared to the highly charged glass spheres. Therefore the differences we 
observe in the propensity of these materials to activate FXII are not related to differences 
in their surface charge but to their hydrophilicity/hydrophobicity. Indeed, while some 
authors suggest that there is little difference in terms of FXII activation between 
Figure 2-3 - Percentage of Factor XII Activation, as compared to glass microspheres (+ Control), over time of bacterial 
cellulose (BC), bacterial cellulose/polyvinyl alcohol (BC/PVA), expanded polytetrafluoroethylene (ePTFE) and 
polystyrene plate (- control). Measurements were obtained from absorbance of chromogenic substrate S-2302 
(chromogenix). 
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hydrophobic and hydrophilic surfaces [27], others assert that hydrophilic surfaces are 
more prone to induce Factor XII activation [22]. This is thought to happen due to the so-
called adsorption-dilution that occurs on the hydrophobic surfaces, where more proteins 
adsorb in general and FXII is diluted [27]. We observe the opposite: the more hydrophilic 
BC and BC/PVA hydrogels are less effective in activating FXII than the hydrophobic 
ePTFE.  
It must be realized, however, that activation of Factor XII does not suffice for the 
activation of the intrinsic pathway, the complex interactions between several proteins on 
the surface of the materials may result in more or less effective amplification [30]. 
 
Platelet Adhesion and Activation Studies 
 
While platelet adhesion to BC [31] and PVA grafts [32] has already been described in the 
literature, the detailed characterization of platelet response on these surfaces, especially 
the newly developed PVA-modified BC surface, has not been done. Here we studied the 
Figure 2-4 - Absorbance of Adhered Factor XII on the surface of bacterial cellulose (BC), bacterial cellulose/polyvinyl 
alcohol (BC/PVA) and expanded polytetrafluoroethylene (ePTFE) over time. The activity of Factor XII was measures by 
use of chromogenic substrate S-2302 (chromogenix). 
 
Chapter 2 – Hemocompatibility study of a bacterial cellulose/polyvinyl alcohol nanocomposite 
AF Leitão 61 
adhesion and activation of platelets upon interaction with the BC-based materials. To do 
so, we exposed BC and BC/PVA membranes to PRP for different time periods—10, 30, 50 
and 180min—at 37oC and assayed for the expression of the activation markers on the 
surface-adhered platelets and on the platelets in the bulk solution above the surfaces by 
immunostaining.  
We studied four classical markers of platelet activation: transmembrane proteins CD62P 
(P-selectin) and CD63 (present in the membranes of the granules stored inside the resting 
platelets and brought to the surface upon activation), active conformation of the integrin 
complex GPIIb-IIIa, (constitutively expressed on platelet surfaces but undergoes 
conformation changes upon activation), and phospholipid phosphatidyl serine (located 
in the cytoplasmic leaflet of the cell membrane in the resting platelets but is brought to 
the outer leaflet upon activation) [33]. Surface-adhering platelets were studied using 
confocal laser scanning microscopy (CLSM). The results of these experiments, performed 
with BC, BC/PVA and ePTFE are shown in Figure 2-5. After 10min, very few platelets 
adhered on either BC or BC/PVA as compared to ePTFE, which showed a higher level of 
platelet adhesion (c.f. the number of platelets on the various surfaces in Figure 2-5A). 
More platelets were found on BC and BC/PVA surfaces after 50min of incubation, while 
no significant difference in the number of platelets between 10 and 50min was observed 
on ePTFE (Figure 2-5B); larger patches/clusters could sometimes be observed after 50 
min (arrowhead in Figure 2-5B). Surface-adhered platelets were found to be activated 
(expressed CD62P and CD63) on BC and ePTFE surfaces both after 10 and 50min (Figure 
2-5-A, B). Judging from the level of fluorescence intensity, the level of expression of 
CD62P and CD63 was higher on ePTFE than on BC. BC/PVA-adhered platelets were 
activated only after 50min (Figure 2-5B). The level of activation in this case was also 
lower than that observed on ePTFE. Similar results were obtained for purified platelets 
incubated with surfaces in the absence of calcium (data not shown). Platelet response 
observed on ePTFE is consistent with the literature where it has been stated that protein 
adsorption on the ePTFE surface leads to adhesion and activation of platelets [34].  
In order to have a better understanding of the interactions between platelets and these 
materials, we further studied the behavior of platelets in the bulk solution, above the 
biomaterial surface. Previous studies have shown that in addition to platelets adhering 
to the material surface, the non-adherent platelets may get activated upon blood-
biomaterial interaction [34, 35]. These fluid-phase activated platelets contribute to 
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thrombotic and inflammatory reactions at a distance from the original implantation site 
[36-38]. The activation of non-adherent platelets was investigated using flow cytometry 
[39]. The results for these experiments are shown in Figure 2-6 and 2-7. We determined 
the percentage of cells positive for a particular surface marker (Figure 2-6) and also the 
level of expression of that marker (calculated from mean fluorescence intensity) on the 
positive cells (Figure 2-7). The degree of non-adhered platelet activation upon contact 
with the surface is here presented as an increase in the expression of a particular marker 
as compared to the freshly isolated resting platelets (Figure 2-7, Mean fluorescence 
intensities ratio, MFIR). Both PRP and purified platelets were used in the experiments. 
For PRP, CD62P and CD63 expression were used to monitor activation, while for purified 
platelets all four activation markers (CD62P, CD63, PS and activated GPIIb/IIIa) were 
used. This is because detection of PS and activated GPIIb/IIIa expression requires 
extracellular Ca [40, 41], which would induce clotting when using PRP.  
Figure 2-5 - Images obtained by confocal laser scanning microscopy of the surfaces of bacterial cellulose (BC), bacterial 
cellulose/polyvinyl alcohol nanocomposite (BC/PVA) and ePTFE after incubation with platelet rich plasma (PRP) for 10 
and 50 minutes. The platelets were marked with antibodies for CD41a (a platelet marker) and the activated platelet 
markers CD63 and CD62P. 
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Freshly isolated platelets were in their quiescent state (Figure 2-7) and showed negligible 
expression of the activation markers until stimulation with TRAP or PMA (positive 
controls). Following incubation with PRP, no discernible difference in the expression of 
the activation markers CD62P and CD63 was observed for all 3 biomaterials at time 
points of 10, 30 and 50min (Figure 2-7A, B). However, a significant difference in the 
CD62P and CD63 expression was observed after 180 min: ePTFE showed a 13 fold 
increase in CD62P expression level as compared to BC and BC/PVA, which showed a 
modest 2-3 fold increase relative to the quiescent platelets (Figure 2-7A). Similarly, the 
increase in CD63 expression was 9 fold for ePTFE and 2 fold for BC and BC/PVA (Figure 
2-7B). Additionally, the results for percentage of cells (Figure 2-6) positive for these 2 
markers were also in accordance with the trends obtained for their expression levels. For 
BC and BC/PVA, only 16% and 18% of cells, respectively, showed CD62P expression 
whereas for ePTFE it was almost much higher (67%) of BC and BC/PVA (Figure 2-6A). 
Again, for CD63, ePTFE presented much more CD63 positive cells (Figure 2-6B) as 
compared to BC materials (80% and 40%, respectively). These results support our claim 
that, in the presence of plasma proteins, BC and BC/PVA prove to be more 
hemocompatible as compared to ePTFE in terms of plasma recalcification profiles, Factor 
XII activation, platelet adhesion and activation (both in bulk and on surface of the 
biomaterials). 
To complement the results obtained with PRP, we also studied the activation of purified 
platelets in the presence, as well as in the absence, of calcium. Direct effects of bare 
surfaces on platelets have previously been reported [24, 42-46]. The results obtained 
with surface adhered platelets were already discussed above (Figure 2-5), while the 
results of platelet activation in solution are shown in Figure 2-6 and 2-7 together with 
those of PRP. The non-adherent platelets incubated with ePTFE showed almost no 
CD62P/CD63 expression, both in the presence and absence of calcium, for all time points 
(Figure 2-7-A,B). After 180min, in the absence of calcium, platelets incubated with BC and 
BC/PVA showed roughly a 2 fold increases in CD62P and CD63 expression, further 
increased by about 8 and 2 fold, in the presence of calcium, for the same markers. 
Similarly, BC and BC/PVA presented higher percentage of cells positive for CD62P and 
CD63 as compared to ePTFE (Figure 2-6-A,B).  
In the case of purified platelets, we could also study the effect of surface interaction on 
the expression of PS and the active form of GPIIb/IIIa. No increase in the expression of  
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activated form of GPIIb/IIIa relative to that in quiescent platelets was observed for any 
of the three surfaces (Figure 2-6D and 7D). PS expression was found to fluctuate (Figure  
Figure 2-6 - Percentage of platelets (Plt) with a positive marking for CD62P (A), CD63 (B), PS (C) and GPIIB/IIIa (D), as 
counted using a flow cytometer, on platelet surfaces exposed to bacterial cellulose (BC), of a bacterial cellulose/polyvinyl 
alcohol nanocomposite (BC/PVA) and ePTFE. The samples were incubated for 10, 30, 50 and 180 minutes with platelet 
rich plasma (PRP) and also a platelet solution with (Plt+Ca) and without (Plt-Ca) 2mM Ca added to the solution. 
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2-7C). After 180min, the PS expression is lower (25 fold increase) for BC/PVA as 
compared to BC (60 fold increase) and ePTFE (50 fold).  
Figure 2-7 - Mean fluorescence intensities (MFIR) , as obtained by flow cytometry, for the expression of CD62P (A), CD63 
(B), PS (C) and GPIIB/IIIa (D) on platelet surface after exposure to BC, PC/PVA and ePTFE for 10, 30, 50 and 180 
minutes. The surface were incubated with platelet rich plasma (PRP) and also a platelet solution with (Plt+Ca) and 
without (Plt-Ca) 2mM Ca added to the solution. 
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The observed PS fluctuations are interesting, but their significance is not altogether clear. 
They may be related to platelet activation or reflect the loss of PS in the microparticles 
generated upon activation. The consensus is that PS exposure on the platelet surface is 
necessary for thrombin generation, but whether it is sufficient for the pro-coagulant 
function of platelets is still debated [47]. Moreover, there are inconsistencies in literature 
regarding PS detection, because annexin A5 binding may be interfered with by other PS 
binding proteins, including the factors of the clotting cascade. Some authors suggest that 
activation leads to different platelet subpopulations, only some of which expressing PS 
[48].  
In summary, it appears that in the absence of plasma proteins (that is, when using 
purified platelets), BC and BC/PVA surfaces activate platelets in the bulk more efficiently 
than ePTFE. Therefore, their superior performance noted in PRP (which better mimic the 
in vivo conditions) is most likely due to a passivating layer of plasma proteins.  
As noted above, the hydrophilic surface of BC and BC/PVA does not favor protein 
unfolding/conformational changes, hence not leading to Factor XII activation and not 
causing as much platelet activation as protein layers on other surfaces. These results are 
also in accordance with the findings of Sperling and colleagues [22] who showed that 
platelet adhesion and activation was favored by highly hydrophobic surfaces. 
 
Hemolytic Index  
 
The hemolytic index is a direct measure of free hemoglobin present in plasma after 
exposure to a given material or stressor. An isotonic solution (PBS) served as the negative 
control and distilled water as the corresponding positive control, inducing osmotic stress 
that ruptures red blood cells. The assay was performed as according to the Standard 
Practice for Assessment of Hemolytic Properties of Materials from the American Society 
for Testing and Materials (ASTM F756-00, 2000); the standard classifies the material as 
non-hemolytic (0-2% of hemolysis), slightly hemolytic (2-5% of hemolysis) and 
hemolytic (>5% of hemolysis). Our results (Table 1) show that both BC and BC/PVA are 
classified, as according to the standard, as non-hemolytic while, ePTFE is classified as 
slightly hemolytic. 
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Table 2-1 - Hemoglobin index blood after contact with of bacterial cellulose (BC), bacterial cellulose/polyvinyl alcohol 
(BC/PVA) and expanded polytetrafluoroethylene (ePTFE). 
Sample % 
PBS 1.84 
mQ H20 (C+) 95.34 
BC 1.85 
BC/PVA 1.94 
ePTFE 2.42 
 
Complement System Activation 
 
In order to further study the blood/material interaction, we also looked at the activation 
of the complement system by BC and BC/PVA. Among the three possible mechanisms the 
alternative activation pathway is of particular importance. In blood/biomaterial 
interactions the alternative activation pathway is triggered directly by foreign surfaces 
that do not provide adequate down-regulation of the protease C3-convertase.  
We determined the overall percentage of C3 cleavage products, by semi-quantitative 
Western blot analysis, in order to determine the degree of activation of the complement 
system. The results are presented as the percentage of cleaved products as compared to 
the positive control, obtained by addition of cobra venom factor to the plasma. Our results 
show that both BC and BC/PVA significantly activate complement (Figure 2-8). 
Complement activation of the BC samples presents an average of 64.5±4.2%. The effect is 
slightly mitigated in the case of BC/PVA with an average of 55.6±5.0% activation. 
Considering the negative control presents an average 39.6±4.0% this means an increase 
of 24.9% for BC and 16.0% for BC/PVA. Additionally, dry BC was also tested (results not 
shown) and was found not to activate the complement system, the values obtained were 
lower than those of the negative control. 
The mechanisms by which complement is activated are still not fully understood but it is 
well established that different biomaterial surfaces have different complement-activating 
properties. Physical properties such as hydrophobicity affect the activating ability. 
Hydrophobic surfaces are more potent activators than hydrophilic ones, and 
incorporation of chemical groups such as –NH2, -OH or -COOH influences the activation 
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of complement [49]. Both BC and BC/PVA have many surface -OH groups which would in 
turn activate the complement system to some extent. However, the total increase of C3 
cleavage products is relatively low, as compared to the negative control.  
Interestingly, in both the presence of PVA and in the dry BC membranes, complement 
system activation is mitigated or canceled out. This may be due to a probable reduction 
of the total number of free surface -OH groups, resulting in reduced biomaterial derived 
C3 cleavage [49]. 
 
Conclusions 
 
BC and PVA have been extensively studied by various research groups for biomedical 
applications in blood contacting materials. This is the first study, to our knowledge, to 
present extensive results on the hemocompatibility of a nanocomposite of BC 
impregnated with PVA, namely in regards to platelet activation profiles on BC and the 
Figure 2-8 - Representative images of Western Blot and Percentage of C3 Cleavage for BC and BC/PVA. Both BC and 
BC/PVA were tested under 5 conditons: (1) 2 hour preincubation at 37oC with active plasma and then 1 hour incubation 
with plasma and Veronal buffer at 37oC; (2) ) 2 hour preincubation at 37oC with inactive plasma and then 1 hour 
incubation with plasma and Veronal buffer at 37oC, (3) 1 hour incubation with plasma and Veronal buffer for 1hour at 
37oC, (4) 3 hour incubation with plasma at 37oC and (5) 3 hour incubation with plasma and Veronal buffer at 37oC. 
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BC/PVA nanocomposite. The results consistently show that these materials have a good 
hemocompatibility, probably due to both low activation of platelets and Factor XII. 
The results for platelet adhesion and activation profiles demonstrate that both BC and 
BC/PVA exhibit superior performance as compared to ePTFE. Platelet activation on 
ePTFE seems to be mediated by plasma proteins. It appears that, on ePTFE, activation of 
the intrinsic pathway (higher Factor XII activation, Figure 2-3) leads to higher thrombin 
generation and this could explain the high level of platelet activation observed on this 
surface. The indication that platelets can be activated by BC and BC/PVA is relevant; 
however, it seems to be mitigated by the presence of other plasma constituents. BC 
appears thus as a suitable material for the development of cardiovascular grafts. 
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Chapter 3 
Production and Characterization of a New 
Bacterial Cellulose/Poly(Vinyl Alcohol) 
Nanocomposite 
 
Adapted from: Leitão A.F.; Silva, J.P.; Dourado, F.; Gama, M.; Production and Characterization of a New 
Bacterial Cellulose/Poly(Vinyl Alcohol) Nanocomposite; Materials; Volume 6, pp 1956-1966; 2013 
(DOI:10.3390/ma6051956) 
 
 
 
Bacterial cellulose (BC) is characterized for its high water holding capacity, high 
crystallinity, an ultrafine fiber network and high tensile strength. This work 
demonstrates the production of a new interpenetrated polymer network nanocomposite 
obtained through the incorporation of poly(vinyl alcohol) (PVA) on the BC matrix and 
evaluates the effect of oven drying on the morphological, mechanical and mass transfer 
properties of the composite membranes. Both the addition of PVA and oven drying induce 
the appearance of larger pores (circa 1–3µm in average diameter) in dried BC/PVA 
membranes. Both types of treatments also affect the permeability of the composite, as 
assessed by the diffusion coefficients of polyethylene glycol (PEG) molecules (900, 8,000, 
35,000 and 100,000Da) across the membranes. Finally, the Young’s modulus of dry 
pristine BC decreases following PVA incorporation, resulting in a change from 3.5GPa to 
1GPa and a five-fold loss in tensile strength. 
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Introduction 
 
Bacterial cellulose (BC) is produced mainly by Gluconacetobacter strains as a hydrated 
membrane or pellicle at the air-medium interface and represents a promising biomaterial 
that has been the subject of intensive research and development. It is formed by repeated 
dimers of β-1,4 linked D-glucose units and reveals unique properties, including high 
water holding capacity, high crystallinity, an ultrafine fiber network, high tensile strength 
and a relatively simple, cost-efficient production [1, 2]. Moreover, its membrane 
morphology, along with its physicochemical properties, may be easily manipulated by 
controlling growth conditions (in situ modifications) and/or by chemical modifications 
(ex situ modifications) that allow the desired functionality [3].  
For the past years, BC has gained interest in the field of tissue engineering, being studied 
by several research groups as a scaffold for cartilage [4, 5], wound dressing [6, 7], dental 
implants [8, 9], nerve regeneration [10] and vascular grafts [11-13]. The incorporation of 
living cells into the material is highly desirable; however, the limited porosity precludes 
proper tissue ingrowth.  
Mass transfer limitations may have a major impact on cell growth and differentiation and 
even compromise the utility of the scaffold or its usage as a drug delivery device [14, 15]. 
Thus, it is important that a material, once implanted, allows the permeation of water, 
metabolic products and chemical signals in the aqueous physiological environment [16]. 
Mass transfer experiments previously conducted by Sokolnicki and colleagues [3], who 
aimed at determining the transport and interaction parameters of selected molecules 
through a hydrated BC system, indicated the presence of dual transport mechanisms, for 
solute transport through the continuous water phase and cellulose matrix, with some 
hindrance of molecular diffusion via fiber obstruction. 
In addition to suitable mass transfer properties, the geometry of the material at the nano- 
and micro-scales has already been shown to affect cell behavior [17]. For example, the 
geometry of the microenvironment around osteoprogenitor cells has been shown to 
regulate the progress of osteoinduction in bone grafts and scaffolds [18]. Thus, the 
control of BC structure and porosity at the nano and microscales assumes great relevance 
for applications in which BC is used as a cell scaffold and has been a focus of research 
[17]. 
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Poly(vinyl alcohol) (PVA) is a synthetic hydrophilic biocompatible homopolymer with 
desirable characteristics for biomedical applications, such as hemocompatibility and 
non-linear mechanical properties, both in tension and compression and viscoelastic 
behavior [19-21]. Additionally, it can be physically cross-linked by a low temperature 
thermal cycling process. This physical cross-linking has the advantage of not leaving 
residual amounts of any chemical cross-linking agent [22]. Moreover, its mechanical 
properties can be modified by regulating parameters, like the PVA concentration, the 
number of freeze/thaw cycles, thawing rate, the freezing holding time and freezing 
temperature [23]. The combination of PVA and BC has been previously proposed by 
Millon and Wan [23]; however, these authors used PVA as the matrix for their 
nanocomposite, adding BC fibers homogenates to the PVA solution. The PVA/BC 
suspension is then cast to a desired shape. It can then be fine-tuned to exhibit varying 
mechanical properties via the thermal cycle process [23].  
Herein, we describe the PVA cross-linking on an intact BC membrane originating a double 
network where the PVA fibers fill the porous BC matrix. The composite obtained is 
therefore an interpenetrating polymer network. This composite has been reported before 
[24], but has remained relatively unstudied. The preparation method we adopted, in 
regards to impregnation of a BC hydrogel with a PVA solution, is similar to that one 
presented by Gea and colleagues [24]. However, our nanocomposite differs in terms of 
PVA concentration, impregnation time and the molecular size of the PVA used. In order 
to better understand the nanocomposite we are using, we have characterized the surface 
morphology, permeability, mass transfer and mechanical properties of the composite in 
this work. To our knowledge, this is the first study to present an interrelation between 
the morphology, mechanical properties and the permeability of a BC/PVA composite. 
 
Experimental Section 
Bacterial Cellulose and Bacterial Cellulose/Poly(Vinyl Alcohol) 
 
Gluconacetobacter xylinus (ATCC 700178) was grown in a modified Hestrin-Schramm 
medium, supplemented with 2% Corn Steep Liquor and 0.6% ethanol, at pH 5.0. 
Inoculated Erlenmeyer flasks were then placed in an incubator, and the culture was 
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allowed to grow for 7 days, at 30°C, under static conditions. The resulting BC membranes 
were washed thoroughly with distilled water and further purified with 4% NaOH at 60°C 
for 90 min, after which they were again washed thoroughly with distilled water until the 
pH of the membranes was the same as that of distilled water. The membranes where then 
cut thinly into 2–3 mm thick membranes. 
In order to produce the BC/PVA nanocomposite, the purified BC membranes were 
immersed in a 10% PVA solution (Mw = 30–50,000g/mol) for 24h at 80°C. The 
membranes were then frozen at −20 °C for 24 h, after which they were thawed at room 
temperature in distilled water and washed to remove any excess PVA from the 
membranes. 
Dry BC and BC/PVA samples were obtained by thoroughly drying the samples in an 
incubator oven at 50°C for a minimum of 12h. The membranes obtained through this 
drying process suffer a significant loss in thickness as compared to the never dried 
membranes, while only slight variation in thickness was registered in the freeze-dried 
samples. 
 
SEM Imaging 
 
BC and BC/PVA samples were prepared in 2 ways: “dried” (d) at 50°C overnight, so as to 
remove all residual water, and then rehydrated before freeze-drying; or “never-dried” 
(nd), which were freeze-dried directly after production and then sputter-coated with a 
gold/palladium mixture. Each sample, whether dried first or maintained wet until freeze-
drying, was initially 3mm thick. The sample’s morphology was then observed with a Nova 
NanoSEM 200 Scanning Electron Microscope operating at 5kV (FEI Europe, Eindhoven, 
The Netherlands). 
 
Stress-Strain Analysis 
 
Dry BC and BC/PVA strips, with 5 × 1cm, were cut from a single sheet of each material 
and then analyzed using on a Shimadzu AG-X 50 kN at a traction speed of 5mm/min and 
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a load cell of 1kN. Each sheet was initially 1.5cm thick and then dried at 50°C overnight, 
so as to remove all the water. BC strips were on average 0.065 ± 0.005mm thick, whereas 
BC/PVA strips were on average 0.480 ± 0.050mm thick. Six replicates per sample 
material were tested in order to obtain a significant set of data. Special care was taken in 
order to attempt to prevent sample slipping from the hydraulic grips by using both fine 
grain sandpaper and construction paper.  
 
Diffusion Assays  
 
Diffusion assays were carried out using custom-built diffusion cells. Each cell consisted 
of a donor chamber and a receptor chamber separated by a membrane of either never-
dried (nd) or dry (d) BC or BC/PVA with 9.61cm2. Four different molecular mass 
polyethylene glycol (PEG) solutions were used in these assays: 900, 8000, 35,000 and 
100,000Da at a concentration of 50mg/mL. 
Each donor chamber was filled with 3.5mL of PEG solution and the receptor chamber 
with 3.5mL of distilled water. 100µL samples were taken at specific intervals to 
determine the retention time for each of the solutions. The refraction index of the samples 
was measured on a Knauer RI Detector K-2300 (Knauer) connected to Pharmacia LKB 
LCC-500 Plus FPLC (GE Healthcare Life Sciences) in order to obtain the diffusion profiles 
for each molecular weight PEG through ndBC, dBC, ndBC/PVA and dBC/PVA. 
Membrane thickness (L) was determined with a standard outside micrometer at three 
different locations on each membrane and then averaged. The diffusion coefficients (D) 
were calculated by testing the retention time, estimated from the slope of the linear 
regressions in the diffusion curves (θ), before running into the balance state, according 
to the following equation: 
D ＝ L2/6θ 
Reagents 
 
All reagents used were acquired from Sigma-Aldrich Quimica, S.L. (Sintra, Portugal). 
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Results and Discussion 
Morphology and Characterization of BC and BC/PVA Membranes 
 
SEM imaging was used to reveal the morphological features of the BC and BC/PVA 
membranes. The three-dimensional structure of the BC hydrogel is well documented as a 
fibrous, porous network of un-oriented nanofibers [5, 25, 26]. The membranes were 
freeze-dried so that the three-dimensional morphology would be preserved as in a 
hydrated state, before and after an initial drying step. The scanning electron micrographs 
obtained (Figure 3-1) show the fibrous morphology of the network. All samples 
presented similar morphological characteristics in terms of the fiber thickness, 
randomness of fiber distribution and three-dimensional orientation.  
The main and most noticeable differences have to do with the relative dimension and 
overall number of pores, which is associated with the preparation method and 
composition of the membrane. The incorporation of PVA (Figure 3-1B) is clearly 
noticeable in the composite membranes, although, other than some fibers that project 
from the membrane surface, the BC and PVA fibers where rather similar, slightly varying 
in thickness. It was possible to distinguish, to some degree, the PVA from BC fibers in two 
ways: BC fibers degraded slightly quicker under the electron beam of the SEM than PVA 
and, also, some from PVA fibers that project and loop from the surface of the BC 
membrane. These are PVA fibers that formed on top of the BC surface. 
Previous work had shown that the BC/PVA nanocomposite was made up of 
interpenetrated fibers [24]. The molecular size and concentration of PVA used does not 
allow for a PVA hydrogel to form; therefore, rather than a PVA matrix embedding the BC 
fibers, we have found, as expected, PVA fiber wells integrated into the original BC 
hydrogel forming an interpenetrated network. The PVA fibers inside the BC membrane 
randomly bridge individual BC fibers, rising the overall density of the hydrogels. 
Comparison between the morphology of never-dried (nd) (Figure 3-1A, B) and dried (d) 
(Figure 3-1C, D) membranes showed clear and marked structural differences. Once BC 
membranes are dried, the overall thickness of the membranes greatly decreases, 
resulting in a higher fiber density and, consequently, a much less porous membrane, as 
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can be observed in Figure 3-1C, when compared to the ndBC membrane (Figure 3-1A). 
The most remarkable structural difference is observed in the morphology of the dBC/PVA 
membranes (Figures 3-1D and 3-2). In this case, there are two very clearly distinct 
regions comprised of different fiber structures. A large portion of the membrane 
contained large pores ranging from 500nm to 2µm in diameter (in ndBC, the largest 
measurable pores were 120nm in diameter) that are separated by very densely 
compacted regions with no discernible pore structures (Figure 3-2). PVA was largely 
present in the porous regions, with BC making up much of the denser regions. It should 
be noted, however, that both BC and PVA fibers could be observed across the entirety of 
the membrane. 
Figure 3-1 - SEM micrographs of (A) never-dried bacterial cellulose (BC); (B) never-dried BC/poly(vinyl alcohol) (PVA); 
(C) dried BC; and (D) BC/PVA at 100,000× magnification. 
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The porous and densely compacted regions of the dried BC/PVA membranes (Figure 3-
2) are due to the presence of PVA. When BC dries, the fibers collapse onto each other and, 
due to the lack of elasticity, should maintain their overall relative position. When PVA 
fibers dry or are heated, they contract [27]. As the PVA fibers contract inside the BC 
network and due to a non-uniform integration of PVA that is associated with the 
heterogeneity of the BC network, regions with a higher BC fiber density bundle together. 
The remaining spaces, where the overall number of BC fibers was lower, are bridged by 
PVA and a few random BC fibers originating in the porous regions.  
 
Mechanical Characterization of Dry BC and Dry BC/PVA Membranes 
 
BC is known for its high tensile strength, with a Young’s modulus’ ranging from 1MPa to 
114GPa [24, 28-31], varying according to the membrane’s density, dimensions, treatment 
and preparation methods. Generally, BC is regarded as lacking elastic properties, since 
hydrogen bonds formed between individual BC strands contribute to the stiffness of the 
hydrogel. PVA, on the other hand, is known for its elasticity and relatively low tensile 
strength [24]. As found by Gea and colleagues [24], the impregnation of PVA into the BC 
network affects the tensile strength of the nanocomposite. This occurs by steric 
hindrance, where the overall number of hydrogen bonds formed between individual BC 
fibers during the drying process lowers, due to the presence of PVA [31, 32].  
Our findings are in accordance with this theory. dBC resisted better to tensile stress 
deforming, slightly before abruptly rupturing along the midriff of the strips, with no 
Figure 3-2 - Three SEM micrographs of the same dry BC/PVA membrane at 15,000× magnification with two very distinct 
regions of densely compacted fibers and regions with large pores. 
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discernible tearing prior rupture, at a tensile strength of 1.306 ± 0.297GPa. Whereas, 
dBC/PVA under lower tensile stress started to gradually rip, and so, consequently, tensile 
strength was nearly five-times lower, 0.271 ± 0.036GPa. The effect of PVA addition on the 
Young’s modulus is also noticeable. The Young’s modulus for dBC and dBC/PVA was, 
respectively, 3.5 ± 0.5GPa and 1 ± 0.3GPa (Figure 3-3).  
SEM micrographs also present a supporting explanation for the loss in tensile strength. 
The uneven distribution of PVA across the nanocomposite contributes to the reduction in 
overall mechanical performance, due to the heterogeneity of the dBC/PVA membrane. 
The dBC/PVA membrane presents regions with large pores, which, as mentioned 
previously, have a lower fiber density, a large portion of which is PVA. The end results of 
the combination of large pores and high PVA content is that, ultimately, these are 
mechanically weaker than the surrounding, denser, regions. Therefore the membranes 
would rupture more easily across these areas. This also explains why the dBC/PVA rather 
than rupturing abruptly, as with dBC, tended to rip. The force applied would cause stress 
failure on the weaker regions, and the uneven impregnation of the BC hydrogel with PVA 
negatively affected the tensile strength and the Young’s modulus of the nanocomposite. 
The same did not occur with the dBC membranes. In this case, the drying process does 
not result in higher surface heterogeneity and/or pore distribution. The dBC membranes 
Figure 3-3 Stress-strain curves of dry strips of BC and BC/PVA. Each strip of 5 × 1 cm (length × width) was 
cut from a single sheet of material and measured multiple times (n = 6). The results here are the averaged 
curves obtained up to the rupture point. 
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present a uniform and non-oriented distribution of fibers (Figure 3-1C), which has the 
end-result of a greater tensile strength and Young’s modulus. 
 
Diffusion Assays 
 
Solute transport has been classified according to two mechanisms: the pore and the 
partition (or sorption) mechanisms [33, 34]. The former states that solutes diffuse 
through micro-channels in the membrane; as for the partition mechanism, the solute 
dissolves or is adsorbed onto the membrane itself and diffuses through or along fibers. 
As described above, the BC and BC/PVA hydrogels are more porous in nature, forming a 
series of channels that would allow for solute diffusion across the membrane via the pore 
mechanism.  
As to test the effect of the structural and morphological changes incurred by the drying 
process on the mass transfer properties, the diffusion across the never-dried (nd) and dry 
(d) states of the materials was tested using PEG probes and the diffusion coefficients 
determined using the time-retention method. It would be expected that the denser the 
membrane (as is the case with the dry membranes), the harder it would be for solutes to 
diffuse across the membrane, since the overall interconnection of pores and channels in 
the membrane would be much lower [35]. Additionally, molecule size would also effect 
diffusion across the membranes, given the low diffusion coefficient in the liquid phase 
and also because molecule collision with the fibers would increase with molecule size. 
The higher the value for the diffusion coefficient, the more permeable the membrane is 
and the easier solutes pass through the membrane matrix. Our results show that in both 
the case of BC and BC/PVA, solute diffusion across the never-dried membranes is easier 
than in the dried membranes (Table 3 - 1). The ndBC membranes presented the highest 
diffusion coefficient values and, so, were the most permeable of the membranes with 
ndBC/PVA second, followed by dBC/PVA and, finally, dBC. 
These results can mostly be explained due to the fiber density of the materials. A less 
dense material will have less fibers in the transport path [3]. ndBC was therefore expected 
to be the most permeable of the membranes. Similarly, the second least dense  
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Table 3-1 - Diffusion coefficients of four different Mw polyethylene glycol (PEG) in BC and BC/PVA samples. 
PEG Mw Diffusion Coefficient (cm2/sec) 
(Da) ndBC dBC ndBC/PVA dBC/PVA 
900 7.40 × 10−5 1.12 × 10−7 4.48 × 10−5 1.16 × 10−5 
8000 2.71 × 10−5 1.79 × 10−8 1.28 × 10−5 1.88 × 10−6 
35000 2.27 × 10−5 1.53 × 10−8 1.10 × 10−5 1.68 × 10−6 
100000 1.95 × 10−5 1.41 × 10−8 9.82 × 10−6 1.50 × 10−6 
 
hydrogel was the ndBC/PVA nanocomposite that, despite the formation and 
entanglement of PVA nanofibers in the BC network (thus, adding to the overall number 
of fibers), still allows for a porous structure similar to that of ndBC. The two denser 
materials would be the dry membranes, due to the aforementioned collapse of fibers onto 
each other, thus blocking and reducing in number the pathways available for solute 
diffusion. However, in the case of the theoretically densest sample, dBC/PVA, the 
diffusion coefficient values present as the third least permeable material. As revealed by 
the SEM imaging (Figure 3-2), the two very distinct regions observed are the reason for 
this occurrence. While, in all the other cases, the pores, regardless of their number, 
distribution and size, are distributed randomly across the entirety of the 3D-structure of 
the membrane. Contrarily, on the dBC/PVA, there are very compact regions and others 
with very large pores. Solute diffusion is facilitated across these extremely porous 
regions, but hindered in the densely compacted regions. Apparently, the balance between 
densely compacted and porous regions must slightly tend towards the latter, due to the 
delay in retention time and, consequently, reduction of the diffusion coefficient.  
Our results are similar to the findings of Sokolnicki [3], which tested the diffusion of 
dextran molecules and showed that molecular size has little effect on diffusion. Higher 
molecule size dictates collisions with the hydrogel fibers, temporary immobilization 
and/or possible rerouting around narrowed passages, according to each. The larger the 
molecule, the likelier it is for these interactions to occur, resulting in a delay in diffusion 
times. The overall number of pores and pathways across the materials, due to overall 
fiber number and density, seems to be the main factor responsible for a slower diffusion. 
This means that diffusion in these membranes is mainly governed by the pore 
mechanism. 
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Conclusions 
 
Previous researchers had shown that a BC hydrogel impregnated with PVA had some 
potential in biomedicine, namely in cardiovascular applications. The work we present 
here shows the mechanical, permeability and morphology changes incurred by both 
incorporation of PVA, in a different concentration and molecular size than previously 
proposed, and the effect of drying the materials.  
Both ndBC and ndBC/PVA are similar in terms of morphology of the hydrogels and fiber 
distribution, with an increase in overall fiber number in BC/PVA. When dried, the 
morphology of both materials change, BC fibers collapse, forming a denser membrane, 
which leads to a decrease in the permeability. Dry BC/PVA membranes suffer dramatic 
changes in terms of morphology, creating two distinct regions: densely compacted 
regions leaving other regions mostly consisting of PVA fibers with large pores. The dual 
nature of the dried BC/PVA membrane affects both the permeability and mechanical 
behavior of the material. The tensile strength of BC decreases, due to the presence of PVA 
impeding the interactions of BC fibers and creating large porous regions that are easier 
to rupture. Potentially, these large pores could serve in aiding cell migration into the 
material and nutrient diffusion across the membrane. Therefore, we here show that by 
promoting physical changes and/or altering the composition of a BC hydrogel, it is 
possible to alter its morphology, mechanical characteristics and permeability. 
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Vascular grafts are used to replace, bypass or maintain function of damaged, occluded or 
diseased blood vessels. Towards   that end several polymers, of both synthetic and natural 
origin, have been studied as small caliber vascular graft alternatives. Bacterial cellulose (BC) 
is among one of those polymers, being studied as an off-the-shelf and ready to use vascular 
graft. Herein, we present a novel, facile and cost-effective method for the production of small 
caliber BC grafts with minimal processing or the requirement for complex bioreactor 
systems. The unique morphology of the graft wall translated into tensile strength above that 
of a native vessel while providing similar values of compliance, out-performing commercial 
alternatives in this regard. As an additional result of the production method the luminal 
surface of the graft presents similar topography to that of native vessels. We have also 
studied the in vivo behavior of these BC graft in a pig model in order to further demonstrate 
their viability. In these preliminary studies, 1 month patency was achieved, with the 
presence of neo-vessels and endothelial cells on the luminal surface of the graft; with no 
evident signs of a foreign body response or fibrosis.   
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Introduction 
 
Data from the World Health Organization (WHO) suggests that the number of people that 
suffer from cardiovascular diseases (CVDs) will increase from 17.3, in 2008, to 23.3 million 
by 2030. In vascular surgery, surgical bypass is fundamental in the treatment of some 
diseases. Vascular grafts replace, bypass or maintain function of damaged, occluded or 
diseased blood vessels. The chosen conduit and its success depend on several factors such 
as availability, size, ease of handling and technical facility, thrombogenicity, resistance to 
infection and dilation, durability, long-term patency and price. 
The most common, and generally considered ideal grafts, are autografts, i.e., vessels collected 
from the patient. There are generally two major downsides to the use of autografts. The first 
is the need for prior surgical interventions, before the actual bypass surgeries, in order to 
collect the autologous vessel. Along with this, the actual availability of these vessels may be 
limited, due to prior interventions. Secondly, these grafts are subject to the natural 
progression of the patient’s disease which can lead to deterioration, over time, of the 
biological grafts [1] and so synthetic grafts have been used for potential application as 
cardiovascular grafts.  
Polyethylene terephthalate (PET or Dacron) and expanded polytetrafluoroethylene (ePTFE) 
grafts are the gold standard, at the moment, for synthetic grafts in large and medium 
diameter (>6 mm) vessels. However, these synthetic alternatives are not yet the ideal 
solution. While demonstrating acceptable results in larger diameter grafts, as internal 
diameter decreases so does its long-term patency [2, 3]. These grafts ultimately fail under 
6mm in diameter, due to surface adsorption of proteins to the luminal and consequent 
activation of platelet activity resulting in clot formation and subsequent thrombosis [4, 5]. 
A large amount of work has therefore been aimed at finding alternative solutions to these 
materials through either natural or synthetic polymer materials [6-8]. The field is ever 
growing and the lack of a clear optimal polymer has led, and continues to lead, to many 
potential options. By either, further development and research into the already existing 
grafts (PET and ePTFE) or the creation of new non-degradable grafts of polyurethane, 
polyvinyl alcohol or bacterial cellulose (BC). Another option is researching and developing 
temporary grafts that ultimately allow for a tissue engineered solution, either by prior cell-
seeding or allowing for native cell migration, attachment and ingrowth. Ultimately these 
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tissue engineered grafts would end up producing a new vessel out of native tissue from a 
scaffold of collagen, fibrin, elastin, silk and polycaprolactone [9-12]. 
One promising candidate is BC. This polymer is a highly pure linear polysaccharide, 
consisting of β (1→4)–linked D-glucose monomers. It is secreted by bacteria of the 
Gluconacetobacter genus. Once secreted, it forms a fibrous network hydrogel that has been 
extensively studied for biomedical applications due to its morphology, high purity, water-
holding capacity, tensile strength, malleability and biocompatibility [13-15] and has been 
proposed for applications such as wound dressings [16], artificial skin[17] or blood vessels 
[18-20] and as a scaffold for tissue engineering [15, 21, 22]. The hemocompatibility of BC has 
been comprehensively studied in our group, with rather promising results (19). 
Many methods have been proposed and patented [23-30] for the production of BC tubular 
grafts. Generally, the methods employed take advantage of the way the BC hydrogel is 
produced at air-medium interfaces [14, 31]. However, these production methods require 
dedicated bioreactors specifically designed for graft production. By using an oxygen 
permeable scaffold upon which BC is produced there are limits to the thickness and density 
of the BC structures because the oxygen rich environment produced by the likes of silicone 
tubing is limited to the immediate vicinity of that tube. Additionally, the oxygen permeable 
scaffold must allow oxygen to permeate consistently and homogenously throughout its 
surface. Otherwise the BC on the material surface will not be produced in a homogenously. 
Also, some cases develop interconnected sheets or layers of BC in the wall of the graft. These 
sheets can potentially delaminate under arterial pressure resulting in pockets of pooled 
blood and pressure build-up which results in the graft ballooning and bursting. This 
heterogeneity in the BC structure translates to varying mechanical properties along and 
across a single BC tube. Meeting these conditions for heterogeneity, along with the logistic 
costs of producing and maintaining a series of graft producing bioreactors, oxygen to inflate 
the permeable scaffold, the oxygen permeable scaffold per se with appropriate 
characteristics and the inevitable optimization processes involved have yet to produce a 
viable model for large scale BC graft production. 
As mentioned, BC has several properties that make it a good prospect as a biomaterial for 
biomedical applications and has shown potential as an in vivo vascular grafts [14, 18, 20, 23]. 
It is already widely produced commercially in membranes or sheets with varying 
thicknesses and scale depending on the producer and method adopted for production. We 
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believe these methods for graft production, as presented to date, have an inherent inability 
to assure an economically viable and reproducible approach to the graft production. In this 
paper we present a novel approach to small caliber BC graft (<6mm) production that is both 
easily reproducible and provides a graft with adequate mechanical and biocompatible 
properties and, through in vivo experimentation, has already demonstrated promising 
patency. 
 
Material and Methods 
Graft Fabrication 
 
Bacterial cellulose was produced by Gluconacetobacter xylinus (ATCC 53582) in a modified 
Hestrin-Schramm medium, supplemented with 2% Corn Steep Liquor (Sigma Aldrich, 
Germany) and 0.6 % ethanol, at pH 5.0. The resulting BC membranes were then washed in 
4% (w/v) NaOH. The membranes were then thoroughly washed with distilled water until 
pH was neutral. Finally, endotoxin removal was accomplished by further washing in 5% SDS 
(w/v). The water and detergent solutions were changed after 24 hours over the course of 2 
days.  
Endotoxin removal was performed as follows: quadruplicate BC samples (1.5 x 2.5 x 4cm 
(height x width x length) were placed in 200ml of distilled water (control) and 5% SDS (w/v). 
The water and detergent solutions were changed after every 24 hours over the course of 3 
days. At each exchange, duplicate BC samples were taken and washed abundantly with 
distilled water and freeze-dried.  The samples were subsequently cut into samples of the 
same weight 20 ± 4mg and rehydrated with 500µl of apyrogenic water. The concentration of 
endotoxin in each sample determined using the Pierce LAL Chromogenic Endotoxin 
Quantitation Kit and the standard protocol included (Thermo Scientific, Rockford, IL USA). 
Additionally, a non-washed BC graft was implanted in a single in vivo assay (as described 
ahead) and compared to the subsequent in vivo assays performed with the SDS washed BC 
grafts. 
BC grafts were prepared by cutting large BC sheets (1.5x25x30cm) into 1.5 x 2.5 x 7cm 
(height x width x length) blocks. These were perforated along the center of the sample with 
a sharp 4mm (outer diameter) metallic needle and then dried by mass transfer of water from 
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the hydrogel to blotting paper until a final wall thickness of roughly 2mm was achieved. The 
resulting tubular structures were then freeze-dried and stored at room temperature until 
needed (see Figure 4-1). All grafts tested herein have a luminal caliber of 4mm and 
independently of the final length used in the varying assays were initially 7cm long. The BC 
grafts used for in vivo experimentation were rehydrated in sterile 0.9% (w/v) saline solution 
and autoclaved at 121oC for 20 min 72 hours before surgery. 
 
Surface Profilometry 
 
BC grafts, created as previously described, were split open longitudinally and fixed with 
double-sided tape to glass slides. PFA, commercial ePTFE and Dacron grafts were also split 
longitudinally and affixed the same way (Dacron grafts were stretched as much as possible 
in order to remove the kinking inherent to the graft). The sample surface profiles were then 
measured 5 times along the same surface (each measurement roughly 1mm apart) with a 
KLC TENCOR D-100 profilometer along 20mm (for Porcine Femoral Artery, ePTFE and PET) 
and 30mm for BC at set speed of 0.2mm/second and a resolution of 2000 points per mm. The 
results were then plotted on a 3D graph so to convey an idea of the 3 dimensional surface of 
the each sample. Roughness was calculated as the amplitude between maximum peak height 
and minimum valley depth. 
 
Cryo-SEM Imaging 
 
Cross sections of the BC grafts were imaged via Cryo-SEM on a JEOL JSM 6301F/ Oxford INCA 
Energy 350/ Gatan Alto 2500. The graft samples were prepared as described above and then 
cut into 1mm wide sections and placed upright in a metallic support. The samples were then 
rapidly cooled by plunging them into sub-cooled nitrogen (slush nitrogen) and transferred 
under vacuum to the cold stage of the preparation chamber. The samples were then 
fractured, sublimated for 180 seconds at -90°C, and coated with Au/Pd by sputtering for 40 
seconds. The samples were finally transferred into the SEM chamber and imaged at -150°C. 
Pore size was estimated from the micrographs using Image J software. 
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Mechanical Tests 
Tensile Strength Determination 
 
BC grafts along with untreated BC (these are grafts that were not freeze-dried and as such 
did not finish the graft processing), ePTFE and porcine femoral artery (PFA) were tested for 
their tensile strength in quintuplicate (n=5) on a Shimadzu AG-X 50 kN at a traction speed of 
5mm/min and a load cell of 1kN. Each sample tested was split open longitudinally and the 
materials thickness and width was measured with digital calipers and accounted for in the 
calculations of the strength parameters. Special care was taken in order to prevent sample 
slipping from the hydraulic grips by using both fine grain sandpaper and construction paper. 
 
Suture Retention Assay 
 
BC grafts with 6 cm length (4mm internal diameter and 7mm external diameter) were fixed 
the top clamp of a Z2.5 Zwick/Roell (Zwick GmbH & Co. KG; Ulm; Germany). A 4-0 Prolene® 
suture (0.15mm diameter; Ethicon) was placed approximately 7mm from the edge of the 
prosthesis (measured with a digital micrometer) and looped around the bottom clamp 
before clamping. The assay was then carried out in quintuplicate, on both freeze-dried and 
non-freeze-dried bacterial cellulose prosthetics, at a set speed of 10mm/min and a 1N pre-
load. 
 
Compliance Characterization 
 
Compliance characterization of BC grafts (n=5) was performed using the system and method 
described previously by Diamantouros and colleagues [32]. Briefly, the grafts were fixed into 
a chamber and initially exposed to a steady flow of purified water.  A pulse (1Hz) was added 
by a linear magnetic actuator. The pressures were stabilized at 80-120mmHg. Variations in 
the outer diameter were measured by an optical micrometer sensor (LS-7030(M); Keyence 
Deutschland GmbH, Neu-Isenburg, Germany) placed perpendicularly to the graft. Pressures 
were recorded by pressure transducers (CODAN pvd Critical Care GmbH; Forstinning, 
Chapter 4 – A Novel Small-Caliber Bacterial Cellulose Vascular Prosthesis: Production, Characterization and 
Preliminary In vivo Testing 
AF Leitão 
98 
Germany). The measurements were realized for 30 seconds once the pressures were stable. 
Variations in the outer diameter and pressures were recorded by a LabVIEW™ application 
(National Instruments; Texas, USA). The circumferential compliance was then calculated 
with the following equation: 
 =
( − 
) 

 − 
   100 
Where C is compliance (%/mmHg), D is diameter (µm) and P is pressure (mmHg). “Syst” and 
“Diast” stand for the systolic and diastolic phase respectively. 
A slight addition to the method presented by Diamantouros, consisting of the use of 
ultrasound imaging equipment (Vivid I, GE Healthcare; Freiburg, Germany), allowed for the 
acquisition of video of the changes in internal diameter in response to pressure variation. 
The videos were then converted to still frames and the diameter of the lumen determined 
with Image J software on three points per image. Care was taken so that the measurements 
from each video would be performed at the same coordinates in each individual frame so as 
to account, as much as possible, for human error. 
 
In vivo Experimentation and Histological Analysis 
Surgical procedure 
 
Four female domestic pigs (Sus scrofa domesticus) with weight ranging from 30-40kgs were 
restrained from food (24 hours) and water (6 hours) before each surgical procedure. All 
experiments were conducted according to the European Union Directive no.86/609/CEE for 
the use of animals in research and approved by the board for the ethical treatment of animals 
of the Faculty of Medicine of the University of Porto (ORBEA, FMUP, Oporto, Portugal). All 
procedures were performed under general anesthesia, with endotracheal intubation and 
spontaneous ventilation. A pre-anesthesia intramuscular injection of 32mg/ml azaperone 
(Stressnil®, Esteve Veterinaria) at a dose of 4 mg/kg reconstituted with 1mg/ml midazolam 
(Dormicum®, Roche) at a dose of 0.15–0.2ml/kg was administered. Venous access was 
obtained through an IV line placed in the marginal ear vein. Anesthesia was induced with 
3μg/kg fentanyl (Fentanest®, Janssen-Cilag), and sodium thiopental (12.5 mg/kg IV initially 
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and then to effect Tiopental 0,5 B Braun®, B. Braun). After orotracheal intubation, the 7- to 
7.5-mm tube was connected to the anesthetic equipment (Ohmeda, Boc Health Care), and 
anesthesia was maintained with a mixture of isoflurane (1.5% to 2.5%; Isoflo®, Esteve 
Veterinaria) in 100% oxygen and fentanyl at constant-rate infusion of 30-50 μg/kg/h. 
Afterwards an epidural analgesia protocol was implemented with application of 1 mg/kg 
morphine (Morfina 1% Braun®, B. Braunl). To address infection prophylaxis, all animals 
received intramuscular injection of 1g ceftriaxone (Rocephin®, Roche) before surgery.  End-
tidal CO2, oxygen saturation, electrocardiography and temperature were monitored 
continuously (Cygnus 1000C Vet® Monitor, Servive Portugal). Pigs were placed in supine 
position and shaved, and electrocardiographic electrodes were attached to the chest for 
continuous evaluation of cardiac electrical function. Normal saline (2 to 4 mL/kg hourly) was 
infused through the venous cannula in the auricular vein during surgery, to maintain 
adequate preload stability. 
Open surgery was then performed with isolation of the common femoral artery, the 
profunda femoris artery and the superficial artery. The BC grafts were anastomosed in the 
left hind limb in a homolateral -femoral artery bypass. Papaverine was administered 
topically to the artery to avoid arterial spasm. The animals were heparinized systemically 
with an intravenous bolus injection of 200units/kg of heparin (Heparina Sódica B.Braun®, 
B.Braun), five minutes before clamping of the target arteries. BC grafts were then 
anastomosed with continuous suturewith 6/0 monofilament polypropylene sutures 
(Prolene®, Ethicon). The femoral artery from the right hind limb was sham-operated with 
all the surgical procedures being equally performed, excluding the implantation of the graft.  
After the surgery, the pigs were transported back to their quarters, only when arterial 
oxygen tension stabilized above 95%. Pigs were monitored until their body temperature 
normalized (with digital thermometers) and they were able to ambulate. They then were 
observed at least 2 or 3 times daily for locomotor activity, respiratory changes, body 
temperature, and food and water intake. Analgesia was maintained during the first 24 h after 
surgery by using meloxicam (0.5 mg/kg IM; Metacam, Boehringer Ingelheim). Acetylsalicylic 
acid (150mg/animal per os daily; Ácido Acetilsalicílico ratiopharm 100 mg, Ratiopharm) was 
given once daily until euthanasia, to prevent platelet aggregation. 
After the designated times, the animals were sacrificed by IV KCl injection after sedation with 
azaperone reconstituted with midazolam administered IM prior to induction with sodium 
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thiopental (12.5 mg/kg IV initially and then to effect) and the grafts and sham-operated 
arteries were harvested and histologically evaluated for signs of chronic inflammation, 
infection, foreign body responses, clot formation, cell ingrowth, and diameter via electron 
microscopy. 
Histology 
 
Tissues were preserved in formalin for a minimum of 4 days and were embedded in paraffin 
in an automated tissue processor (Microm STP 120). Tissues were then transferred to 
embedding workstation to obtain paraffin blocks. From these, sections (2µm) were cut on a 
rotary microtome (Leica RM 2035) and stained with Hematoxylin and Eosin (H&E) for light 
microscopic examination. Observations and photographs were made using an Olympus 
BX51 microscope with an Olympus camera attached. 
 
Immunohistochemistry 
 
Immunostaining of endothelial cells was performed using the primary antibody – Mouse Anti 
Pig CD31 (AbD Serotec; Oxford, England). This is a mouse monoclonal antibody designed to 
detect porcine CD31. The slides were immersed in 10mM sodium citrate (pH 6.0) buffer, and 
and heated in a water bath (95-99oC) for antigen retrieval. Antigen visualization was done 
with the Novocastra Novolink Polymer Detection System (Leica Microsystems GmbH, 
Wetzlar, Germany) and involved the following steps: Sections were incubated with H2O2 
(3%) for 10min to eliminate endogenous peroxidase activity followed by a 5min incubation 
with a protein blocking agent. Sections were subsequently incubated overnight at 4oC with 
the primary antibody diluted at 1:100 with BSA (5%), and on the following day, washed in 
TBS-buffered saline solution before incubation for 30min with the secondary antibody 
system using diaminobenzidine (DAB) as a chromogen. 
Statistical Data Analysis 
All data and statistical analysis was performed using both GraphPad Prism and Origin Pro 9 
software. Statistical significances were determined via One-way and Two-Way ANOVA tests 
after verifying the Normal distribution (p<0.05) of the data. 
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Results 
Graft Fabrication 
 
The novel methodology presented herein for production of the BC graft is schematically 
outlined in Figure 4-1. The BC grafts were produced with needles that were purposely built, 
regularly sharpened and exchanged in order to assure consistent perforation. Special care 
was taken during perforation in order assure a smooth luminal channel. An unsharpened 
needle resulted in tears during the perforation with the appearance of “flaps” that could 
occlude or restrict flow through the graft. Also, while all grafts produced and presented in 
this work were 4mm in diameter we found that by using different diameter needles allows 
the production of grafts with different diameters. 
The drying and shaping was performed with the needle in place with special care to avoid 
changes to the luminal diameter of the graft and an irregular topography of the external 
surface. Also, the grafts were found to dry quickly during the freeze-drying process (a 
maximum of 2 days is required for complete drying) and the least irregular grafts were 
obtained the quicker this process was performed. 
 
Figure 4-1 - Schematic representation BC vascular graft formation process. From left to right: the BC perforated with a sharp 
metallic needle, dried by capillary action and shaped into a cylinder and finally freeze-dried. 
 
Surface Profilometry 
 
The surface profiles we present here were obtained by 5 consecutive measurements that 
were 1 mm spaced (side-by-side) and plotted together in a three-dimensional topological 
graph so as to convey an idea of the topography of the materials (see Figure 4-2). Our results 
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show that the surface roughness of BC is in the same range of that of porcine femoral artery, 
ranging roughly 300nm in both cases from highest peaks to lowest valley, with no 
statistically significant difference between them (p>0.05). On the other hand, both ePTFE 
and, to a greater extent, PET show a much greater surface roughness with a distance of 
approximately 600 and 1600 nm between peaks and valleys respectively. 
 
Figure 4-2 - Surface profiles of Porcine Femoral Artery (A), BC graft (B), ePTFE graft (C) and a PET graft (D). The plots were 
obtained from 5 separate linear measurements (2000 points/mm) over 2 cm (3cm for BC), spaced 1mm apart and plotted in a 
3D graph. 
 
Cryo-SEM Imaging 
 
Several BC grafts samples, and several different regions of each graft, were observed via 
Cryo-SEM so as to maintain the hydrated three-dimensional structure of the grafts; the 
images presented here are representative of those observations (Figure 4-3). The fibril 
distribution inside of our grafts showed markedly different structures throughout the graft 
wall that are well distributed throughout. In lower magnifications dense sheets of BC fibers 
intersecting each other are visible and appear in wave-like patterns, parallel to the luminal 
surface of the graft (Figure 4-3A, B and C). Dense sheets are surrounded by low density open 
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porous regions (Figure 4-3D) with pore sizes ranging from 1 to 5 µm in diameter. 
Additionally, there seems to be a consistent and dense single layer of BC fibers over the entire 
luminal surface of the graft that is immediately followed by open porous regions (Figure 4-
3E).  
 
Figure 4-3 - Cryo-SEM images of a portion of the cross-section of the graft wall. (A) and (B) 4000x magnification with noticeable 
dense regions layered between open-pore structures; (C) 10000x magnification of the dense BC regions; (D) 10000x 
magnification of the open-pore structures and (E) 10000x magnification of the edge of the luminal surface of the graft. (F) is a 
schematic representation of the interface between the luminal surface and inner wall structure. 
 
Endotoxin Removal Study 
 
Endotoxin (Lipopolysaccharide; LPS) concentration on non-washed and SDS washed BC was 
determined with the Pierce LAL Chromogenic Endotoxin Quantitation Kit. Total LPS 
concentration on non-washed BC over the course of the study was 2.65 ± 0.27EU/ml 
(Endotoxin Units/ml) and dropped to 0.43 ± 0.15, 0.06 ± 0.04 and 0.003 ± 0.02EU/ml over 
the following 3 days (Figure 4-4). Total LPS concentration was shown to be significantly 
different between washed and non-washed BC (p<0.05). Results also show a significant 
difference between a single and twice washed (p<0.05) and no significant difference 
between the second and third washes. 
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Figure 4-4 - Endotoxin (LPS) concentration in EU/ml (Endotoxin Units/ml) as determined over 3, 24 hour, washes in 5% SDS 
and water (negative control). 
 
Mechanical Tests 
Tensile Strength Determination 
 
Mechanical testing demonstrated marked differences between porcine femoral artery (PFA), 
ePTFE and BC (both as a graft and untreated) - see Table 4–1. The BC graft and untreated BC 
show no statistically significant difference between them (p>0.05) in regards to any of the 
parameters though. However, the BC graft did show higher values for maximum tensile 
strength (Max Force), maximum stress and strain. PFA, while mechanically weak as 
compared to the other materials in regards to strength, was by far the most elastic, 
deforming 133% before rupture. Also noteworthy, ePTFE was shown to be most rigid of the 
tested materials, with the highest values in all the parameters. The BC grafts thus better 
resembles the biological vessels than ePTFE, in the sense that it presents higher elasticity, 
translated in a Young modulus in the same order of magnitude as PFA´s. 
Table 4-1 - Mechanical test results for Porcine Femoral Artery (PFA), ePTFE the BC Graft and unprocessed BC (n=5). Values 
marked with an asterisk (*) are not statistically different from each other in their respective columns (p>0.05). Data is 
presented as mean ± standard deviation. 
Material Young's Modulus (N/mm2) Max Force (N) Max Stress (N/mm2) Max Strain (%) 
PFA 2.58 ± 0.95 10.05 ± 3.39 1.15 ± 0.39* 133.46 ± 11.25 
ePTFE 125.40 ± 24.33 198.54 ± 13.33 23.57 ± 1.00 40.62 ± 9.92* 
BC Graft 10.56 ± 1.53* 95.92 ± 5.62* 2.75 ± 0.38* 41.08 ± 8.65* 
BC 10.70 ± 2.23* 91.47 ± 16.33* 2.10 ± 0.26* 34.5 ± 4.27* 
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Suture Retention Strength 
 
Results show that untreated BC and our BC grafts demonstrate suture retention strength of 
3.94 ± 0.38 and 4.20 ± 0.99N respectively, with no statistically significant difference between 
them (p>0.05). The results demonstrate a superior performance of the BC grafts, as 
compared to most materials, presenting a suture retention strength comparable to that of 
ePTFE. 
Table 4-2 - Suture Retention strength (N) of several autologous and synthetic grafts for Tissue Engineered Blood Vessels 
(TEBV), Internal Mammary Artery (IMA), Polytetrafluoroethylene (ePTFE), Fibrin and Fibrin/polylactic acid (PLA), Human 
Saphenous Vein (HSV), Collagen and Bacterial Cellulose (BC). Suture retention strength for the BC graft and untreated BC are 
not statistically different (p>0.05; n=4) 
Graft Material Retention Strength (N) SD References 
IMA 1.35 ± 0.49 29 
HSV 2.60  30 
TEBV 1.49 ± 0.49 29 
Fibrin 0.19 ± 0.05 31 
Fibrin/PLA 1.32 ± 0.58 31 
Collagen 0.82-2.87 ± 0.12-0.09 32 
ePTFE 4.70 ± 0.50 33 
BC graft 4.20 ± 0.99 -- 
BC 3.94 ± 0.38 -- 
 
Compliance Characterization Assay 
 
We measured the compliance for our BC grafts externally via laser detector and estimated 
compliance internally by sonography imaging. Results show a significant difference between 
the compliance of the BC graft in regards to the internal and external measurements (see 
Table 4–3). Externally compliance was measured as being 0.4x10-2 %/mmHg while 
internally graft compliance was determined to be 9.5x10-2 %/mmHg. While the external 
compliance falls far from the results for the most of the other materials found in the literature 
internally compliance seems to be much better matching, in most regards, the compliance 
values found for autografts. 
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Table 4-3 - Compliance (presented as value x10-2 %/mmHg) with standard deviation (SD) as collected from the literature for 
Internal Mammary Artery (IMA), Human Saphenous Vein (HSV), Human Iliac Artery (HIA), Tissue Engineered Blood Vessel 
(TEBV), Polyurethane (PU), Polyethylene terephthalate (PET), expanded Polytetrafluoroethylene (ePTFE), Bacterial 
Cellulose/Chitosan blend (BC/Chi) and measurements for the compliance of the BC grafts as measured externally and 
internally (n=5). 
Graft Material Compliance (%/mmHg; x10-2) SD References 
IMA 11.5 ± 3.9 29 
HSV 3.7-12.8 ± 1.3-1.9 34 
HIA 8 ± 5.9 35 
TEBV 1.5-3.4 ± 0.3 29; 30 
PU 8.1 ± 0.4 35 
PET 1.8 ± 1.2 35 
ePTFE 1.2-1.6 ± 0.3 35; 36 
BC/Chi 5.9 ± 2.7 36 
BC graft External 0.4 ± 0.1 -- 
BC graft Internal 9.5 ± 2.8 -- 
 
In vivo Experimentation and Histological Analysis 
 
As a preliminary in vivo assay, 4 surgical procedures have been performed to date, with 
implantation of the BC graft in a femoral-femoral artery bridge on the left hind limb of female 
domestic pigs (see Figure 4-5A). The right femoral artery was also isolated in a sham-
operated procedure and served as a control for the implanted graft. No significant changes 
to the arterial wall of the control vessel were detected. 
During the first surgical intervention severe arterial spasm and contraction was noted 
during, and after, the procedure. There was noticeably reduced pulse immediately after graft 
implantation and the limb was found to be slightly cold to the touch 24 hours post-
operatively both situations indirectly attributed to arterial contraction and restricted blood 
flow. All further procedures were performed with papaverine administration, via topical 
wash to the artery in order to facilitate anastomosis and avoid the transitory arterial spasms 
in the immediate moments post-op. The following three procedures resulted in 1 month 
patency that were all confirmed via Doppler ultrasound imaging (results not shown) being 
terminated at that point for explantation of the BC graft and subsequent histological analysis. 
Histological analysis and Immunohistochemistry staining were performed on the grafts 
harvested after the experiments were terminated. The BC grafts that were recovered one 
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month after surgical intervention were intact and well integrated into the surrounding tissue 
with no significant fibrosis or macroscopic evidence of inflammation. Later histological 
analysis showed a distinct, three-layered, structure with cellular adhesion and infiltration on 
both the luminal and adventitial surfaces of the graft and an unpopulated and larger BC 
central region. CD31 positive cells were detected on the luminal surface and are believed to 
be endothelial or progenitor endothelial cells that migrated from the adjoining femoral 
artery (Figure 4-5B and F). The presence of neo-vessel formation was detected in the cell 
population on both the adventitial and luminal surfaces (see Figure 4-5C and E). It should be 
Figure 4-5 - Representative photographs of the microscopy images of in vivo tests. (A) Femoral-femoral artery BC 
graft placement, (B) luminal surface of the graft with cell adhesion on the surface of the graft along and some cell 
infiltration, (C) external surface of BC graft showing formation of neo-vessels (arrow), (D) Close-up detail of 
external surface of the graft with giant cells (red arrow) and macrophages (green arrow) among fibroblasts, (E) 
immunohistochemistry staining of CD31 positive cells forming neo-vessels on the luminal surface of the graft, (F) 
CD31 positive cell clusters on the luminal surface of the grafts. 
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noted that a significant amount of background staining occurred due the unspecific staining 
of BC in the immunohistochemistry staining and so the exact extent of the CD31 positive cells 
cannot be accurately assessed. Figure 4-5D is representative of the cellular infiltration and 
population found on the adventitial surface of all the recovered grafts. The cell populations 
in the adventitial regions were determined to be composed, mostly, of fibroblasts, 
macrophages and some giant cells with a small population of lymphocytes also present. 
 
Discussion 
 
The method for BC graft production, as described herein, is hinged on its simplicity and a few 
crucial steps, namely: perforation, simultaneous drying and shaping and freeze-drying 
(Figure 4-1). By processing a single BC sheet this method can render multiple grafts while 
allowing fine control over the luminal diameter, thickness, and consequently density, of the 
graft wall. 
Perforation of the graft by a sharp needle allows a precise control over the luminal diameter 
of the graft and directly affects the structure of the luminal surface of the graft (Figure 4-1). 
There seems to be a consistent and dense (and apparently single layer, see Figure 4-3E) of 
BC fibers over the entire luminal surface of the graft that is immediately followed by an open 
porous regions (discussed ahead). The uniform layer that forms the luminal wall results from 
the perforation process used to create the luminal canal. As the needle penetrates the 
cellulose block it pushes BC fibers out of its way and to the sides, the end result is a dense 
inner wall of BC fibers. This luminal surface plays an important role in containing the blood 
in the lumen of the graft while serving as a semi-permeable barrier to plasma and potentially 
adhered cells.  
Additionally, the surface created by this layer of BC fibers is quite smooth and, in regards to 
its profile, similar to that of a native artery (Figure 4-2). Blood flow and shear stress have 
been shown to contribute to plaque formation due to non-uniform blood flow [41, 42]. 
Physiological levels of shear maintain the homeostatic functioning of vessels and so, ideally, 
grafts should aim for physiological levels of shear [43-47]. In this regard the topography of 
both ePTFE and Dacron are quite different from that of both BC and the artery (Figure 4-2). 
The similarities between the surface roughness/topography of the BC grafts and that of the 
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arterial wall should theoretically match and allow for an un-interrupted and consistent 
blood flow over the transition from artery to graft maintaining physiological levels which, in 
the end, is beneficial to graft performance. 
The subsequent partial capillary drying, shaping and freeze-drying steps are largely 
responsible for the final structural and mechanical properties of the resulting grafts. The 
drying and shaping allows the BC block to be shaped into a cylindrical tube with 2mm in wall 
thickness. As a direct result the graft wall density is brought from 0.02g/cm3 to 0.09g/cm3. 
With the final freeze-drying step being required to eliminate the remaining water. This 
allows individual BC fibers to come into contact with each other and form H-bonds [48], 
while maintaining each individual fiber’s spatial position. This step is essential in order to 
reduce swellability of the graft, which would otherwise cause the loss of the cylindrical 
shape, while retaining the malleability, flexibility, the degree of the water retaining capability 
of the BC hydrogel and, above all, the shape of the graft. 
The contact and bonds created between fibers induced morphological changes in the BC 
hydrogel (Figure 4-3). BC has been extensively characterized as presenting an open porous 
structure that is relatively homogenous throughout the hydrogel [14, 48, 49]. Our grafts 
present a dual structure, presenting dense sheets, formed by the collapse of fibers onto each 
other in the drying and with bonds formed during freeze-drying, (Figure 4-3A and B) layered 
in between the characteristic open porous morphology of BC (Figure 4-3D). These two 
distinct regions/structures complement each other structurally and functionally. The dense 
regions observed at a micro/sub-micro scale provide a slight increase in mechanical support 
while allowing the graft to maintain the shape and structural integrity essential to a 
functional vascular graft. Simultaneously, the open-porous regions allow for void space and 
pore interconnectivity that in turn allows the graft to preserve its flexibility while allowing 
cellular migration from the adjoining tissues to the graft.  
A final step in graft preparation was the removal of bacterial lipopolysaccharide (LPS or 
endotoxin) from the grafts by SDS wash. A significant amount of endotoxin (2.65 ± 
0.27EU/ml) remains on BC after alkaline wash, a standard procedure in purifying BC, which 
has been shown to induce a strong inflammatory response [50]. The inflammatory response 
triggers coagulation mechanics and could subsequently cause thrombosis. A 24 hour wash 
was enough to significantly reduce the overall concentration of LPS in BC by over 83%, and 
a subsequent succession of three washes completely removes any presence of LPS. 
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In terms of tensile strength untreated BC and the BC grafts show no statistically significant 
difference between each other; though there seems to be a slight increase in the tensile 
strength of the BC grafts due to the higher number of bonds in the denser regions (95.92 vs 
91.47N). Since, the total number of BC fibers in a given cross-section is essentially identical 
the higher strength of the graft does not translate to significantly higher values. BC fibers are 
characteristically strong yet inelastic [13] as opposed to the elastin in a native vessel which, 
has lower tensile strength though capable of great deformation and shape memory. This is 
evident when comparing the tensile strength (95.92 vs 10.05N) and elasticity, or 
deformation, (41 vs 133%) of the graft compared to a porcine vessel.  
Similar to what happens with the tensile strength of the graft, suture retention of the BC graft 
is influenced by the inelasticity of the BC fibers when compared to that of native vessels. The 
large number of fibers, some organized in the stronger dense regions, provide a solid anchor 
point for the suture. This translates to a suture retention strength that is noticeably higher 
than that of native vessels, which as mentioned, tend to deform rather than resist the tensile 
stress. This suture retention strength is both comparable to that of much stronger and rigid 
materials like ePTFE, which can also be seen when comparing the tensile strength and 
deformation, and also, greatly outperforms other polymers that are being proposed as grafts 
materials (see Table 4–2). 
Another important consequence, of the distribution and layered structure of the graft wall is 
the compliance behavior the graft. Intimal hyperplasia in both autologous saphenous vein 
and synthetic artery bypass grafts is a major reason for graft failure [40] and is closely 
associated with a mismatch in mechanical properties of the native vessel and the bypass 
graft. Diastolic and systolic pressure changes cause vessel walls to expand and contract. A 
mismatch in mechanical properties of native vessels and grafts adds direct stress to ingrown 
tissues. Specifically, at the point where the mechanical properties of the vessel wall changes. 
This can cause lesions to the cell layers which can expose underlying smooth muscle cells 
resulting in an abnormal migration and proliferation, along with the deposition of 
extracellular matrix, in the intimal layer (intimal hyperplasia). This leads to thickening of the 
vessel wall and causing a reduction in the lumen of the vessel, restricting blood flow which 
can eventually cause occlusion [51].  
Therefore, mechanical compliance between the tissue and graft is paramount. The open 
porous regions of the graft, as mentioned, provide void spaces that allow for fiber movement 
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inside the graft wall. The void spaces of the pores allow fiber movement in response to 
pressure changes on the grafts luminal surface. The graft wall seems to absorb the pressure 
change and does not translate outward to the surface of the material. Hence the difference 
in compliance values for the outer (0.4x10-2 %/mmHg) and inner (9.5 x10-2 %/mmHg) 
measurements. Though the method used for measuring the diameter changes of the luminal 
surface is not extremely precise, when compared to the precision of the laser detector, we 
are comfortable in the assessment that inner (luminal) compliance is significantly different 
from that of the outer (adventitial) compliance. While the BC grafts inner and outer surfaces 
comply differently, the end result is that the BC graft and native vessels present similar 
values of compliance on the blood-contacting surface. In this regard, the BC grafts greatly 
outperform the current synthetic materials available, such as ePTFE and PET, by a large 
margin (see Table 4–3).  As a final supporting note, in regards to the mechanical behavior of 
the BC graft, the ANSI/AAMI VP20-2001 standards outlines that arterial constructs are 
required to withstand normal arterial pressures and have a burst strength above 
1680mmHg. We have measured burst pressure of the BC grafts to be above 1900mmHg 
(results not shown).  
As a result of the findings presented in this work and our prior work with BC [18, 19, 52], 
along with all that presented in the literature, there was reason to believe that the graft could 
perform well in vivo. Previous in vivo studies have used rats, sheep and pigs as in vivo models 
for the study of the performance of BC grafts [14, 53, 54]. Due to the similar anatomy and 
physiology, domestic pigs were chosen as a model for this work. Despite drawbacks such as 
the lack of cooperation, without full general anesthesia, and a propensity for rapid growth, 
pigs constitute an optimal, analogous, model for pre-clinical protocol development and 
studies [55]. In order to comply with the set parameter of a small caliber vessel (<6mm) the 
femoral artery was chosen as the sight for implantation of the graft as a femoral artery 
bridge.  
The use of the pig model proved invaluable in determining surgical procedure and 
complications that could otherwise remain undetermined. Namely, failure associated with 
vessel occlusionavoiding due to muscular and arterial spasm and contraction; as was the 
case in the first surgical procedure performed. Normal and physiological Aarterial 
contraction occurred during surgery and persisted, in the immediate time frame, after 
implantation which led to a noticeably restricted blood flow before closing. We believe that 
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the restricted blood flow in these initial moments after implantation led to the collapse of 
the prosthesis and clot formation. The end result was an occluded vessel 15 days after 
surgery, though 24 hours after the procedure pulse was weak and the limb hypothermic. 
Papaverine is an antispasmodic drug commonly used in coronary artery bypass surgery [56] 
and, as a result of this initial experiment, was introduced as a procedural step to the 
implantation protocol. Papaverine has been shown to aid in venous graft performance by 
allowing the smooth muscle of the artery to relax and allow normal blood flow [57, 58]. The 
use of papaverine was therefore introduced in order to aid in assuring an uninterrupted 
blood flow in the initial stages of the grafts implantation.      
The results, in regards to in vivo experimentation, are still in their early stages yet stack up 
well as compared to the findings of both Malm [53] and Wipperman [54]. The luminal surface 
was largely populated by a cell population containing endothelial, or endothelial-like cells 
(which was confirmed via immunohistochemistry), a fibroblast population, along with some 
macrophages and giant cells, covered and infiltrated the adventitial surface. The occurrence 
of neo-vessel formation was found both, on the luminal (via immunohistochemistry staining) 
and adventitial (visible in the H&E staining and later confirmed in the 
immunohistochemistry) surfaces of the grafts. Cell infiltration and adhesion is largely 
limited to the surface and limits of the graft with the center of the BC graft wall which 
remaining largely unpopulated. Both authors reported similar findings though no neo-vessel 
formation was reported in their cases. 
While coverage of the grafts adventitial surface was complete, the exact extension of surface 
coverage on the luminal surface could not be precisely determined. Also, the origin of the 
cells on the adventitial and luminal surfaces is undetermined. However, we believe these to 
be, in large part, cells that would have migrated from the anastomotic sites, at least in regards 
to the luminal surface, rather than circulating cells that adhered to the BC graft surface 
similarly to what was proposed by Malm and colleagues [53]. Finally, the giant cells present, 
consisted of a minimal population, with large vacuoles with what seemed to be a white 
material. We believe this white material to be BC that possibly still contained a small amount 
of endotoxin that would have triggered macrophage activation, the end result being giant 
cell formation. Their presence was largely negligible and absent from the luminal surface. 
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Conclusions 
 
As mentioned, several methods have been proposed and patented for BC graft production 
and which all require dedicated bioreactors and production protocols. Our novel approach 
has allowed us to produce a dense, malleable and mechanically strong tubular BC prosthetic 
that meets most of the mechanical characteristic of native vasculature, most notably 
compliance. Both in vitro and in vivo, the BC grafts herein presented seem to constitute an 
important alternative as synthetic vascular grafts.  
This work is still ongoing mostly in order to expand upon the sample size of the in vivo tests, 
as well as, prolonging those same tests into longer implantation times in order to gain a more 
significant perspective of the feasibility of a BC grafts as a long-term, off-the-shelf and cost-
effective synthetic graft. This further work will demonstrate any potential limitations of the 
grafts, as is, and allow us to address possibilities such as nanocompositing the graft with 
other polymers, such as fibrin, or surface modifications, such as the incorporation of heparin, 
in order to extend implantation times.  
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This work consisted in the development of a viable vascular graft of bacterial 
cellulose (BC). Initially the worked focused on enhancing the production method 
described in the literature and implemented by a colleague in the course of a 
previous PhD. By feeding oxygen through an oxygen permeable silicone tubing and 
harnessing the way in which the bacteria produce bacterial cellulose the tubes were 
formed. However, they were found to be lacking in the mechanical properties that 
were required of a viable graft. As such, a nanocomposite based off of the bacterial 
cellulose hydrogel and containing poly(vinyl alcohol) (PVA) was devised, developed 
and characterized. 
Before any further development the blood-material characterization was essential. 
If the material did not perform in regards to hemocompatibility and non-
thrombogenicity there would be no reason to pursue it. There was a beneficial, side-
effect of the addition on PVA; namely a slight improvement to the hemocompatibility 
and non-thrombogenicity of the material. Results showed that the BC/PVA 
nanocomposite outperformed the industry standard, ePTFE, in regards to 
blood/material interactions. Though the differences between the 
hemocompatibility parameters were comparable to those of BC; in all of them, there 
was a tendency for BC/PVA to also outperform BC.  
Results showed that the addition of PVA did not, however, have the desired effect of 
improving the mechanical behavior of the BC hydrogel when the samples were dried 
completely. This was found to be due to changes that occurred on an organizational 
level of the fibrous network with noticeably large porous regions in dry BC/PVA 
contributing significantly to the mechanical behavior of the material. 
Observationally, the BC/PVA nanocomposite if never dried seemed to provide a 
mechanical resistance that was higher to that of BC but, this was never confirmed.  
Through the successive developmental stages of the graft and various different 
configurations and production methods a novel and cost-effective method was 
discovered. This methodology allowed the consistent production of viable grafts 
with the mechanical and morphological characteristics that a vascular graft required 
with no need for additional manipulation and formulation. The cost-effective nature 
and logistically uncomplicated method of production also proved beneficial aspects. 
BC had already been shown to have potential in vivo and as such live animal testing 
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was performed that also showed viability with 1 month patency being shown. The 
presence of an endothelial cell population on the luminal surface also gave support 
to the notion that the grafts could become a viable option. This work ultimately led 
to the application for a provisionary patent. 
Currently, studies are still ongoing and any future perspectives of the work, at the 
moment, will focus on continued in vivo studies and improvement so as to determine 
the long-term viability of the BC grafts. The intent is to attempt to achieve 3 month, 
6 month and ultimately 1 year patency of the graft. Additionally, the vascular graft 
production method should also be optimized so as to automate and scale-up the 
production method. Most noticeably the use of laser cutting technology to perforate 
the BC hydrogels may be the ideal solution rather than a mechanical perforation, as 
is currently used. Also, the addition of bioactive molecules to the luminal surface of 
the graft are also a possible prospect. The addition of heparin, or other such 
chemicals may improve biocompatibility and allow long-term patency of the graft. 
Also, the possibility of a new nanocomposite, such as BC/fibrin, may prove a viable 
course of action. The mechanical behavior of BC would support the graft while fibrin 
would allow the material surface, at the least, to be populated with endothelial cells 
that would in turn, also, allow the grafts long-term performance. 
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DESCRIPTION 
“Tubular bacterial cellulose grafts for vascular applications and method of 
production” 
 
Field of the Invention 
 
The present invention relates to a method of production of graft for vascular 
application. More specifically consists in the production of a tubular, three-
dimensional, bacterial cellulose structures for applications as a cardiovascular 
bypass grafts or other similar tubular structures. 
 
Background of the invention 
 
Data from the World Health Organization (WHO) suggests that the number of people 
that suffer from cardiovascular diseases (CVDs) will increase from 17.3, in 2008, to 
23.3 million by 2030. In vascular surgery, surgical bypass is fundamental in the 
treatment of some diseases. Vascular grafts replace, bypass or maintain function of 
damaged, occluded or diseased blood vessels. The chosen conduit and its success 
depend on several factors such as availability, size, ease of handling and technical 
facility, thrombogenicity, resistance to infection and dilation, durability, long-term 
patency and price. 
The most common, and generally considered ideal grafts, are autografts, i.e., vessels 
collected from the patient. There are generally two major downsides to the use of 
autografts. The first is the need for prior surgical interventions, before the actual 
bypass surgeries, in order to collect the autologous vessel. Along with this, the actual 
availability of these vessels may be limited, due to prior interventions. Secondly, 
these grafts are subject to the natural progression of the patient’s disease which can 
lead to deterioration, over time, of the biological grafts [1] and so synthetic grafts 
have been used for potential application as cardiovascular grafts.  
Polyethylene terephthalate (PET or Dacron) and expanded polytetrafluoroethylene 
(ePTFE) grafts are the gold standard, at the moment, for synthetic grafts in large and 
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medium diameter (>6 mm) vessels. However, these synthetic alternatives are not 
yet the ideal solution. While demonstrating acceptable results in larger diameter 
grafts, as internal diameter decreases so does its long-term patency [2, 3]. These 
grafts ultimately fail under 6mm in diameter, due to surface adsorption of proteins 
to the luminal and consequent activation of platelet activity resulting in clot 
formation and subsequent thrombosis [4, 5]. 
A large amount of work has therefore been aimed at finding alternative solutions to 
these materials through either natural or synthetic polymer materials [6-8]. The 
field is ever growing and the lack of a clear optimal polymer has led, and continues 
to lead, to many potential options. By either, further development and research into 
the already existing grafts (PET and ePTFE) or the creation of new non-degradable 
grafts of polyurethane, polyvinyl alcohol or bacterial cellulose (BC). Another option 
is researching and developing temporary grafts that ultimately allow for a tissue 
engineered solution, either by prior cell-seeding or allowing for native cell 
migration, attachment and ingrowth. Ultimately these tissue engineered grafts 
would end up producing a new vessel out of native tissue from a scaffold of collagen, 
fibrin, elastin, silk and polycaprolactone [9-12]. 
One promising solution for these problems is BC. This polymer is a highly pure linear 
polysaccharide, consisting of β (1→4)–linked D-glucose monomers. It is secreted by 
bacteria of the Gluconacetobacter genus. Once secreted, it forms a fibrous network 
hydrogel that has been extensively studied for biomedical applications due to its 
morphology, high purity, water-holding capacity, tensile strength, malleability and 
biocompatibility [13-15] and has been proposed for applications such as wound 
dressings [16], artificial skin[17] or blood vessels [18-20] and as a scaffold for tissue 
engineering [15, 21, 22]. The hemocompatibility of BC has been comprehensively 
studied in our group, with rather promising results (19). 
Many methods have been proposed and patented [23-30] for the production of BC 
tubular grafts. Generally, the methods employed take advantage of the way the BC 
hydrogel is produced at air-medium interfaces [14, 31]. However, these production 
methods require dedicated bioreactors specifically designed for graft production. 
By using an oxygen permeable scaffold upon which BC is produced there are limits 
to the thickness and density of the BC structures because the oxygen rich 
environment produced by the likes of silicone tubing is limited to the immediate 
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vicinity of that tube. Additionally, the oxygen permeable scaffold must allow oxygen 
to permeate consistently and homogenously throughout its surface. Otherwise the 
BC on the material surface will not be produced in a homogenously. Also, some cases 
develop interconnected sheets or layers of BC in the wall of the graft. These sheets 
can potentially delaminate under arterial pressure resulting in pockets of pooled 
blood and pressure build-up which results in the graft ballooning and bursting. This 
heterogeneity in the BC structure translates to varying mechanical properties along 
and across a single BC tube. Meeting these conditions for heterogeneity, along with 
the logistic costs of producing and maintaining a series of graft producing 
bioreactors, oxygen to inflate the permeable scaffold, the oxygen permeable scaffold 
per se with appropriate characteristics and the inevitable optimization processes 
involved have yet to produce a viable model for large scale BC graft production. 
As mentioned, BC has several properties that make it a good prospect as a 
biomaterial for biomedical applications and has shown potential as an in vivo 
vascular grafts [14, 18, 20, 23]. It is already widely produced commercially in 
membranes or sheets with varying thicknesses and scale depending on the producer 
and method adopted for production. However, these methods for graft production, 
as presented to date, have an inherent inability to assure an economically viable and 
reproducible approach to the graft production. The present invention is a novel 
approach to small caliber BC graft (<6mm) production that is both easily 
reproducible and provides a graft with adequate mechanical and biocompatible 
properties and, through in vivo experimentation, has already demonstrated 
promising patency. 
 
General Description 
 
The method for BC graft production, as described herein, is hinged on its simplicity 
and a few crucial steps, namely: perforation, simultaneous drying and shaping and 
freeze-drying (Figure A-1). By processing a single BC sheet this method can render 
multiple grafts while allowing fine control over the luminal diameter, thickness, and 
consequently density, of the graft wall. 
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Perforation of the graft by a sharp needle allows a precise control over the luminal 
diameter of the graft and directly affects the structure of the luminal surface of the 
graft (Figure A-1). There seems to be a consistent and dense (and apparently single 
layer, see Figure A-3E) of BC fibers over the entire luminal surface of the graft that 
is immediately followed by an open porous regions. The uniform layer that forms 
the luminal wall results from the perforation process used to create the luminal 
canal. As the needle penetrates the cellulose block it pushes BC fibers out of its way 
and to the sides, the end result is a dense inner wall of BC fibers. This luminal surface 
plays an important role in containing the blood in the lumen of the graft while 
serving as a semi-permeable barrier to plasma and potentially adhered cells.  
Additionally, the surface created by this layer of BC fibers is quite smooth and, in 
regards to its profile, similar to that of a native artery (Figure A-2). Blood flow and 
shear stress have been shown to contribute to plaque formation due to non-uniform 
blood flow [41, 42]. Physiological levels of shear maintain the homeostatic 
functioning of vessels and so, ideally, grafts should aim for physiological levels of 
shear [43-47]. In this regard the topography of both ePTFE and Dacron are quite 
different from that of both BC and the artery (Figure A-2). The similarities between 
the surface roughness/topography of the BC grafts and that of the arterial wall 
should theoretically match and allow for an un-interrupted and consistent blood 
flow over the transition from artery to graft maintaining physiological levels which, 
in the end, is beneficial to graft performance. 
The subsequent partial capillary drying, shaping and freeze-drying steps are largely 
responsible for the final structural and mechanical properties of the resulting grafts. 
The drying and shaping allows the BC block to be shaped into a cylindrical tube with 
2mm in wall thickness. As a direct result the graft wall density is brought from 
0.02g/cm3 to 0.09g/cm3, theoretically the density can range between 0.02-
0.15g/cm3. With the final freeze-drying step being required to eliminate the 
remaning water. This allows individual BC fibers to come into contact with each 
other and form H-bonds [48], while maintaining each individual fiber’s spatial 
position. This step is essential in order to reduce swellability of the graft, which 
would otherwise cause the loss of the cylindrical shape, while retaining the 
malleability, flexibility, the degree of the water retaining capability of the BC 
hydrogel and, above all, the shape of the graft. 
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The contact and bonds created between fibers induced morphological changes in 
the BC hydrogel (Figure A-3). BC has been extensively characterized as presenting 
an open porous structure that is relatively homogenous throughout the hydrogel 
[14, 48, 49]. The grafts developed presents a dual structure, presenting dense sheets, 
formed by the collapse of fibers onto each other in the drying and with bonds formed 
during freeze-drying, (Figure A–3A and B) layered in between the characteristic 
open porous morphology of BC (Figure A–3D). These two distinct 
regions/structures complement each other structurally and functionally. The dense 
regions observed at a micro/sub-micro scale provide a slight increase in mechanical 
support while allowing the graft to maintain the shape and structural integrity 
essential to a functional vascular graft. Simultaneously, the open-porous regions 
allow for void space and pore interconnectivity that in turn allows the graft to 
preserve its flexibility while allowing cellular migration from the adjoining tissues 
to the graft.  
A final step in graft preparation was the removal of bacterial lipopolysaccharide 
(LPS or endotoxin) from the grafts by SDS wash. A significant amount of endotoxin 
(2.65 ± 0.27EU/ml) remains on BC after alkaline wash, a standard procedure in 
purifying BC, which has been shown to induce a strong inflammatory response [50]. 
The inflammatory response triggers coagulation mechanics and could subsequently 
cause thrombosis. A 24 hour wash was enough to significantly reduce the overall 
concentration of LPS in BC by over 83%, and a subsequent succession of three 
washes completely removes any presence of LPS. 
In terms of tensile strength untreated BC and the BC grafts show no statistically 
significant difference between each other; though there seems to be a slight increase 
in the tensile strength of the BC grafts due to the higher number of bonds in the 
denser regions (95.92 vs 91.47N). Since, the total number of BC fibers in a given 
cross-section is essentially identical the higher strength of the graft does not 
translate to significantly higher values. BC fibers are characteristically strong yet 
inelastic [13] as opposed to the elastin in a native vessel which, has lower tensile 
strength though capable of great deformation and shape memory. This is evident 
when comparing the tensile strength (95.92 vs 10.05N) and elasticity, or 
deformation, (41 vs 133%) of the graft compared to a porcine vessel.  
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Similar to what happens with the tensile strength of the graft, suture retention of 
the BC graft is influenced by the inelasticity of the BC fibers when compared to that 
of native vessels. The large number of fibers, some organized in the stronger dense 
regions, provide a solid anchor point for the suture. This translates to a suture 
retention strength that is noticeably higher than that of native vessels, which as 
mentioned, tend to deform rather than resist the tensile stress. This suture retention 
strength is both comparable to that of much stronger and rigid materials like ePTFE, 
which can also be seen when comparing the tensile strength and deformation, and 
also, greatly outperforms other polymers that are being proposed as grafts materials 
(see Table A-2). 
Another important consequence, of the distribution and layered structure of the 
graft wall is the compliance behavior the graft. Intimal hyperplasia in both 
autologous saphenous vein and synthetic artery bypass grafts is a major reason for 
graft failure [40] and is closely associated with a mismatch in mechanical properties 
of the native vessel and the bypass graft. Diastolic and systolic pressure changes 
cause vessel walls to expand and contract. A mismatch in mechanical properties of 
native vessels and grafts adds direct stress to ingrown tissues. Specifically, at the 
point where the mechanical properties of the vessel wall changes. This can cause 
lesions to the cell layers which can expose underlying smooth muscle cells resulting 
in an abnormal migration and proliferation, along with the deposition of 
extracellular matrix, in the intimal layer (intimal hyperplasia). This leads to 
thickening of the vessel wall and causing a reduction in the lumen of the vessel, 
restricting blood flow which can eventually cause occlusion [51].  
Therefore, mechanical compliance between the tissue and graft is paramount. The 
open porous regions of the graft, as mentioned, provide void spaces that allow for 
fiber movement inside the graft wall. The void spaces of the pores allow fiber 
movement in response to pressure changes on the grafts luminal surface. The graft 
wall seems to absorb the pressure change and does not translate outward to the 
surface of the material. Hence the difference in compliance values for the outer 
(0.4x10-2 %/mmHg) and inner (9.5 x10-2 %/mmHg) measurements. Though the 
method used for measuring the diameter changes of the luminal surface is not 
extremely precise, when compared to the precision of the laser detector, we are 
comfortable in the assessment that inner (luminal) compliance is significantly 
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different from that of the outer (adventitial) compliance. While the BC grafts inner 
and outer surfaces comply differently, the end result is that the BC graft and native 
vessels present similar values of compliance on the blood-contacting surface. In this 
regard, the BC grafts greatly outperform the current synthetic materials available, 
such as ePTFE and PET, by a large margin (see Table A-3).  As a final supporting note, 
in regards to the mechanical behavior of the BC graft, the ANSI/AAMI VP20-2001 
standards outlines that arterial constructs are required to withstand normal arterial 
pressures and have a burst strength above 1680mmHg. We have measured burst 
pressure of the BC grafts to be above 1900mmHg (results not shown).  
As a result of the findings presented in this work and our prior work with BC [18, 
19, 52], along with all that presented in the literature, there was reason to believe 
that the graft could perform well in vivo. Previous in vivo studies have used rats, 
sheep and pigs as in vivo models for the study of the performance of BC grafts [14, 
53, 54]. Due to the similar anatomy and physiology, domestic pigs were chosen as a 
model for this work. Despite drawbacks such as the lack of cooperation, without full 
general anesthesia, and a propensity for rapid growth, pigs constitute an optimal, 
analogous, model for pre-clinical protocol development and studies [55]. In order to 
comply with the set parameter of a small caliber vessel (<6mm) the femoral artery 
was chosen as the sight for implantation of the graft as a femoral artery bridge.  
The use of the pig model proved invaluable in determining surgical procedure and 
complications that could otherwise remain undetermined. Namely, failure 
associated with vessel occlusion due to muscular and arterial spasm and 
contraction; as was the case in the first surgical procedure performed. Arterial 
contraction occurred during surgery and persisted after implantation which led to 
noticeably restricted blood flow before closing. The end result was an occluded 
vessel 15 days after surgery, though 24 hours after the procedure pulse was weak 
and the limb hypothermic. Papaverine is an antispasmodic drug commonly used in 
coronary artery bypass surgery [56] and, as a result of this initial experiment, was 
introduced as a procedural step to the implantation protocol.  
The results, in regards to in vivo experimentation, are still in their early stages yet 
stack up well as compared to the findings of both Malm [53] and Wipperman [54]. 
The luminal surface was largely populated by endothelial, or endothelial-like cells 
(which was confirmed via immunohistochemistry). A fibroblast population, along 
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with some macrophages and giant cells, covered and infiltrated the adventitial 
surface with neo-vessel formation occurring inside these infiltrated regions. The 
third and larger structure was the center of the BC graft wall which remained largely 
unpopulated. Both authors reported similar findings though no neo-vessel 
formation was reported in their cases. 
While coverage of the grafts adventitial surface was complete, the exact extension 
of surface coverage on the luminal surface could not be precisely determined. Also, 
the origin of the cells on the adventitial and luminal surfaces is undetermined. 
However, we believe these to be, in large part, cells that would have migrated from 
the anastomotic sites, at least in regards to the luminal surface, rather than 
circulating cells that adhered to the BC graft surface similarly to what was proposed 
by Malm and colleagues [53]. Finally, the giant cells present, consisted of a minimal 
population, with large vacuoles with what seemed to be a white material. We believe 
this white material to be BC that possibly still contained a small amount of endotoxin 
that would have triggered macrophage activation, the end result being giant cell 
formation. Their presence was largely negligible and absent from the luminal 
surface.  
 
Method 
 
In general, the process consists in Isolate a single bacterial cellulose block from a 
larger bacterial cellulose sheet with predetermined dimensions. The block is then 
perforated along the center line before a drying and shaping step until a desired wall 
thickness is achieved. The tubular structure is then freeze-dried (one or more times) 
in order to obtain the final tubular structure (Figure A-1). 
The perforation of the bacterial cellulose block can be performed by mechanical and 
physical perforation. The initial perforation of the luminal channel can be created 
by mechanical perforation using a, periodically sharpened, metallic needle. 
Alternatively, the application of a laser, or other physical or chemical process, can 
be used to form an initial luminal channel; however, care should be taken in regards 
to the choice of gas for the laser since surface modification can incur from this 
process. The luminal diameter is determined by the application of a metallic needle 
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or rod, after or during perforation, that will widen the channel to a final desired 
diameter. The final luminal diameter can vary from 2mm to 10mm, ideally 4-5mm 
for small caliber grafts. 
The drying process can be performed by mass transfer of water via capillary action, 
evaporation or compression that allows the controlled removal of water from the 
bacterial cellulose hydrogel. Mass transfer can be performed on blotting paper, or 
other such materials, at room temperature, same applies for compression. 
Evaporation should occur at temperatures ranging from 50-80oC in order to allow 
adequate control over final external diameter. 
Shaping of the external surface should occur during, but is not limited to, the drying 
step. Shaping can be performed by mechanical application of an external force that 
results in a cylindrical shape. The external force can be applied by hands or any 
equipment suitable to deliver a consistent and controlled external force. If need be 
the external surface can be trimmed, sanded or shaved in order to produce an 
external surface that presents a smoother topography. Trimming or shaving should 
be performed after freeze-drying on the completely dried material, for operability. 
The best conditions for this depend on the graft. 
Both the drying and shaping steps can be performed in order to control the final 
thickness of the wall of the tubular structure. Wall thickness is not limited to a 
predetermined thickness but should range between 1-4mm depending on luminal 
diameter ideally a 2mm thickness for a 4-8mm diameter graft. The total amount of 
bacterial cellulose used to form the final tubular structures dictates wall density and 
wall density dictates mechanical behavior of the final structure. A denser graft wall 
will translate to higher mechanical strength due to the total number of BC fibers in 
a same cross-section and can be adjusted accordingly (the ideal density should be 
0.1g/cm3 but can range from 0.02 to 0.15g/cm3) 
Surface modifications of the graft can be performed on the luminal and external 
surfaces in order to better accommodate for final desired application and the 
performance of the graft. The surface chemistry can be altered in order to improve 
biocompatibility and cell adhesion, by addition of RGD sequences or other cell 
signaling molecules, and/or reduce thrombogenicity, by addition of heparin for 
example. Surface modification can be performed chemically or physically through 
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methods such as covalent binding of the bioactive molecules or radicals and/or 
plasma-surface modifications. 
The final lyophilization step is not limited to a freeze-drying process. The objective 
is the complete removal of water without altering the 3-dimensional shape of the 
graft and as such, any other methods, such as supercritical drying, can be performed. 
As mentioned, mechanical properties of the tubular structure can be controlled by 
controlling wall density of the graft via inclusion of a larger amount of bacterial 
cellulose into the initial perforation step. Also, mechanical behavior of the graft can 
be controlled by controlling the number of freeze-drying cycles. The strength of the 
graft derives from the number of individual fibers in a cross-section and the amount 
of interaction between each fiber. Higher densities increase the number of fibers in 
a cross-section and cycle numbers increase the interaction levels both can be 
adjusted to improve mechanical behavior. We have found that the, aforementioned, 
ideal density for a 4mm graft is 0.1g/cm3 and a single freeze-drying cycle are 
sufficient. 
Complete removal of water via lyophilization can be performed before the initial 
perforation. However, all following steps must be performed sequentially. This may 
be beneficial logistically since dry cellulose is easier to handle. 
 
Detailed description 
Material and Methods 
Graft Fabrication 
 
Bacterial cellulose was produced by Gluconacetobacter xylinus (ATCC 53582), or any 
other BC producing bacteria, in a modified Hestrin-Schramm medium, 
supplemented with 2% Corn Steep Liquor (Sigma Aldrich, Germany) and 0.6 % 
ethanol, at pH 5.0. The resulting BC membranes were then washed in 4% (w/v) 
NaOH. It should also be noted that any culture medium capable of supporting the 
production of BC can also be used. The membranes were then thoroughly washed 
with distilled water until pH was neutral. Finally, endotoxin removal was 
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accomplished by further washing in 5% SDS (w/v). The water and detergent 
solutions were changed after 24 hours over the course of 2 days. 
Endotoxin removal was performed as follows: quadruplicate BC samples (1.5 x 2.5 
x 4cm (height x width x length) were placed in 200 ml of distilled water (control) 
and 5% SDS (w/v). The water and detergent solutions were changed after every 24 
hours over the course of 3 days. At each exchange, duplicate BC samples were taken 
and washed abundantly with distilled water and freeze-dried.  The samples were 
subsequently cut into samples of the same weight 20 ± 4mg and rehydrated with 
500µl of apyrogenic water. The concentration of endotoxin in each sample 
determined using the Pierce LAL Chromogenic Endotoxin Quantitation Kit and the 
standard protocol included (Thermo Scientific, Rockford, IL USA). Additionally, a 
non-washed BC graft was implanted in a single in vivo assay (as described ahead) 
and compared to the subsequent in vivo assays performed with the SDS washed BC 
grafts. 
BC grafts were prepared by cutting large BC sheets (1.5x25x30cm) into 1.5 x 2.5 x 
7cm (height x width x length) blocks with scissors. These were perforated along the 
center of the sample with a sharp 4mm (outer diameter) metallic needle and then 
dried by mass transfer of water from the hydrogel to blotting paper until a final wall 
thickness of roughly 2mm was achieved. The resulting tubular structures were then 
freeze-dried and stored at room temperature until needed (see Figure A-1). All 
grafts tested herein have a luminal caliber of 4mm and independently of the final 
length used in the varying assays were initially 7cm long. The BC grafts used for in 
vivo experimentation were rehydrated in sterile 0.9% (w/v) saline solution and 
autoclaved at 121oC for 20min 72 hours before surgery. 
 
Surface Profilometry 
 
BC grafts, created as previously described, were split open longitudinally and fixed 
with double-sided tape to glass slides. PFA, commercial ePTFE and Dacron grafts 
were also split longitudinally and affixed the same way (Dacron grafts were 
stretched as much as possible in order to remove the kinking inherent to the graft). 
The sample surface profiles were then measured 5 times along the same surface 
Annex A - Provisionary Patent Application 
AF Leitão 
136 
(each measurement roughly 1mm apart) with a KLC TENCOR D-100 profilometer 
along 20mm (for Porcine Femoral Artery, ePTFE and PET) and 30mm for BC at set 
speed of 0.2mm/second and a resolution of 2000 points per mm. The results were 
then plotted on a 3D graph so to convey an idea of the 3 dimensional surface of the 
each sample. Roughness was calculated as the amplitude between maximum peak 
height and minimum valley depth. 
 
Cryo-SEM Imaging 
 
Cross sections of the BC grafts were imaged via Cryo-SEM on a JEOL JSM 6301F/ 
Oxford INCA Energy 350/ Gatan Alto 2500. The graft samples were prepared as 
described above and then cut into 1mm wide sections and placed upright in a 
metallic support. The samples were then rapidly cooled by plunging them into sub-
cooled nitrogen (slush nitrogen) and transferred under vacuum to the cold stage of 
the preparation chamber. The samples were then fractured, sublimated for 180 
seconds at -90°C, and coated with Au/Pd by sputtering for 40 seconds. The samples 
were finally transferred into the SEM chamber and imaged at -150°C. Pore size was 
estimated from the micrographs using Image J software. 
 
Mechanical Tests 
Tensile Strength Determination 
 
BC grafts along with untreated BC (these are grafts that were not freeze-dried and 
as such did not finish the graft processing), ePTFE and porcine femoral artery (PFA) 
were tested for their tensile strength in quintuplicate (n=5) on a Shimadzu AG-X 50 
kN at a traction speed of 5mm/min and a load cell of 1kN. Each sample tested was 
split open longitudinally and the materials thickness and width was measured with 
digital calipers and accounted for in the calculations of the strength parameters. 
Special care was taken in order to prevent sample slipping from the hydraulic grips 
by using both fine grain sandpaper and construction paper. 
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Suture Retention Assay 
 
BC grafts with 6cm length (4mm internal diameter and 7mm external diameter) 
were fixed the top clamp of a Z2.5 Zwick/Roell (Zwick GmbH & Co. KG; Ulm; 
Germany). A 4-0 Prolene® suture (0.15mm diameter; Ethicon) was placed 
approximately 7mm from the edge of the prosthesis (measured with a digital 
micrometer) and looped around the bottom clamp before clamping. The assay was 
then carried out in quintuplicate, on both freeze-dried and non-freeze-dried 
bacterial cellulose prosthetics, at a set speed of 10mm/min and a 1N pre-load. 
 
Compliance Characterization 
 
Compliance characterization of BC grafts (n=5) was performed using the system and 
method described previously by Diamantouros and colleagues [32]. Briefly, the 
grafts were fixed into a chamber and initially exposed to a steady flow of purified 
water. A pulse (1Hz) was added by a linear magnetic actuator. The pressures were 
stabilized at 80-120mmHg. Variations in the outer diameter were measured by an 
optical micrometer sensor (LS-7030(M); Keyence Deutschland GmbH, Neu-
Isenburg, Germany) placed perpendicularly to the graft. Pressures were recorded 
by pressure transducers (CODAN pvd Critical Care GmbH; Forstinning, Germany). 
The measurements were realized for 30 seconds once the pressures were stable. 
Variations in the outer diameter and pressures were recorded by a LabVIEW™ 
application (National Instruments; Texas, USA). The circumferential compliance 
was then calculated with the following equation: 
 =
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
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   100 
Where C is compliance (%/mmHg), D is diameter (µm) and P is pressure (mmHg). 
“Syst” and “Diast” stand for the systolic and diastolic phase respectively. 
A slight addition to the method presented by Diamantouros, consisting of the use of 
ultrasound imaging equipment (Vivid I, GE Healthcare; Freiburg, Germany), allowed 
for the acquisition of video of the changes in internal diameter in response to 
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pressure variation. The videos were then converted to still frames and the diameter 
of the lumen determined with Image J software on three points per image. Care was 
taken so that the measurements from each video would be performed at the same 
coordinates in each individual frame so as to account, as much as possible, for 
human error. 
 
In vivo Experimentation and Histological Analysis 
Surgical procedure 
 
Four female domestic pigs (Sus scrofa domesticus) with weight ranging from 30-
40kgs were restrained from food (24 hours) and water (6 hours) before each 
surgical procedure. All experiments were conducted according to the European 
Union Directive no.86/609/CEE for the use of animals in research and approved by 
the board for the ethical treatment of animals of the Faculty of Medicine of the 
University of Porto (ORBEA, FMUP, Oporto, Portugal). All procedures were 
performed under general anesthesia, with endotracheal intubation and 
spontaneous ventilation. A pre-anesthesia intramuscular injection of 32mg/ml 
azaperone (Stressnil®, Esteve Veterinaria) at a dose of 4 mg/kg reconstituted with 
1mg/ml midazolam (Dormicum®, Roche) at a dose of 0.15–0.2ml/kg was 
administered. Venous access was obtained through an IV line placed in the marginal 
ear vein. Anesthesia was induced with 3μg/kg fentanyl (Fentanest®, Janssen-Cilag), 
and sodium thiopental (12.5mg/kg IV initially and then to effect Tiopental 0.5 B 
Braun®, B. Braun). After orotracheal intubation, the 7- to 7.5-mm tube was 
connected to the anesthetic equipment (Ohmeda, Boc Health Care), and anesthesia 
was maintained with a mixture of isoflurane (1.5% to 2.5%; Isoflo®, Esteve 
Veterinaria) in 100% oxygen and fentanyl at constant-rate infusion of 30-
50μg/kg/h. Afterwards an epidural analgesia protocol was implemented with 
application of 1mg/kg morphine (Morfina 1% Braun®, B. Braunl). To address 
infection prophylaxis, all animals received intramuscular injection of 1g ceftriaxone 
(Rocephin®, Roche) before surgery. End-tidal CO2, oxygen saturation, 
electrocardiography and temperature were monitored continuously (Cygnus 1000C 
Vet® Monitor, Servive Portugal). Pigs were placed in supine position and shaved, 
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and electrocardiographic electrodes were attached to the chest for continuous 
evaluation of cardiac electrical function. Normal saline (2 to 4mL/kg hourly) was 
infused through the venous cannula in the auricular vein during surgery, to maintain 
adequate preload stability. 
Open surgery was then performed with isolation of the common femoral artery, the 
profunda femoris artery and the superficial artery. The BC grafts were implanted in 
the left hind limb in a femoro-femoral artery bridge. Papaverine was administered 
via wash to the artery to avoid arterial spasm. The animals were heparinized 
systemically with an intravenous bolus injection of 200units/kg of heparin 
(Heparina Sódica B.Braun®, B.Braun), five minutes before clamping of the target 
arteries. BC grafts were then sutured with continuous 6-0 monofilament 
polypropylene sutures (Prolene®, Ethicon). The femoral artery from the right hind 
limb was sham-operated with all the surgical procedures being equally performed, 
excluding the implantation of the graft.  
After the surgery, the pigs were transported back to their quarters, only when 
arterial oxygen tension stabilized above 95%. Pigs were monitored until their body 
temperature normalized (with digital thermometers) and they were able to 
ambulate. They then were observed at least 2 or 3 times daily for locomotor activity, 
respiratory changes, body temperature, and food and water intake. Analgesia was 
maintained during the first 24h after surgery by using meloxicam (0.5mg/kg IM; 
Metacam, Boehringer Ingelheim). Acetylsalicylic acid (150mg/animal per os daily; 
Ácido Acetilsalicílico ratiopharm 100mg, Ratiopharm) was given once daily until 
euthanasia, to prevent platelet aggregation. 
After the designated times, the animals were sacrificed by IV KCl injection after 
sedation with azaperone reconstituted with midazolam administered IM prior to 
induction with sodium thiopental (12.5mg/kg IV initially and then to effect) and the 
grafts and sham-operated arteries were harvested and histologically evaluated for 
signs of chronic inflammation, infection, foreign body responses, clot formation, cell 
ingrowth, and diameter via electron microscopy. 
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Histology 
 
Tissues were preserved in formalin for a minimum of 4 days and were embedded in 
paraffin in an automated tissue processor (Microm STP 120). Tissues were then 
transferred to embedding workstation to obtain paraffin blocks. From these, 
sections (2µm) were cut on a rotary microtome (Leica RM 2035) and stained with 
Hematoxylin and Eosin (H&E) for light microscopic examination. Observations and 
photographs were made using an Olympus BX51 microscope with an Olympus 
camera attached 
 
Immunohistochemistry 
 
Immunostaining of endothelial cells was performed using the primary antibody – 
Mouse Anti Pig CD31 (AbD Serotec; Oxford, England). This is a mouse monoclonal 
antibody designed to detect porcine CD31. The slides were immersed in 10mM 
sodium citrate (pH 6.0) buffer. Antigen visualization was done with the Novocastra 
Novolink Polymer Detection System (Leica Microsystems GmbH, Wetzlar, Germany) 
and involved the following steps: Sections were incubated with H2O2 (3%) for 10 
min to eliminate endogenous peroxidase activity followed by a 5 min incubation 
with a protein blocking agent. Sections were subsequently incubated overnight at 4 
oC with the primary antibody diluted at 1:100 with BSA (5%), and on the following 
day, washed in TBS-buffered saline solution before incubation for 30 min with the 
secondary antibody system using diaminobenzidine (DAB) as a chromogen. 
 
Statistical Data Analysis 
 
All data and statistical analysis was performed using both GraphPad Prism and 
Origin Pro 9 software. Statistical significances were determined via One-way and 
Two-Way ANOVA tests after verifying the Normal distribution (p<0.05) of the data. 
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Results 
Graft Fabrication 
 
The novel methodology presented herein for production of the BC graft is 
schematically outlined in Figure A-1. The BC grafts were produced with needles that 
were purposely built, regularly sharpened and exchanged in order to assure 
consistent perforation. Special care was taken during perforation in order assure a 
smooth luminal channel. An unsharpened needle resulted in tears during the 
perforation with the appearance of “flaps” that could occlude or restrict flow 
through the graft. Also, while all grafts produced and presented in this work were 
4mm in diameter we found that by using different diameter needles allows the 
production of grafts with different diameters. 
The drying and shaping was performed with the needle in place with special care to 
avoid changes to the luminal diameter of the graft and an irregular topography of 
the external surface. Also, the grafts were found to dry quickly during the freeze-
drying process (a maximum of 2 days is required for complete drying) and the least 
irregular grafts were obtained the quicker this process was performed. 
Surface Profilometry 
 
The surface profiles we present here were obtained by 5 consecutive measurements 
that were 1 mm spaced (side-by-side) and plotted together in a three-dimensional 
topological graph so as to convey an idea of the topography of the materials (see 
Figure A-1 - Schematic representation BC vascular graft formation process. From left to right: the BC perforated 
with a sharp metallic needle, dried by capillary action and shaped into a cylinder and finally freeze-dried. 
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Figure A-2). Our results show that the surface roughness of BC is in the same range 
of that of porcine femoral artery, ranging roughly 300nm in both cases from highest 
peaks to lowest valley, with no statistically significant difference between them 
(p>0.05). On the other hand, both ePTFE and, to a greater extent, PET show a much 
greater surface roughness with a distance of approximately 600 and 1600nm 
between peaks and valleys respectively.  
 
Cryo-SEM Imaging 
 
Several BC grafts samples, and several different regions of each graft, were observed 
via Cryo-SEM so as to maintain the hydrated three-dimensional structure of the 
grafts; the images presented here are representative of those observations (Figure 
A-3). The fibril distribution inside of our grafts showed markedly different 
structures throughout the graft wall that are well distributed throughout. In lower 
magnifications dense sheets of BC fibers intersecting each other are visible and 
appear in wave-like patterns, parallel to the luminal surface of the graft (Figure A- 
Figure A-2 - Surface profiles of Porcine Femoral Artery (A), BC graft (B), ePTFE graft (C) and a PET graft (D). The 
plots were obtained from 5 separate linear measurements (2000 points/mm) over 2 cm (3cm for BC), spaced 
1mm apart and plotted in a 3D graph. 
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3A, B and C). Dense sheets are surrounded by low density open porous regions 
(Figure A-3D) with pore sizes ranging from 1 to 5 µm in diameter. Additionally, there 
seems to be a consistent and dense single layer of BC fibers over the entire luminal 
surface of the graft that is immediately followed by open porous regions (Figure A-
3E). 
 
Endotoxin Removal Study 
 
Endotoxin (Lipopolysaccharide; LPS) concentration on non-washed and SDS 
washed BC was determined with the Pierce LAL Chromogenic Endotoxin 
Quantitation Kit. Total LPS concentration on non-washed BC over the course of the 
study was 2.65 ± 0.27EU/ml (Endotoxin Units/ml) and dropped to 0.43 ± 0.15, 0.06 
± 0.04 and 0.003 ± 0.02EU/ml over the following 3 days (Figure A-4). Total LPS 
concentration was shown to be significantly different between washed and non-
washed BC (p<0.05). Results also show a significant difference between a single and 
Figure A - 3 - Cryo-SEM images of a portion of the cross-section of the graft wall. (A) and (B) 4000x magnification 
with noticeable dense regions layered between open-pore structures; (C) 10000x magnification of the dense BC 
regions; (D) 10000x magnification of the open-pore structures and (E) 10000x magnification of the edge of the 
luminal surface of the graft. (F) is a schematic representation of the interface between the luminal surface and 
inner wall structure.  
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twice washed (p<0.05) and no significant difference between the second and third 
washes. 
 
Mechanical Tests 
Tensile Strength Determination 
 
Mechanical testing demonstrated marked differences between porcine femoral 
artery (PFA), ePTFE and BC (both as a graft and untreated) - see Table A-1. The BC 
graft and untreated BC show no statistically significant difference between them 
(p>0.05) in regards to any of the parameters though. However, the BC graft did show 
higher values for maximum tensile strength (Max Force), maximum stress and 
strain. PFA, while mechanically weak as compared to the other materials in regards 
to strength, was by far the most elastic, deforming 133% before rupture. Also 
noteworthy, ePTFE was shown to be most rigid of the tested materials, with the 
highest values in all the parameters. The BC grafts thus better resembles the 
biological vessels than ePTFE, in the sense that it presents higher elasticity, 
translated in a Young modulus in the same order of magnitude as PFA´s. 
 
Figure A-4 - Endotoxin (LPS) concentration in EU/ml (Endotoxin Units/ml) as determined over 3, 24 hour, washes 
in 5% SDS and water (negative control). 
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Table A-1 - Mechanical test results for Porcine Femoral Artery (PFA), ePTFE the BC Graft and unprocessed BC 
(n=5). Values marked with an asterisk (*) are not statistically different from each other in their respective 
columns (p>0.05). Data is presented as mean ± standard deviation. 
Material Young's Modulus (N/mm2) Max Force (N) Max Stress (N/mm2) Max Strain (%) 
PFA 2.58 ± 0.95 10.05 ± 3.39 1.15 ± 0.39* 133.46 ± 11.25 
ePTFE 125.40 ± 24.33 198.54 ± 13.33 23.57 ± 1.00 40.62 ± 9.92* 
BC Graft 10.56 ± 1.53* 95.92 ± 5.62* 2.75 ± 0.38* 41.08 ± 8.65* 
BC 10.70 ± 2.23* 91.47 ± 16.33* 2.10 ± 0.26* 34.5 ± 4.27* 
 
Suture Retention Strength 
 
Results show that untreated BC and our BC grafts demonstrate suture retention 
strength of 3.94 ± 0.38 and 4.20 ± 0.99 N respectively, with no statistically significant 
difference between them (p>0.05). The results demonstrate a superior performance 
of the BC grafts, as compared to most materials, presenting a suture retention 
strength comparable to that of ePTFE.  
Table A-2 Suture Retention strength (N) of several autologous and synthetic grafts for Tissue Engineered Blood 
Vessels (TEBV), Internal Mammary Artery (IMA), Polytetrafluoroethylene (ePTFE), Fibrin and Fibrin/polylactic 
acid (PLA), Human Saphenous Vein (HSV), Collagen and Bacterial Cellulose (BC). Suture retention strength for the 
BC graft and untreated BC are not statistically different (p>0.05; n=4) 
Graft Material Retention Strength (N) SD References 
IMA 1.35 ± 0.49 29 
HSV 2.60  30 
TEBV 1.49 ± 0.49 29 
Fibrin 0.19 ± 0.05 31 
Fibrin/PLA 1.32 ± 0.58 31 
Collagen 0.82-2.87 ± 0.12-0.09 32 
ePTFE 4.70 ± 0.50 33 
BC graft 4.20 ± 0.99 -- 
BC 3.94 ± 0.38 -- 
 
Compliance Characterization Assay 
 
We measured the compliance for our BC grafts externally via laser detector and 
estimated compliance internally by sonography imaging. Results show a significant 
difference between the compliance of the BC graft in regards to the internal and 
external measurements (see Table A-3). Externally compliance was measured as 
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being 0.4x10-2 %/mmHg while internally graft compliance was determined to be 
9.5x10-2 %/mmHg. While the external compliance falls far from the results for the 
most of the other materials found in the literature internally compliance seems to 
be much better matching, in most regards, the compliance values found for 
autografts.  
 
Table A-3 - Compliance (presented as value x10-2 %/mmHg) with standard deviation (SD) as collected from the 
literature for Internal Mammary Artery (IMA), Human Saphenous Vein (HSV), Human Iliac Artery (HIA), Tissue 
Engineered Blood Vessel (TEBV), Polyurethane (PU), Polyethylene terephthalate (PET), expanded 
Polytetrafluoroethylene (ePTFE), Bacterial Cellulose/Chitosan blend (BC/Chi) and measurements for the 
compliance of the BC grafts as measured externally and internally (n=5). 
Graft Material Compliance (%/mmHg; x10-2) SD References 
IMA 11.5 ± 3.9 29 
HSV 3.7-12.8 ± 1.3-1.9 34 
HIA 8 ± 5.9 35 
TEBV 1.5-3.4 ± 0.3 29; 30 
PU 8.1 ± 0.4 35 
PET 1.8 ± 1.2 35 
ePTFE 1.2-1.6 ± 0.3 35; 36 
BC/Chi 5.9 ± 2.7 36 
BC graft External 0.4 ± 0.1 -- 
BC graft Internal 9.5 ± 2.8 -- 
 
In vivo Experimentation and Histological Analysis 
 
As a preliminary in vivo assay 4 surgical procedures have been performed to date, 
with implantation of the BC graft in a femoral-femoral artery bridge on the left hind 
limb of female domestic pigs (see Figure A-5A). The right femoral artery was also 
isolated in a sham-operated procedure and served as a control for the implanted 
graft. No significant changes to the arterial wall of the control vessel were detected. 
During the first surgical intervention severe arterial spasm and contraction was 
noted during, and after, the procedure. There was noticeably reduced pulse after 
graft implantation and the limb was slightly cold to the touch 24 hours post-
operatively both situations attributed to arterial contraction. All further procedures 
were performed with papaverine administration, via topical wash to the artery. The 
following three procedures resulted in 1 month patency that were all confirmed via 
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Doppler ultrasound imaging (see Figure A-5B) being terminated at that point for 
explantation of the BC graft and subsequent histological analysis.  
Histological analysis and Immunohistochemistry were performed on the grafts 
harvested after the experiments were terminated. The BC grafts that were 
recovered one month after surgical intervention were intact and well integrated into 
the surrounding tissue with no significant fibrosis or macroscopic evidence of 
inflammation. Later histological analysis showed a distinct, three-layered, structure 
with cellular adhesion and infiltration on both the luminal and adventitial surfaces 
of the graft and an unpopulated and larger BC central region. The cells detected on 
the luminal surface were believed initially, and later confirmed via 
immunohistochemistry, to be endothelial or progenitor endothelial cells that are 
believed to have migrated from the adjoining femoral artery (Figure A-5C). Figure 
A-5E and F are representative of the cellular infiltration and population found on 
the adventitial surface of all the recovered grafts with special note to the presence 
of neo-vessels inside the BC graft itself (see Figure A-5D). The cell populations in 
these regions were determined to be composed mostly of fibroblasts, macrophages 
and some giant cells.  
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Figure A-5 Representative photographs and Haematoxylin and Eosin histopathological microscopy images of in 
vivo tests. (A) Femoral-femoral artery BC graft placement, (B) Doppler Sonography screenshot showing blood 
flow through the BC graft after one month of implantation, (C) 100x magnification of the luminal surface of the 
graft with cell adhesion on the surface of the graft along and some cell infiltration, (D) 200x External surface of 
BC graft showing formation of neo-vessels (arrow), (E) External surface of the BC grafts showing a smooth 
transition from surrounding tissues into the BC graft with cell infiltration, (F) 200x magnification of a cell 
population in a transitional region from adventitia into the BC grafts. 
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CLAIMS 
 
1. Method for production of tubular bacterial cellulose grafts for use in vascular 
applications comprising the following steps: 
- isolate a single bacterial cellulose block from a larger bacterial cellulose sheet 
with predetermined dimensions; 
- perform 2 to 4 24 hour washes  of the bacterial cellulose blocks in SDS at a 
concentration of 2-5% (w/v) followed by 5 washes a day over 3 days in water; 
- perforate the bacterial cellulose block along the center line with a needle or a 
laser or physical or chemical process in a manner to get a luminal channel; 
- maintain the needle inside the block or insert one after the laser or physical or 
chemical process of perforation;  
- perform a drying process by mass transfer of water via capillary action, or 
evaporation or compression for the removal of water from the bacterial cellulose;  
- shape the external surface by mechanical application of an external force in 
manner to result in a cylindrical shape; 
- remove the needle; 
- perform a freeze-drying process; 
 
2. Method, according to previous claim, wherein the drying process and the 
shaping are optionally made simultaneously. 
 
3. Method, according to previous claims, wherein optionally the surface is 
trimmed, or sanded or shaved in order to produce an external surface with a 
smoother topography. 
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4. Method, according to claim 1, wherein preferably is used a sharpened and 
metallic needle to perforate the bacterial cellulose block. 
 
5. Method, according to previous claim, wherein the luminal channel produced by 
the needle has a diameter between 2mm and 10mm, preferably 4-5mm. 
 
6. Method, according to claim 1, wherein the mass transfer or compression is 
performed on blotting paper at room temperature. 
 
7. Method, according to claim 1, wherein the evaporation occur at temperatures 
ranging from 50-80oC. 
 
8. Method, according to claim 1, wherein the external force of the shaping consists 
in a mechanical force applied uniformly over the surface. 
 
9. Tubular bacterial cellulose grafts for use in vascular applications, according to 
claims 1 to 8 wherein the graft has a wall density ranging from 0.02 to 0.15g/cm3 
and a wall thickness ranging from 1 to 4mm. 
 
10. Tubular bacterial cellulose graft, according to previous claim, wherein the 
preferable wall density is 0.1g/cm3 to 0.09g/cm3. 
 
11. Tubular bacterial cellulose graft, according to previous claim, wherein the 
preferable wall thickness is 2 mm. 
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12. Tubular bacterial cellulose graft, according to claims 9 to 11, wherein can have 
a surface altered by addition of RGD sequences or other cell signaling molecules, 
and/or any other bioactive molecules such as, heparin . 
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